Back to GetFilings.com
================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C., 20549
-----------------
FORM 10-K
[X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 1997
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED]
For the transition period from _____ to _____
Commission File No. 0-20260
Commission File No. 1-11440
INTEGRAMED AMERICA, INC.
(Exact name of registrant as specified in its charter)
Delaware
(State or other jurisdiction of incorporation or organization)
06-1150326
(I.R.S. Employer Identification No.)
One Manhattanville Road
Purchase, New York 10577
(Address of principal executive offices) (Zip Code)
(914) 253-8000
(Registrant's telephone number, including area code)
----------------------------
Securities registered pursuant to Section 12(b) of the Act:
None
Securities registered pursuant to Section 12(g) of the Act:
Series A Cumulative Convertible Preferred Stock, $1.00 par value
Common Stock, $.01 par value
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
Indicate by check mark if disclosure of delinquent filer pursuant to Item
405 of Regulation S-K (17 CRF ss. 229.405) is not contained herein, and will not
be contained, to the best of registrant's knowledge, in definitive proxy or
information statements incorporated by reference in Part III of this form 10-K
or any amendment to this Form 10-K [ ]
Aggregate market value of voting stock (Common Stock, $.01 par value and
Preferred Stock, $1.00 par value) held by non-affiliates of the Registrant was
approximately $33.5 million on March 19, 1998 based on the closing sale price of
the Common Stock and Preferred Stock on such date.
The aggregate number of shares of the Registrant's Common Stock, $.01 par
value, outstanding was approximately 21,344,423 on March 19, 1998.
================================================================================
DOCUMENTS INCORPORATED BY REFERENCE
See Part III hereof with respect to incorporation by reference from the
Registrant's definitive proxy statement for the fiscal year ended December
31, 1997 to be filed pursuant to Regulation 14A under the Securities
Exchange Act of 1934 and the Exhibit Index hereto.
PART I
ITEM 1. Business
Company Overview
IntegraMed America, Inc. (the "Company") is a physician practice management
company specializing in women's reproductive health care, with a focus on
infertility and assisted reproductive technology ("ART") services. The Company
provides comprehensive management services to a nationwide network of medical
providers currently consisting of twelve sites (each, a "Network Site"). Each
Network Site consists of a location or locations where the Company has a
management agreement with a physician group or hospital (each, a "Medical
Practice") which employs the physicians or where the Company directly employs
the physicians.
The Company operates under two divisions: the Reproductive Science Center
Division (the "RSC Division"), which provides management services to Medical
Practices focused on infertility and ART services, and the Adult Women's Medical
Division (the "AWM Division"), which provides management services to Medical
Practices focused on health care services for peri- and post-menopausal women.
Currently, there are eleven Network Sites in the RSC Division (the "Reproductive
Science Centers") with twenty-three locations in ten states and the District of
Columbia. Currently, there is one Network Site with two locations under the AWM
Division which commenced operations in June 1996.
Industry
Physician Practice Management
The health care industry in the United States is undergoing significant
changes in an effort to manage costs more efficiently while continuing to
provide high quality health care services. The United States Health Care
Financing Administration has estimated that national health care expenditures in
1996 were over $1,035 billion, with approximately $202 billion directly
attributable to physician services. Historically, health care in the United
States has been delivered through a fragmented system of health care providers.
Concerns over the accelerating costs of health care have resulted in
increased pressures from payors, including governmental entities and managed
care organizations, on providers of medical services to provide cost-effective
health care. Many payors are increasingly expecting providers of medical
services to develop and maintain quality outcomes through utilization review and
quality management programs. In addition, such payors typically desire that
physician practices share the risk of providing services through capitation and
other arrangements that provide for a fixed payment per member for patient care
over a specified period of time. This focus on cost-containment and financial
risk sharing has placed physician groups and sole practitioners at a significant
competitive disadvantage because they typically have high operating costs,
limited purchasing power with suppliers and limited abilities to purchase
expensive state-of-the-art equipment and invest effectively in sophisticated
information systems.
In response to reductions in the levels of reimbursement by third-party
payors and the cost-containment pressures on health care providers, physicians
are increasingly seeking to affiliate with larger organizations, including
physician practice management companies, which manage the nonmedical aspects of
physician practices, such as billing, purchasing and contracting with payor
entities. In addition, affiliation with physician practice management companies
2
provides physician groups with improved access to (i) state-of-the-art
laboratory facilities, equipment and supplies, (ii) the latest technology and
diagnostic and clinical procedures, (iii) capital and informational, managerial
and administrative resources and (iv) access to managed care relationships.
The trends that are leading physicians to affiliate with physician practice
management companies are magnified in the field of reproductive medicine due to
several factors, including (i) the increasingly high level of specialized skills
and technology required for comprehensive patient treatment, (ii) the capital
intensive nature of acquiring and maintaining state of-the-art medical equipment
and laboratory and clinical facilities, (iii) the need to develop and maintain
specialized management information systems to meet the increasing demands of
technological advances, patient monitoring and third-party payors, and (iv) the
need for seven-days-a-week service to respond to patient needs and to optimize
the outcomes of patient treatments.
Reproductive Medicine
Reproductive medicine encompasses several medical disciplines that focus on
male and female reproductive systems and processes. Within the field of
reproductive medicine, there are several subspecialties, such as obstetrics and
gynecology, infertility and reproductive endocrinology. While there are many
reasons why couples have difficulty conceiving, the single most prominent course
of infertility therapy involves management of the women's endocrine system to
optimize an opportunity for pregnancy. Most obstetricians perform ovulation
induction, and many gynecologists perform conventional infertility treatments.
Infertility specialists are gynecologists who perform more sophisticated medical
and surgical infertility treatments. Reproductive endocrinology refers to the
diagnosis and treatment of all hormonal problems that lead to abnormal
reproductive function or have an effect on the reproductive organs. Reproductive
endocrinologists are physicians who have completed four years of residency
training in obstetrics and gynecology and have at least two years of additional
training in an approved subspecialty fellowship program.
Conventional infertility services include diagnostic tests performed on the
female, such as endometrial biopsy, laparoscopy/hysteroscopy examinations and
hormone screens, and diagnostic tests performed on the male, such as semen
analysis and tests for sperm antibodies. Depending on the results of the
diagnostic tests performed, conventional treatment options may include, among
others, fertility drug therapy, artificial insemination and infertility
surgeries. These conventional infertility services are not classified as ART
services. Current types of ART services include in vitro fertilization, gamete
intrafallopian transfer, zygote intrafallopian transfer, tubal embryo transfer,
frozen embryo transfer and donor egg programs. Current ART techniques used in
connection with ART services include intra-cytoplasmic sperm injection, assisted
hatching and cryopreservation of embryos.
According to The American Society for Reproductive Medicine, it is
estimated that in 1995 approximately 10% of women between the ages of 15 and 44,
or 6.1 million women, had impaired fertility. According to industry sources,
annual expenditures relating to infertility services exceed $1 billion. The
Company believes that multiple factors over the past several decades have
affected fertility levels. A demographic shift in the United States toward the
deferral of marriage and first birth has increased the age at which women are
first having children. This, in turn, makes conception more difficult and
increases the risks associated with pregnancy, thereby increasing the demand for
ART services. In addition, the technological advances in the diagnosis and
treatment of infertility have enhanced treatment outcomes and the prognoses for
many couples.
Traditionally, conventional infertility services generally have been
covered by managed care payors and indemnity insurance, while ART services have
been paid for directly by patients. Currently, there are several states that
mandate offering benefits of varying degrees for infertility services, including
ART services. In some states, the mandate is limited to an obligation on the
part of the payor to offer the benefit to employers. In Massachusetts, Rhode
Island, Maryland, Arkansas, Illinois and Hawaii, the mandate requires coverage
of conventional infertility services as well as ART services.
In the United States, there are approximately 38,000 OB/GYNs and
approximately 1,500 infertility specialists of which approximately 600 are
reproductive endocrinologists. There are approximately 400 facilities providing
3
ART services in the United States, of which approximately half are
hospital-affiliated and half are free-standing physician practices.
Increasingly, hospital affiliated programs are moving out of the hospital and
into lower cost physician practice settings.
Adult Women's Health Care
The wide range of medical conditions that frequently emerge in women in
menopause comprise a critical element of adult women's health care. When many
women reach menopause, they begin to experience a number of associated physical
and psychological conditions. For example, women entering menopause frequently
have a condition known as estrogen deficiency. Low levels of estrogen have been
associated with osteoporosis, cardiovascular disease, and metabolic and
endocrine disorders. Furthermore, women in menopause are at increased risk for a
number of other conditions, including various cancers, arthritis, urinary
incontinence, and visual and hearing disorders. In addition to the range of
physical symptoms, women in menopause frequently experience psychological
disorders, including depression and other emotional problems.
In the United States, there are over 20 million peri-menopausal women (ages
40-50) and approximately 39 million post-menopausal women (over age 50). An
additional 42 million women in the United States will reach age 50 over the next
20 years. Most women in the peri-menopausal range are asymptomatic, but have
underlying health issues that begin to emerge with the onset of menopause.
Traditionally, women in menopause have been treated by their OB/GYN with hormone
replacement therapy and are referred to a specialist if there is suspicion of
more complicated health problems. The additional conditions and symptoms
associated with menopause are typically treated by a disconnected array of other
physicians, including those specializing in primary care, endocrinology,
internal medicine, orthopedic medicine, psychiatry and others, often leading to
increased patient inconvenience and higher costs.
The Company believes there is a significant unmet medical need for a
comprehensive diagnostic and treatment approach to the broad range of medical
conditions that emerge in peri- and post-menopausal women. While a number of
physician practice management companies have developed a focus on obstetrics and
gynecology, the Company believes that there are currently no well organized
medical delivery systems that fully address the preventative and therapeutic
needs of peri- and post-menopausal woman. The Company believes that peri- and
post-menopausal women's health and well being can be vastly improved through a
comprehensive program of preventative and curative treatment and guidance.
Company Strategy
The Company's objective is to develop, manage and integrate a nationwide
network of Medical Practices specializing in the provision of high quality,
cost-effective women's reproductive health care services. The primary elements
of the Company's strategy include (i) establishing additional Network Sites,
(ii) increasing revenues at the Network Sites, (iii) increasing operating
efficiencies at the Network Sites, (iv) developing a nationwide integrated
information system and (v) further developing the AWM Division.
Establishing Additional Network Sites
The Company intends to further develop its nationwide network of Medical
Practices by acquiring certain assets of and the right to manage leading
physician practices specializing in infertility and ART services. The Company
will primarily focus its acquisition activities on larger group practices
operating in major cities, as Medical Practices providing infertility and ART
services require high fixed overhead which smaller physician group practices
(two physicians) and sole practitioners have difficulty in supporting. The
Company believes that a number of beneficial factors will contribute to the
successful expansion of its network. These factors include (i) the high quality
reputation of the Company in providing management services in the areas of
infertility and ART services, (ii) the Company's experience and expertise in
increasing revenues and lowering costs at its Medical Practices, (iii) the
Company's success in improving patient outcomes by providing management services
4
to its Medical Practices and (iv) the Company's affiliations and relationships
with leading academic institutions, health care companies and managed care
organizations and other third-party payors.
Increasing Revenues at the Network Sites
The Company intends to increase revenues derived under its management
agreements by assisting the Medical Practices in (i) adding additional
physicians to achieve multi-physician group practices with sizable market
presence, (ii) adding services offered at the Medical Practices which have
previously been outsourced, such as laboratory and ART services, (iii)
increasing marketing and practice development efforts and (iv) increasing the
participation of the Medical Practices in clinical trials of new drugs under
development.
Increasing Operating Efficiencies at the Network Sites
The Company intends to increase the operating efficiencies of its Network
Sites. Medical Practices will be able to reduce the costs of supplies, drugs,
equipment, services and insurance by contracting through the Company on a
consolidated group basis. In addition, by eliminating the administrative and
management burdens of running a Medical Practice, the Company enables physicians
to devote a greater portion of their efforts and time to meeting the medical
needs of their patients, which the Company believes leads to improved clinical
outcomes and greater patient satisfaction at lower costs.
Developing a Nationwide, Integrated Information System
The Company plans to utilize its established base of Network Sites to
develop a nationwide, integrated information system to collect and analyze
clinical, patient, administrative and financial data. The Company believes it
will be able to use this data to control expenses, measure patient outcomes,
improve patient care, develop and manage utilization rates and maximize
reimbursements. The Company also believes an integrated information system will
allow the Medical Practices to more effectively compete for and price managed
care contracts, in large part because an information network can provide these
managed care organizations with access to patient outcomes and cost data.
Further Developing the AWM Division
With the establishment of its current AWM Network Site, the Company has
developed a clinical care model, which it is still refining, whereby it can
effectively provide the broad range of medical services necessary for the
treatment of peri- and post-menopausal women. The Company's AWM Network Site
offers a multidisciplinary approach, integrating "under one roof" the physicians
and other medical specialists necessary for the prevention, diagnosis and
treatment of peri- and post-menopausal conditions. The Company intends to seek
to enter into long-term management agreements with hospitals pursuant to which
the Company would assist hospitals so that they may offer a multidisciplinary
approach for the treatment of peri- and post-menopausal women. In addition, the
Company intends to continue to expand the participation of the AWM Division in
the clinical testing of new drugs to treat women's health care conditions and
the promotion of educational programs relating to menopause.
5
Management Services
The Company provides comprehensive management services to support the
Medical Practices. In particular, the Company provides (i) administrative
services, including accounting and finance, human resource functions, and
purchasing supplies and equipment, (ii) access to capital, (iii) marketing and
practice development, (iv) information systems and assistance in developing
clinical strategies and (v) access to technology. These services allow the
physicians to devote a greater portion of their efforts and time to meeting the
medical needs of their patients, which the Company believes leads to improved
outcomes and greater patient satisfaction at lower costs.
Administrative Services
The Company provides all of the administrative services necessary for the
non-medical aspects of the Medical Practices, including (i) accounting and
finance services, such as billing and collections, accounts payable, payroll,
and financial reporting and planning, (ii) recruiting, hiring, training and
supervising all non-medical personnel, and (iii) purchasing of supplies,
pharmaceuticals, equipment, services and insurance. By providing the Medical
Practices relief from increasingly complex administrative burdens, the Company
enables physicians at the Medical Practices to devote their efforts on a
concentrated and continuous basis to the rendering of medical services.
Furthermore, the economies of scale inherent in a network system enable the
Company to reduce the operating costs of its affiliated Medical Practices by
centralizing certain management functions and by contracting for group
purchases.
Access to Capital
The Company provides the Network Sites increased access to capital.
Increased access to capital allows for expansion and growth of the Medical
Practices, as well as the acquisition of state-of-the-art laboratory, diagnostic
and clinical facilities needed to conduct advanced procedures and to achieve
successful clinical outcomes. For example, many ART procedures, which are being
performed in hospital settings, result in higher costs and less revenues to the
physicians. By providing ART facilities, the Company enables Medical Practices
to reduce costs and increase revenues by removing these procedures from hospital
settings.
Marketing and Practice Development
In today's highly competitive health care environment, marketing and
practice development are essential for the growth and success of physician
practices. However, these marketing and development efforts are often too
expensive for many physician practice groups. Affiliation with the Company's
network provides physicians access to significantly greater marketing and
practice development capabilities than would otherwise be available. The
Company's marketing services focus on revenue and referral enhancement,
relationships with local physicians, media and public relations and managed care
contracting.
The Company believes that participation in its network will assist Medical
Practices in establishing contracts with managed care organizations. With
respect to the RSC Division, the Company believes that integrating infertility
physicians with ART facilities produces a full service Medical Practice that can
compete more effectively for managed care contracts. With respect to the AWM
Division, the Company believes that the clinical care model developed at the AWM
Network Site, which the Company is still refining, and the preventative nature
of the services offered will be well received by managed care organizations.
Information Systems and Clinical Strategies
The Company provides the Medical Practices with information systems and
assists Medical Practices in developing clinical strategies and implementing
quality assurance and risk management programs in order to improve patient care
and clinical outcomes. For example, the RSC Division has instituted a pregnancy
rate improvement program that focuses the physicians and laboratory technicians
on the principal elements necessary to achieve successful outcomes and
incorporates periodic quality review programs. The Company believes that this
6
program has contributed to improved pregnancy rates at the RSC Network Sites.
Physicians at the Medical Practices also can access a number of customized
practice and research based systems designed by the Company for analyzing
clinical data.
Access to Technology
By affiliating with the Company's network, Medical Practices gain access to
advanced technologies, as well as diagnostic and clinical procedures. For
example, through participation in clinical trials of new drugs under development
for major pharmaceutical companies, Medical Practices have the opportunity to
apply technologies developed in a research environment to the clinical setting.
Additionally, participation in clinical trials gives Medical Practices
preferential involvement in cutting edge therapies and provide these practices
with an additional source of revenue. Furthermore, the Company sponsors research
conducted at leading ART programs, including Monash University, Australia.
The Network Sites
Each of the Company's Network Sites consists of a location or locations
where the Company has a management agreement with a Medical Practice, which in
turn employs the physicians or where, in the case of the AWM Network Site, the
Company owns the Medical Practice and directly employs the physicians. At
certain Network Sites, Medical Practices have agreements with physicians who are
not employed by the particular Medical Practices or the Company for such
physicians to use the Network Sites' facilities.
7
Current Network Sites
The Company currently has a nationwide network consisting of twelve Network
Sites with 25 locations in eleven states and the District of Columbia and 58
physicians. The following table describes in detail each Network Site:
Initial
Number of Number of Management
Network Site City Locations Physicians(1) Contract Date
------------ ---- --------- ------------- -------------
RSC DIVISION
Reproductive Science Center of Boston........ Waltham, MA 2 5 July 1988
Reproductive Science Associates.............. Mineola, NY 2 10 June 1990
(Long Island)
Institute of Reproductive Medicine and
Science of Saint Barnabas Medical Center... Livingston, NJ 1 5 December 1991
Reproductive Science Center of
Greater Philadelphia....................... Wayne, PA 1 7 May 1995
Reproductive Science Associates.............. Kansas City, MO 1 1 November 1995
Reproductive Science Center of Walter Reed
Army Medical Center........................ Washington, DC 1 7 December 1995
Reproductive Science Center of Dallas........ Carrollton, TX 1 1 May 1996
Reproductive Science Center of the Bay Area
Fertility and Gynecology Medical Group..... San Ramon, CA 1 3 January 1997
Reproductive Sciences Medical
Center of San Diego........................ La Jolla, CA 1 1 June 1997
Fertility Centers of Illinois, S.C........... Chicago, IL 8 9 August 1997
Shady Grove Fertility Centers................ Rockville, MD
Annandale, VA
Washington, DC 4 6 March 1998
AWM DIVISION
Women's Medical & Diagnostic Center......... Gainesville, FL 2 3 June 1996 (2)
- ----------
(1) Includes physicians employed by the Medical Practices or the Company, as
well as physicians who have arrangements to utilize the Company's
facilities.
(2) Represents the date of acquisition of the AWM Network Site.
Recent Acquisitions
In January 1997, the Company acquired certain assets of Bay Area Fertility
and acquired the right to manage the Bay Area Fertility and Gynecology Medical
Group, Inc., a California professional corporation which is the successor to Bay
Area Fertility's medical practice. The aggregate purchase price was
approximately $2.1 million, consisting of $1.5 million in cash and 333,333
shares of Common Stock. The majority of the purchase price was allocated to
exclusive management rights.
In June 1997, the Company acquired certain assets of and the right to
manage Reproductive Sciences Medical Center, Inc. ("RSMC"), a California
professional corporation located near San Diego, CA (the "San Diego
Acquisition"). The aggregate purchase price for the San Diego Acquisition was
approximately $900,000, consisting of $50,000 in cash and 145,454 shares of
Common Stock payable at closing and $650,000 payable upon the achievement of
certain specified milestones, at RSMC's option, in cash or in shares of the
Company's Common Stock, based on the closing market price of the Common Stock on
8
the third business day prior to issuance. On March 10, 1998, the Company
received notice from RSMC claiming that the Company has materially breached its
management agreement with RSMC and demanding that the alleged breaches be
remedied. Contrary to RSMC's assertions, the Company believes both that it has
materially performed its obligations under the management agreement with RSMC
and that RSMC has materially breached its obligations to the Company under the
management agreement, as well as other agreements with the Company. While the
Company continues to perform, it is endeavoring to submit the dispute to binding
arbitration, which is the governing dispute-resolution process required under
the management agreement, and may be compelled to seek rescission of all
agreements with RSMC. The Company can offer no assurance that resolution of this
matter will not result in the termination of the management agreement or
otherwise adversely impact the Company.
In August 1997, the Company acquired certain fixed assets of and the right
to manage Fertility Centers of Illinois, S.C. ("FCI"), a physician group
practice comprised of six physicians and six locations in the Chicago, Illinois
area. The aggregate purchase price was approximately $8.6 million, consisting of
approximately $6.6 million in cash and 1,009,464 shares of Common Stock.
Approximately $8.0 million of the aggregate purchase price was allocated to
exclusive management rights and $559,000 was allocated to certain fixed assets.
Simultaneous with closing on the FCI transaction, the Company, on behalf of
FCI, completed its first in-market merger with the addition of Edward L. Marut,
MD to the FCI practice. The aggregate purchase price was $803,000 in cash, of
which $750,000 was allocated to exclusive management rights and $53,000 was
allocated to certain fixed assets.
In January 1998, the Company completed its second in-market merger with the
addition of two physicians to the FCI practice. The Company acquired certain
assets of Advocate Medical Group, S.C. ("AMG") and Advocate MSO, Inc. and
acquired the right to manage AMG's infertility practice conducted under the name
Center for Reproductive Medicine ("CFRM"). Simultaneous with closing on this
transaction, the Company amended its management agreement with FCI to include
two of the three physicians practicing under the name CFRM. The aggregate
purchase price was approximately $1.5 million, consisting of approximately $1.2
million in cash and 184,314 shares of Common Stock. The majority of the purchase
price was allocated to exclusive management rights.
In March 1998, the Company acquired the majority of the capital stock of
Shady Grove Fertility Centers, Inc. ("Shady Grove"), currently a Maryland
business corporation which provides management services, and formerly a Maryland
professional corporation engaged in providing infertility services. Prior to the
closing of the transaction, Shady Grove had entered into a twenty-year
management agreement with Levy, Sagoskin and Stillman, M.D., P.C. (the "Shady
Grove P.C."), an infertility physician group practice comprised of six
physicians and four locations surrounding the greater Washington, D.C. area. The
Company will acquire the balance of the Shady Grove capital stock on or about
November 1, 1998. The aggregate purchase price for all of the Shady Grove
capital stock was approximately $5.7 million, consisting of approximately $2.8
million in cash, $1.4 million in Common Stock, and $1.5 million in promissory
notes. The purchase price was allocated to the various assets and liabilities
assumed and the balance was allocated to exclusive management rights.
In regard to the shares of Company Common Stock issued in the above
transactions, with the exception of the shares issued in the Bay Area Fertility
transaction, Gerardo Canet, President and Chief Executive Officer of the
Company, was granted a voting proxy with respect to (i) the election of
Directors or any amendment to the Company's Certificate of Incorporation
affecting Directors and (ii) any change in stock options for management and
directors for a two-year period from each transaction's respective closing date.
The Company is evaluating and is engaged in discussions with regard to
several potential acquisitions. However, the Company has no agreements relating
to any acquisitions and there can be no assurance that any definitive agreements
will be entered into by the Company or that any additional acquisitions will be
consummated.
9
Clinical and Medical Services
RSC Network Sites
The RSC Network Sites offer conventional infertility and ART services and
either have, or subcontract with, a state- of-the-art laboratory providing the
necessary diagnostic and therapeutic services. Multi-disciplinary teams help
infertile couples identify and address distinct physical, emotional,
psychological and financial issues related to infertility. Following a
consultation session, a patient couple is advised as to the treatment that has
the greatest probability of success in light of the couple's specific
infertility problem. At this point, a couple may undergo conventional
infertility treatment or, if appropriate, may directly undergo ART treatment.
Infertility and ART Services
Conventional infertility procedures include diagnostic tests performed on
the female, such as endometrial biopsy, post-coital test, laparoscopy
examinations as well as hormone screens, and diagnostic tests performed on the
male, such as semen analysis and tests for sperm antibodies. Depending on the
results of the diagnostic tests performed, conventional services may include
fertility drug therapy, tubal surgery and intrauterine insemination ("IUI"). IUI
is a procedure utilized generally to address male factor or unexplained
infertility. Depending on the severity of the condition, the man's sperm is
processed to identify the most active sperm for insemination into the woman, who
must have a normal reproductive system for this procedure. Such conventional
infertility services are not classified as ART services and are traditionally
performed by infertility specialists.
Current types of ART services include in vitro fertilization ("IVF"),
gamete intrafallopian transfer ("GIFT"), zygote intrafallopian transfer
("ZIFT"), tubal embryo transfer ("TET"), frozen embryo transfer ("FET") and
donor egg and sperm programs. IVF is performed by combining an egg and sperm in
a laboratory and, if fertilization is successful, transferring the resulting
embryo into the woman's uterus. GIFT is performed by inserting an egg and sperm
directly into a woman's fallopian tube with a resulting embryo floating into the
uterus. ZIFT and TET are procedures in which an egg is fertilized in the
laboratory and the resulting embryo is then transferred to the woman's fallopian
tube. ZIFT and TET are identical except for the timing of the transfer of the
embryo. FET is a procedure whereby previously harvested embryos are transferred
to the woman's uterus. Women who are unable to produce eggs but who otherwise
have normal reproductive systems can use the donor egg program in which a donor
is recruited to provide eggs for fertilization that are transferred to the
recipient woman. Current techniques used in connection with ART services include
intra-cytoplasmic sperm injection, assisted hatching and cryopreservation of
embryos.
Development of New Clinical Services
Since 1989, the Company has sponsored research by Monash University in
Melbourne, Australia ("Monash") relating to the development of new ART services
and techniques. In July 1995, the Company entered into a three-year agreement
with Monash University which provides for Monash to conduct research in ART and
human fertility to be funded by a minimum annual payment of 220,000 Australian
dollars by the Company, the results to be jointly owned by the Company and
Monash. If certain milestones are met as specified in the agreement, the
Company's annual payment may be a maximum of 300,000 Australian dollars in year
two and 380,000 Australian dollars in year three. Minimum payments of 55,000
Australian dollars and payments for the attainment of certain research
milestones will be made quarterly throughout the term of the agreement from July
1, 1995 until June 30, 1998. See "Management's Discussion and Analysis of
Financial Condition and Results of Operations -- Liquidity and Capital
Resources." This research led to the world's first birth of a healthy infant
from immature oocyte (egg) technology in 1994. Immature oocyte services involve
using transvaginal ultrasound-guided aspiration to obtain immature oocytes from
a woman's ovaries, maturing and fertilizing of the oocytes in vitro and
transferring one or more of the resulting embryos into the woman's uterus for
development of a possible pregnancy. The Company anticipates that this
technology may, in certain circumstances, facilitate treatment of infertility by
stimulating follicular development without the use of drugs.
10
The Company also has sponsored research by Genzyme Genetics, a division of
Genzyme Corp., relating to preimplantation embryo genetic testing (the fusion of
advances in genetic testing and embryology). Pursuant to the terms of the
agreement, each party was required to fund certain costs relating to the
research projects as well as to contribute up to an aggregate of $300,000 to
fund the joint development program. This agreement terminated in December 1996.
The Company retains the right to technology developed prior to the termination.
The Company believes that preimplantation embryo genetic testing could
potentially offer infertile couples utilizing ART services a higher probability
of the birth of a healthy baby after fertilization, as well as offer fertile
couples at high risk of transmitting a genetic disorder the option to utilize
ART services to achieve pregnancy with a higher degree of certainty that the
fetus will be free of the genetic disorder for which it was tested.
Laboratory Services
All of the RSC Network Sites either have, or subcontract with, a
state-of-the-art laboratory for the Medical Practice to perform diagnostic
endocrine and andrology laboratory tests on patients receiving infertility and
ART services. Endocrine tests assess female hormone levels in blood samples,
while andrology tests analyze semen samples. These tests are often used by the
physician to determine an appropriate treatment plan. In addition, the majority
of the RSC Network Sites generate additional revenue by providing such endocrine
and andrology laboratory tests for non-affiliated physicians in the geographic
area.
AWM Network Site
The Company's AWM Network Site represents the initial clinical care model
for future AWM Network Sites, although it is still undergoing development. The
AWM Network Site focuses on the identification and treatment needs of peri- and
post-menopausal women and incorporates both preventative and curative health
care. The AWM Network Site combines specialty physicians and other health
professionals to offer a multidisciplinary approach to the diagnosis and
treatment of health care problems common to peri- and post-menopausal women.
Such problems include cardiovascular disease, incontinence, osteoporosis,
metabolic and endocrine conditions, and emotional and psychological disorders.
The AWM Division concentrates its efforts in the following three areas: clinical
care, clinical research and educational programs.
Clinical Care
The AWM Division has adopted a clinical care model based on the fact that
the health risk factors of peri- and post- menopausal women can be objectively
measured and once identified, treated. Clinical services include complete
cardiovascular assessment, urodynamic analysis, bone densitometry, hormone
replacement therapy, physical therapy, exercise stress testing, nutrition
assessment/dietary recommendation, psychological/sexual counseling, as well as
mammography and laboratory tests designed to provide early detection of cancers
of the breast, colon and reproductive organs. Clinical services are provided at
the AWM Network Site by physicians and health professionals who specifically
focus on peri-and post-menopausal women.
Clinical Research
The AWM Division contracts with major pharmaceutical companies to perform
clinical trials on new drugs under development to determine the safety and
efficacy of such drugs. The Company believes that participation in these
clinical trials provides access to advanced therapies for patients not otherwise
readily available and generates additional revenue for the Company and the
Medical Practices.
Educational Programs
The AWM Division offers multifaceted educational programs designed to
increase patient compliance, attract new patients and educate peri- and
post-menopausal women on related health care and quality of life issues. For
example, the AWM Division offers support groups, lectures, resource materials
11
and products designed specifically for the needs of adult women. In addition,
the AWM Division has a 1-900 number available to answer common questions women
have regarding their own health.
Network Site Agreements
In establishing a Network Site, the Company typically (i) acquires certain
assets of a Medical Practice, (ii) enters into a long-term management agreement
with the Medical Practice under which the Company provides comprehensive
management services to the Medical Practice, (iii) requires that the Medical
Practice enter into long-term employment agreements containing non-compete
provisions with the affiliated physicians and (iv) assumes the principal
administrative, financial and general management functions of the Medical
Practice. Typically, the Medical Practice contracting with the Company is a
professional corporation of which the physicians are the sole shareholders.
Management Agreements
Typically, the management agreements obligate the Company to pay a fixed
sum for the exclusive right to manage the Medical Practice, a portion or all of
which is paid at the contract signing with any balance to be paid in future
annual installments. The agreements are typically for terms of ten to 25 years
and are generally subject to termination due to insolvency, bankruptcy or
material breach of contract. Generally, no shareholder of the Medical Practice
may assign his interest in the Medical Practice without the Company's prior
written consent.
The management agreements provide that all patient medical care at a
Network Site is provided by the physicians at the Medical Practice and that the
Company generally is responsible for the management and operation of all other
aspects of the Network Site. The Company provides the equipment, facilities and
support necessary to operate the Medical Practice and employs substantially all
such other non-physician personnel as are necessary to provide technical,
consultative and administrative support for the patient services at the Network
Site. Under certain management agreements, the Company is committed to provide a
clinical laboratory. Under the management agreements, the Company may also
advance funds to the Medical Practice to provide new services, utilize new
technologies, fund projects, purchase the net accounts receivable, provide
working capital or fund mergers with other physicians or physician groups.
Under the Company's current form of management agreement, which is in use
at seven Network Sites, the Company receives as compensation for its management
services a three-part management fee comprised of: (i) a fixed percentage of net
revenues generally equal to 6%; (ii) reimbursed costs of services (costs
incurred in managing a Network Site and any costs paid on behalf of the Network
Site); and (iii) a fixed or variable percentage of earnings after the Company's
management fees and any guaranteed physician compensation, or an additional
fixed or variable percentage of net revenues which generally results in the
Company receiving up to an additional 15% of net revenues.
Under another form of management agreement, which had been in use at two
Network Sites during 1997, the Company recorded all patient service revenues
and, out of such revenues, the Company paid the Medical Practices' expenses,
physicians' and other medical compensation, direct materials and certain
hospital contract fees. Specifically, under the management agreement for the
Boston Network Site, the Company guaranteed a minimum physician compensation
based on an annual budget jointly determined by the Company and the physicians.
Remaining revenues, if any, which represented the Company's management fees,
were used by the Company for other direct administrative expenses which were
recorded as costs of services. Under the management agreement for the Long
Island Network Site, the Company's management fee was payable only out of
remaining revenues, if any, after the payment of all expenses of the Medical
Practice. Under these arrangements, the Company had been liable for payment of
all liabilities incurred by the Medical Practices and had been at risk for any
losses incurred in the operation thereof. Effective in October 1997 and January
1998, due to changes in the management agreements related to the Long Island and
Boston Network Sites, respectively, the Company will no longer display patient
service revenues of the Long Island and Boston Medical Practices in "Revenues,
net" in the Company's consolidated statement of operations. The revised
management agreements provide for the Company to receive a specific management
fee which the Company will report in "Revenues, net" in its consolidated
statement of operations. Under the revised management agreement for the Long
12
Island Network Site, as compensation for its management services the Company
will receive a fixed fee (initially equal to $345,000 per annum), subject to
annual increases, plus reimbursed costs of services. Under the revised
management agreement for the Boston Network Site, as compensation for its
management services the Company will receive a three- part management fee
consistent to the majority of the Company's existing management agreements. The
revised agreements provide for increased incentives and risk-sharing for the
Company's affiliated Medical Providers.
In addition, two of the Company's Network Sites are affiliated with medical
centers. Under one of these management agreements, the Company primarily
provides endocrine testing and administrative and finance services for a fixed
percentage of revenues, equal to 15% of net revenues, and reimbursed costs of
services. Under the second of these management agreements, the Company's
revenues are derived from certain ART laboratory services performed; the Company
directly bills patients for these services, and out of these revenues, the
Company pays its direct costs.
Physician Employment Agreements
Physician employment agreements between the Medical Practices and the
physicians generally provide for an initial term ranging from three to five
years, which may be automatically renewed for successive intervals unless the
physician or the Medical Practice elects not to renew or such agreement is
otherwise terminated for cause or the death or disability of a physician. The
physicians are paid based upon either the number of procedures performed or
other negotiated formulas agreed upon between the physicians and the Medical
Practices, and the Medical Practices provide the physicians with health, death
and disability insurance and other benefits. The Medical Practices are obligated
to obtain and maintain professional liability insurance coverage which is
procured on behalf of the physicians. Pursuant to the employment agreements, the
physicians agree not to compete with the Medical Practices with whom they have
contracted during the term of the agreement and for a certain period following
the termination of such employment agreement. In addition, the agreements
contain customary confidentiality provisions.
In Florida, where the Company's current AWM Network Site is located, there
are currently no prohibitions restricting commercial enterprises from owning
medical service companies. As a result, the Company was able to acquire a direct
ownership interest in the Medical Practice at the AWM Network Site. The Company
entered into employment agreements (containing customary non-compete provisions)
directly with the physicians at the AWM Network Site.
Personal Responsibility Agreements
Commencing with management agreements entered into during 1997, in order to
protect its investment and commitment of resources, the Company has entered into
a Personal Responsibility Agreement (a "PR Agreement") with each of the
physicians of the Medical Practice. If the physician should cease to practice
medicine through the respective contracted Medical Practice during the first
five years of the related management agreement, except as a result of death or
permanent disability, the PR Agreement obligates the physician to repay a
ratable portion of the fee paid by the Company to the Medical Practice for the
exclusive right to manage such Medical Practice. The PR Agreement also contains
covenants for the physician not to compete with the Company during the term of
his or her employment agreement with the Medical Practice and for a certain
period thereafter.
Affiliate Care/Satellite Service Agreements
Medical Practices at the Network Sites may also have affiliate care
agreements and satellite service agreements with physicians who are not employed
by the Medical Practices or the Company located in the geographic area of the
Network Sites. Under an affiliate care agreement, the Medical Practice contracts
with a physician for the Medical Practice to provide certain ART services for
the physician's patients. Under a satellite service agreement, the Medical
Practice contracts with a physician for such physician to provide specific
services for the Medical Practice's patients, such as ultrasound monitoring,
blood drawing and endocrine testing.
13
Reliance on Third-Party Vendors
The RSC Network Sites are dependent on three third-party vendors that
produce fertility medications (Lupron, Metrodin and Fertinex) that are vital to
the provision of infertility and ART services. Should any of these vendors
experience a supply shortage, it may have an adverse impact on the operations of
the RSC Network Sites. To date, the RSC Network Sites have not experienced any
such adverse impacts.
Competition
The business of providing health care services is intensely competitive, as
is the physician practice management industry, and each is continuing to evolve
in response to pressures to find the most cost-effective method of providing
quality health care. The Company experiences competitive pressures for the
acquisition of the assets of, and the provision of management services to,
additional physician practices. Although the Company focuses on physician
practices that provide infertility, ART and adult women's reproductive health
care services, it competes for management contracts with other physician
practice management companies, including those focused on infertility and ART
services, as well as hospitals and hospital-sponsored management services
organizations. If federal or state governments enact laws that attract other
health care providers to the managed care market, the Company may encounter
increased competition from other institutions seeking to increase their presence
in the managed care market and which have substantially greater resources than
the Company. There can be no assurance that the Company will be able to compete
effectively with its current competitors, that additional competitors will not
enter the market, or that such competition will not make it more difficult to
acquire the assets of, and provide management services for, physician practices
on terms beneficial to the Company.
The infertility industry is highly competitive and characterized by
technological improvements. New ART services and techniques may be developed
that may render obsolete the ART services and techniques currently employed at
the RSC Network Sites. Competition in the areas of infertility and ART services
is largely based on pregnancy rates and other patient outcomes. Accordingly, the
ability of a Medical Practice to compete is largely dependent on its ability to
achieve adequate pregnancy rates and patient satisfaction levels.
A number of physician practice management companies have emerged with a
focus on routine obstetrics and gynecology. In addition, other health care
corporations, medical providers and physician practice management companies may
decide to enter into the adult women's health care market, particularly if the
Company's concept to establish a multi-disciplinary approach to treat peri- and
post-menopausal women gains market acceptance. In addition, private practice
physician groups often contract with pharmaceutical companies to perform
clinical trials relating to women's health care. These physician group practices
compete with the AWM Network Site in obtaining contracts for clinical trials.
Effects of Third-Party Payor Contracts
Traditionally, ART services have been paid for directly by patients and
conventional infertility services have been largely covered by indemnity
insurance or managed care payors. Currently, there are several states that
mandate offering certain benefits of varying degrees for infertility and ART
services. In some cases, the mandate is limited to an obligation on the part of
the payor to offer the benefit to employers. In Massachusetts, Rhode Island,
Maryland, Arkansas, Illinois and Hawaii, the mandate requires coverage of
conventional infertility services as well as certain ART services.
Over the past few years much attention has been focused on clinical
outcomes in managed care. Infertility is a disorder which naturally lends itself
to developing a managed care plan. First, infertility has a clearly defined
endpoint: an infertile couple either conceives or does not conceive. Second, the
treatment regimens and protocols used for treating infertile couples have
predictable outcomes that make it possible to develop statistical tables for the
probability of success. Third, it is possible to develop rational treatment
plans over a limited period of time for infertile couples. However, there can be
no assurance that third-party payors will increase reimbursement coverage for
ART services.
14
The RSC Division has invested in information technology that takes into
consideration the cost structure of a full service practice, the probability of
achieving clinical success, and defined treatment plans which result in improved
outcomes and reduced costs. The Company estimates that the majority of the
couples participating in infertility and ART services at an RSC Network Site,
other than in California, Massachusetts and Illinois, have greater than 50% of
their costs reimbursed by their health care insurance carrier. In California,
the majority of the patient costs are not reimbursed. In Massachusetts and
Illinois, where comprehensive infertility and ART services insurance
reimbursement is mandated, virtually all patient costs are reimbursed.
The majority of diagnostic and therapeutic services offered through the
Company's AWM Division are currently covered by third-party payors. As these
services emphasize prevention and screening, the Company believes that they will
continue to be covered by third-party payors.
Government Regulation
As a participant in the health care industry, the Company's operations and
its relationships with the Medical Practices are subject to extensive and
increasing regulation by various governmental entities at the federal, state and
local levels. The Company believes its operations and those of the Medical
Practices are in material compliance with applicable health care laws.
Nevertheless, the laws and regulations in this area are extremely complex and
subject to changing interpretation and many aspects of the Company's business
and business opportunities have not been the subject of federal or state
regulatory review or interpretation. Accordingly, there is no assurance that the
Company's operations have been in compliance at all times with all such laws and
regulations. In addition, there is no assurance that a court or regulatory
authority will not determine that the Company's past, current or future
operations violate applicable laws or regulations. If the Company's
interpretation of the relevant laws and regulations is inaccurate, there could
be a material adverse effect on the Company's business, financial condition and
operating results. There can be no assurance that such laws will be interpreted
in a manner consistent with the Company's practices. There can be no assurance
that a review of the Company or the Medical Practices by courts or regulatory
authorities will not result in a determination that would require the Company or
the Medical Practices to change their practices. There also can be no assurance
that the health care regulatory environment will not change so as to restrict
the Company's or the Medical Practices' existing operations or their expansions.
Any significant restructuring or restriction could have a material adverse
effect on the Company's business, financial condition and operating results.
Corporate Practice of Medicine Laws. The Company's operations in
Massachusetts, New York, New Jersey, Pennsylvania, District of Columbia, Texas,
California, Illinois, Maryland and Virginia may be subject to prohibitions
relating to the corporate practice of medicine. The laws of these states
prohibit corporations other than professional corporations or associations from
practicing medicine or exercising control over physicians, and prohibit
physicians from practicing medicine in partnership with, or as employees of, any
person not licensed to practice medicine and may prohibit a corporation other
than professional corporations or associations (or, in some states, limited
liability companies) from acquiring the goodwill of a medical practice. In the
context of management contracts between a corporation not authorized to practice
medicine and the physicians or their professional entity, the laws of most of
these states focus on the extent to which the corporation exercises control over
the physicians and on the ability of the physicians to use their own
professional judgment as to diagnosis and treatment. The Company believes its
operations are in material compliance with applicable state laws relating to the
corporate practice of medicine. The Company performs only non-medical
administrative services, and in certain circumstances, clinical laboratory
services. The Company does not represent to the public that it offers medical
services, and the Company does not exercise influence or control over the
practice of medicine by physicians with whom it contracts in these states. In
each of these states, the Medical Practice is the sole employer of the
physicians, and the Medical Practice retains the full authority to direct the
medical, professional and ethical aspects of its medical practice. However,
although the Company believes its operations are in material compliance with
applicable state corporate practice of medicine laws, the laws and their
interpretations vary from state to state, and they are enforced by regulatory
authorities that have broad discretionary authority. There can be no assurance
that these laws will be interpreted in a manner consistent with the Company's
practices or that other laws or regulations will not be enacted in the future
that could have a material adverse effect on the Company's business, financial
condition and operating results. If a corporate practice of medicine law is
15
interpreted in a manner that is inconsistent with the Company's practices, the
Company would be required to restructure or terminate its relationship with the
applicable Medical Practice in order to bring its activities into compliance
with such law. The termination of, or failure of the Company to successfully
restructure, any such relationship could result in fines or a loss of revenue
that could have a material adverse effect on the Company's business, financial
condition and operating results. In addition, expansion of the Company's
operations to new jurisdictions could require structural and organizational
modifications of the Company's relationships with the Medical Practices in order
to comply with additional state statutes.
Fee-Splitting Laws. The Company's operations in the states of New York,
California and Illinois are subject to express fee-splitting prohibitions. The
laws of these states prohibit physicians from splitting professional fees with
non- physicians and health care professionals not affiliated with the physician
performing the services generating the fees. In New York, this prohibition
includes any fee the Company may receive from the Medical Practices which is set
in terms of a percentage of, or otherwise dependent on, the income or receipts
generated by the physicians. In certain states, such as California and New York,
any fees that a non-physician receives in connection with the management of a
physician practice must bear a reasonable relationship to the services rendered,
based upon the fair market value of such services. Under Illinois law, the
courts have broadly interpreted the fee-splitting prohibition in that state to
prohibit compensation arrangements that include (i) fees that a management
company may receive based on a percentage of net profits generated by
physicians, despite the performance of legitimate management services, (ii) fees
received by a management company engaged in obtaining referrals for its
physician where the fees are based on a percentage of certain billings collected
by the physician and (iii) purchase price consideration to a seller of a medical
practice based on a percentage of the buyer's revenues following the
acquisition. Several of the other states where the Company has operations, such
as Texas and New Jersey, do not expressly prohibit fee-splitting but do have
corporate practice of medicine prohibitions. In these states, regulatory
authorities frequently interpret the corporate practice of medicine prohibition
to encompass fee-splitting, particularly in arrangements where the compensation
charged by the management company is not reasonably related to the services
rendered.
The Company believes that its current operations are in material compliance
with applicable state laws relating to fee-splitting prohibitions. However,
there can be no assurance that these laws will be interpreted in a manner
consistent with the Company's practices or that other laws or regulations will
not be enacted in the future that could have a material adverse effect on the
Company's business, financial condition and operating results. If a
fee-splitting law is interpreted in a manner that is inconsistent with the
Company's practices, the Company could be required to restructure or terminate
its relationship with the applicable Medical Practice in order to bring its
activities into compliance with such law. The termination of, or failure of the
Company to successfully restructure, any such relationship could have a material
adverse effect on the Company's business, financial condition and operating
results. In addition, expansion of the Company's operations to new jurisdictions
could require structural and organizational modifications of the Company's
relationships with the Medical Practices in order to comply with additional
state statutes.
With respect to the Chicago and Shady Grove Network Sites, the management
agreement between the Company and the affiliated Medical Practice provides that
the Company will be paid a base fee equal to a fixed percentage of the revenues
at the Network Site and, as additional compensation, an additional variable
percentage of such revenues that declines to zero to the extent the costs
relating to the management of the Medical Practice increase as a percentage of
total revenues. The Company and the respective Medical Practice have agreed that
if such compensation arrangement were found to be illegal, unenforceable,
against public policy or forbidden by law, the management fee would be an annual
fixed fee to be mutually agreed upon, not less than $1.0 million per year,
retroactive to the effective date of the agreement. In such event, the
management fees derived from these Medical Practices may decrease. Because the
Company can not predict or guarantee the actions of regulatory authorities,
there is a risk that a regulatory authority may disagree with the compensation
arrangement and challenge the same. In the event of such challenge, the
compensation arrangement may not be upheld. Moreover, if a management agreement
was amended to provide for an annual fixed fee payable to the Company, the
contribution from the Network Site could be materially reduced.
16
Federal Antikickback Law. The Company is subject to the laws and
regulations that govern reimbursement under the Medicare and Medicaid programs.
Currently less than 5% of the revenues of the Medical Practices are derived from
Medicare and none of such revenues are derived from Medicaid. Federal law (the
"Federal Antikickback Law") prohibits, with some exceptions, the solicitation or
receipt of remuneration in exchange for, or the offer or payment of remuneration
to induce, the referral of federal health care program beneficiaries, including
Medicare or Medicaid patients, or in return for the recommendation, arrangement,
purchase, lease or order of items or services that are covered by Medicare,
Medicaid and other federal and state health programs.
With respect to the Federal Antikickback Law, the Office of the Inspector
General ("OIG") has promulgated regulatory "safe harbors" under the Federal
Antikickback Law that describe payment practices between health care providers
and referral sources that will not be subject to criminal prosecution and that
will not provide the basis for exclusion from the federal health care programs.
Relationships and arrangements that do not fall within the safe harbors are not
illegal per se, but will subject the activity to greater governmental scrutiny.
Many of the parties with whom the Company contracts refer or are in a position
to refer patients to the Company. Although the Company believes that it is in
material compliance with the Federal Antikickback Law, there can be no assurance
that such law or the safe harbor regulations promulgated thereunder will be
interpreted in a manner consistent with the Company's practices. The breadth of
the Federal Antikickback Law, the paucity of court decisions interpreting the
law and the safe harbor regulations, and the limited nature of regulatory
guidance regarding the safe harbor regulations have resulted in ambiguous and
varying interpretations of the Federal Antikickback Law. The OIG or the
Department of Justice ("DOJ") could determine that the Company's past or current
policies and practices regarding its contracts and relationships with the
Medical Practices violate the Federal Antikickback Law. In such event, no
assurance can be given that the Company's interpretation of these laws will
prevail. The failure of the Company's interpretation of the Federal Antikickback
Law to prevail could have a material adverse effect on the Company's business,
financial condition and operating results.
Federal Referral Laws. Federal law also prohibits, with some exceptions,
physicians from referring Medicare or Medicaid patients to entities for certain
enumerated "designated health services" with which the physician (or members of
his or her immediate family) has an ownership or investment relationship, and an
entity from filing a claim for reimbursement under the Medicare or Medicaid
programs for certain enumerated designated health services if the entity has a
financial relationship with the referring physician. Significant prohibitions
against physician referrals were enacted by the United States Congress in the
Omnibus Budget Reconciliation Act of 1993. These prohibitions, known as "Stark
II," amended prior physician self-referral legislation known as "Stark I" by
dramatically enlarging the field of physician-owned or physician-interested
entities to which the referral prohibitions apply. The designated health
services enumerated under Stark II include: clinical laboratory services,
radiology services, radiation therapy services, physical and occupational
therapy services, durable medical equipment, parenteral and enteral nutrients,
equipment and supplies, prosthetics, orthotics, outpatient prescription drugs,
home health services and inpatient and outpatient hospital services.
Significantly, certain "in-office ancillary services" furnished by group
practices are excepted from the physician referral prohibitions of Stark II. The
Company believes that its practices either fit within this and other exceptions
contained in such statutes, or have been structured so as to not implicate the
statute in the first instance, and therefore, the Company believes it is in
compliance with such legislation. Nevertheless, future regulations or
interpretations of current regulations could require the Company to modify the
form of its relationships with the Medical Practices. Moreover, the violation of
Stark I or Stark II by the Medical Practices could result in significant fines,
loss of reimbursement and exclusion from the Medicare and Medicaid programs
which could have a material adverse effect on the Company.
Recently, Congress enacted the Health Insurance Portability and Accounting
Act of 1996, which includes an expansion of certain fraud and abuse provisions
(including the Federal Antikickback Law and Stark II) to other federal health
care programs and a separate criminal statute prohibiting "health care fraud."
Due to the breadth of the statutory provisions of the fraud and abuse laws and
the absence of definitive regulations or court decisions addressing the type of
arrangements by which the Company and its Medical Practices conduct and will
conduct their business, from time to time certain of their practices may be
subject to challenge under these laws.
17
False Claims. Under separate federal statutes, submission of claims for
payment that are "not provided as claimed" may lead to civil money penalties,
criminal fines and imprisonment and/or exclusion from participation in the
Medicare, Medicaid and other federally-funded health care programs. These false
claims statutes include the Federal False Claims Act, which allows any person to
bring suit alleging false or fraudulent Medicare or Medicaid claims or other
violations of the statute and to share in any amounts paid by the entity to the
government in fines or settlement. Such qui tam actions have increased
significantly in recent years and have increased the risk that a health care
company will have to defend a false claims action, pay fines or be excluded from
participation in the Medicare and/or Medicaid programs as a result of an
investigation arising out of such an action.
State Antikickback and Self-Referral Laws. The Company is also subject to
state statutes and regulations that prohibit kickbacks in return for the
referral of patients in each state in which the Company has operations. Several
of these laws apply to services reimbursed by all payors, not simply Medicare or
Medicaid. Violations of these laws may result in prohibition of payment for
services rendered, loss of licenses as well as fines and criminal penalties.
State statutes and regulations that prohibit payments intended to induce
the referrals of patients to health care providers range from statutes and
regulations that are substantially the same as the federal laws and the safe
harbor regulations to regulations regarding unprofessional conduct. These laws
and regulations vary significantly from state to state, are often vague, and, in
many cases, have not been interpreted by courts or regulatory agencies. Adverse
judicial or administrative interpretations of such laws could require the
Company to modify the form of its relationships with the Medical Practices or
could otherwise have a material adverse effect on the Company's business,
financial condition and operating results.
In addition, New York, New Jersey, California, Florida, Pennsylvania,
Illinois, Maryland and Virginia have enacted laws on self-referrals that apply
generally to the health care profession, and the Company believes it is likely
that more states will follow. These state self-referral laws include outright
prohibitions on self-referrals similar to Stark or a simple requirement that
physicians or other health care professionals disclose to patients any financial
relationship the physicians or health care professionals have with a health care
provider that is being recommended to the patients. The Company's operations in
New York, New Jersey, California and Illinois have laboratories which are be
subject to prohibitions on referrals for services in which the referring
physician has a beneficial interest. However, New York, New Jersey, California
and Maryland have an exception for "in-office ancillary services" similar to the
federal exception and in Illinois, the self-referral laws do not apply to
services within the health care worker's office or group practice or to outside
services as long as the health care worker directly provides health services
within the entity and will be personally involved with the provision of care to
the referred patient. The Company believes that the laboratories in its
operations fit within exceptions contained in such statutes or are not subject
to the statute at all. Each of the laboratories in the states in which these
self-referral laws apply are owned by the Medical Practice in that state and are
located in the office of such Medical Practice. However, there can be no
assurance that these laws will be interpreted in a manner consistent with the
Company's practices or that other laws or regulations will not be enacted in the
future that could have a material adverse effect on the Company's business,
financial condition or operating results. In addition, expansion of the
Company's operations to new jurisdictions could require structural and
organizational modifications of the Company's relationships with the Medical
Practices in order to comply with new or revised state statutes.
Antitrust Laws. In connection with corporate practice of medicine laws
referred to above, the Medical Practices with whom the Company is affiliated
necessarily are organized as separate legal entities. As such, the Medical
Practices may be deemed to be persons separate both from the Company and from
each other under the antitrust laws and, accordingly, subject to a wide range of
laws that prohibit anti-competitive conduct among separate legal entities. The
Company believes it is in compliance with these laws and intends to comply with
any state and federal laws that may affect its development of health care
networks. There can be no assurance, however, that a review of the Company's
business by courts or regulatory authorities would not have a material adverse
effect on the operation of the Company and the Medical Practices.
18
Government Regulation of ART Services. With the increased utilization of
ART services, government oversight of the ART industry has increased and
legislation has been adopted or is being considered in a number of states
regulating the storage, testing and distribution of sperm, eggs and embryos. The
Company believes it is currently in compliance with such legislation where
failure to comply would subject the Company to sanctions by regulatory
authorities, which could have a material adverse effect on the Company's
business, financial condition and operating results.
Regulation of Clinical Laboratories. The Company's and the Medical
Practices' endocrine and embryology clinical laboratories are subject to
governmental regulations at the federal, state and local levels. The Company
and/or the Medical Practices at each Network Site have obtained, and from time
to time renew, federal and/or state licenses for the laboratories operated at
the Network Sites.
The Clinical Laboratory Improvement Amendments of 1988 ("CLIA 88") extended
federal oversight to all clinical laboratories, including those that handle
biological matter, such as eggs, sperm and embryos, by requiring that all
laboratories be certified by the government, meet governmental quality and
personnel standards, undergo proficiency testing, be subject to biennial
inspections, and remit fees. For the first time, the federal government is
regulating all laboratories, including those operated by physicians in their
offices. Rather than focusing on location, size or type of laboratory, this
extended oversight is based on the complexity of the test the laboratories
perform. CLIA 88 and the 1992 implementing regulations established a more
stringent proficiency testing program for laboratories and increased the range
and severity of sanctions for violating the federal licensing requirements. A
laboratory that performs highly complex tests must meet more stringent
requirements, while those that perform only routine "waived" tests may apply for
a waiver from most requirements of CLIA 88.
The sanctions for failure to comply with CLIA and these regulations include
suspension, revocation or limitation of a laboratory's CLIA certificate
necessary to conduct business, significant fines or criminal penalties. The loss
of license, imposition of a fine or future changes in such federal, state and
local laws and regulations (or in the interpretation of current laws and
regulations) could have a material adverse effect on the Company.
In addition, the Company's clinical laboratory activities are subject to
state regulation. CLIA 88 permits a state to require more stringent regulations
than the federal law. For example, state law may require that laboratory
personnel meet certain more stringent qualifications, specify certain quality
control standards, maintain certain records, and undergo additional proficiency
testing.
The Company believes it is in material compliance with the foregoing
standards.
Other Licensing Requirements. Every state imposes licensing requirements on
individual physicians, and some regulate facilities and services operated by
physicians. In addition, many states require regulatory approval, including
certificates of need, before establishing certain types of health care
facilities, offering certain services, or making certain capital expenditures in
excess of statutory thresholds for health care equipment, facilities or
services. To date, the Company has not been required to obtain certificates of
need or similar approvals for its activities. In connection with the expansion
of its operations into new markets and contracting with managed care
organizations, the Company and the Medical Practices may become subject to
compliance with additional regulations. Finally, the Company and the Medical
Practices are subject to federal, state and local laws dealing with issues such
as occupational safety, employment, medical leave, insurance regulation, civil
rights and discrimination, medical waste and other environmental issues.
Increasingly, federal, state and local governments are expanding the regulatory
requirements for businesses, including medical practices. The imposition of
these regulatory requirements may have the effect of increasing operating costs
and reducing the profitability of the Company's operations.
Future Legislation and Regulation. As a result of the continued escalation
of health care costs and the inability of many individuals to obtain health
insurance, numerous proposals have been or may be introduced in the United
States Congress and state legislatures relating to health care reform. There can
19
be no assurance as to the ultimate content, timing or effect of any health care
reform legislation, nor is it possible at this time to estimate the impact of
potential legislation, which may be material, on the Company.
Liability and Insurance
The provision of health care services entails the substantial risk of
potential claims of medical malpractice and similar claims. The Company does
not, itself, engage in the practice of medicine or assume responsibility for
compliance with regulatory requirements directly applicable to physicians and
requires associated Medical Practices to maintain medical malpractice insurance.
In general, the Company has established a program that provides the Medical
Practices with such required insurance. However, in the event that services
provided at the Network Sites or any affiliated Medical Practice are alleged to
have resulted in injury or other adverse effects, the Company is likely to be
named as a party in a legal proceeding.
Although the Company currently maintains liability insurance that it
believes is adequate as to both risk and amount, successful malpractice claims
could exceed the limits of the Company's insurance and could have a material
adverse effect on the Company's business, financial condition or operating
results. Moreover, there can be no assurance that the Company will be able to
obtain such insurance on commercially reasonable terms in the future or that any
such insurance will provide adequate coverage against potential claims. In
addition, a malpractice claim asserted against the Company could be costly to
defend, could consume management resources and could adversely affect the
Company's reputation and business, regardless of the merit or eventual outcome
of such claim. In addition, in connection with the acquisition of the assets of
certain Medical Practices, the Company may assume certain of the stated
liabilities of such practice. Therefore, claims may be asserted against the
Company for events related to such practice prior to the acquisition by the
Company. The Company maintains insurance coverage related to those risks that it
believes is adequate as to the risks and amounts, although there can be no
assurance that any successful claims will not exceed applicable policy limits.
There are inherent risks specific to the provision of ART services. For
example, the long-term effects of the administration of fertility medication,
integral to most infertility and ART services, on women and their children are
of concern to certain physicians and others who fear the medication may prove to
be carcinogenic or cause other medical problems. Currently, fertility medication
is critical to most ART services and a ban by the United States Food and Drug
Administration or any limitation on its use would have a material adverse effect
on the Company. Further, ART services increase the likelihood of multiple
births, which are often premature and may result in increased costs and
complications.
Employees
As of March 16, 1998, the Company had 372 employees, 4 of whom are
executive management, 343 are employed at the Network Sites and 29 are employed
at the Company's headquarters. Of the Company's employees, 60 persons at the
Network Sites and 4 at the Company's headquarters are employed on a part-time
basis. The Company is not party to any collective bargaining agreement and
believes its employee relationships are good.
ITEM 2. Properties
The Company's headquarters and executive offices are in Purchase, New York,
where it occupies approximately 8,000 square feet under a lease expiring April
14, 2000 at a monthly rental of $12,671, increasing annually to $15,339 per
month in January 1999.
The Company leases, subleases, and/or occupies, pursuant to its management
agreements, each Network Site location from either third-party landlords or from
the Medical Provider(s). Costs associated with these agreements are included in
either "Medical Practice retainage" or in "Cost of services rendered" and, with
regard to agreements entered into in 1995 and thereafter, such costs are
typically reimbursed to the Company as part of its management fee; reimbursed
costs are included in "Revenues, net".
The Company believes its executive offices and the space occupied by the
Network Sites are adequate.
20
ITEM 3. Legal Proceedings
In November 1994, the Company was served with a complaint in a matter
captioned Karlin v. IVF America, et. al., pending in the Supreme Court of the
State of New York, County of Westchester. The suit also named, as co-defendants,
Vicki L. Baldwin, a Director of the Company, United Hospital and Dr. John
Stangel. The action purported to be a class- action, initiated by plaintiffs on
behalf of themselves and a class of persons similarly situated. The Complaint
alleged that the defendants, individually and collectively, had, in the
communication of clinical outcome statistics, inaccurately stated success rates
or failed to communicate medical risks attendant to ART procedures. These
allegations gave rise to the central issue of the case, that of informed
consent. The plaintiffs' application for class certification was denied by the
Court. The Court ruled that the potential class of patients treated at the
Westchester Network Site did not meet the criteria for class action status as
required by New York law. The plaintiffs appealed this decision. In June 1997,
the Appellate Division of the Supreme Court of the State of New York, Second
Department affirmed the lower court decision. As a result of prior court
proceedings and the June 1997 decision, the plaintiffs are left with lack of
informed consent as the sole claim against defendants for which defendants have
moved for summary judgment based on the untimeliness of this claim.
There are a few other legal proceedings to which the Company is a party. In
the Company's view, the claims asserted and the outcome of these proceedings
will not have a material adverse effect on the financial position or the results
of operations of the Company.
ITEM 4. Submission of Matters to a Vote of Security Holders
None.
21
PART II
ITEM 5. Market for Registrant's Common Equity and Related Stockholder Matters
The Company's Common Stock has been traded on the Nasdaq National Market
under the symbol "INMD" since the Company's formal name change in May 1996 and
prior to the name change under the symbol "IVFA" since May 21, 1993. Prior
thereto, the Company's Common Stock had been trading on the Nasdaq SmallCap
Market since October 8, 1992. The following table sets forth the high and low
closing sales price for the Common Stock, as reported on the Nasdaq National
Market.
Common Stock
------------
High Low
---- ---
1996
First Quarter........... $3.75 $2.31
Second Quarter.......... 4.18 2.00
Third Quarter........... 3.50 2.25
Fourth Quarter.......... 2.62 1.25
1997
First Quarter........... $2.50 $1.50
Second Quarter.......... 1.88 1.34
Third Quarter........... 2.50 1.41
Fourth Quarter.......... 2.38 1.31
On March 16, 1998, there were approximately 276 holders of record of the
Common Stock, excluding beneficial owners of shares registered in nominee or
street name.
The Company currently anticipates that it will retain all available funds
for use in the operation of its business and for potential acquisitions, and
therefore, does not anticipate paying any cash dividends on its Common Stock for
the foreseeable future. In addition, no dividends may be paid on the Common
Stock until full dividends have been paid on the Convertible Preferred Stock.
Dividends on the Convertible Preferred Stock are payable at the rate of
$0.80 per share per annum, quarterly on the fifteenth day of August, November,
February and May of each year commencing August 15, 1993. In May 1995, as a
result of the Company's Board of Directors suspending four quarterly dividend
payments, holders of the Convertible Preferred Stock became entitled to one vote
per share of Convertible Preferred Stock on all matters submitted to a vote of
stockholders, including election of directors; once in effect, such voting
rights are not terminated by the payment of all accrued dividends. The Company
does not anticipate the payment of any cash dividends on the Convertible
Preferred Stock in the foreseeable future. As of December 31, 1997, fourteen
quarterly dividend payments have been suspended resulting in approximately
$464,000 of dividend payments being in arrears.
22
ITEM 6. Selected Financial Data
The following selected financial data are derived from the Company's
consolidated financial statements and should be read in conjunction with the
financial statements, related notes, and other financial information included
elsewhere in this Annual Report on Form 10-K.
Statement of Operations Data:
Years ended December 31,
-----------------------------------------------------------
1997 1996 1995 1994 1993
-------- -------- -------- --------- ------
(in thousands, except per share amounts)
Revenues, net................................ $24,169 $18,343 $16,711 $17,578 $16,025
Medical Provider retainage..................` 1,531 2,680 3,063 3,824 4,605
------- ------- ------- ------- -------
Revenues after Medical Provider retainage.... 22,638 15,663 13,648 13,754 11,420
Costs of services rendered................... 17,251 12,398 9,986 10,998 10,222
------- ------- ------- ------- -------
Network Sites' contribution.................. 5,387 3,265 3,662 2,756 1,198
------- ------- ------- ------- -------
General and administrative expenses.......... 4,192 4,339 3,680 3,447 3,079
Equity in loss of Partnerships (1)........... -- -- -- -- 1,793
Total other (income) expenses
(including income taxes)................... 821 416 (88) 123 923
------- ------- ------- ------- -------
Net income (loss)............................ 374 (1,490) 70 (814) (4,597)
Less: Dividends accrued and/or paid on
Preferred Stock........................... 133 132 600 1,146 748
------- ------- ------- ------- -------
Net income (loss) applicable to Common
Stock .................................... $ 241 $(1,622) $ (530) $(1,960) $(5,345)
======= ======= ======== ======= =======
Basic earnings (loss) per share before
consideration for induced conversion
of Preferred Stock (2).................... $ 0.02 $ (0.21) $ (.09) $ (0.32) $ (2.01)
======= ======= ======== ======= =======
Diluted earnings (loss) per share before
consideration for induced conversion
of Preferred Stock (2).................... $ 0.02 $ (0.68) $ (.09) $ (0.32) $ (2.01)
======= ======= ======== ======= =======
Weighted average shares-- basic.............. 2,405 7,602 6,087 6,081 2,654
======= ======= ======== ======= =======
Weighted average shares-- diluted............ 12,616 7,602 6,087 6,081 2,654
======= ======= ======== ======= =======
Balance Sheet Data:
As of December 31,
-------------------------------------------------------------
1997 1996 1995 1994 1993
-------- -------- --------- --------- -------
(in thousands)
Working capital (3).......................... $ 4,082 $ 7,092 $10,024 $ 11,621 $ 14,435
Total assets (3)............................. 36,101 20,850 18,271 17,733 20,238
Total indebtedness (4)....................... 2,928 2,553 1,889 356 708
Accumulated deficit.......................... (20,816) (21,190) (19,700) (19,770) (18,956)
Shareholders' equity......................... 25,993 14,478 12,931 13,819 16,532
(1) Effective September 1, 1993 and December 31, 1993, the Company dissolved
its 50% partnership interests in the Pennsylvania and Michigan
Partnerships, respectively, which had been accounted for under the equity
method. The management fees therefrom were reported under "Revenues, net"
in the consolidated statement of operations.
(2) Refer to Note 11 - Shareholders' Equity to the Company's Consolidated
Financial Statements - regarding the impact of the Company's Second Offer
on net loss per share in 1996.
(3) Includes controlled assets of certain Medical Providers of $0, $650,000,
$1,759,000, $2,783,000 and $3,148,000, at December 31, 1997, 1996, 1995,
1994 and 1993, respectively.
(4) Total indebtedness as of December 31, 1997 and 1996 included $1,863,000 and
$1,435,000 of exclusive management rights obligation, respectively.
23
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
The following is a discussion of the financial condition and results of
operations of the Company for the three years ended December 31, 1997. It should
be read in conjunction with the Company's Consolidated Financial Statements, the
related notes thereto and other financial and operating information included in
this Form 10-K.
Overview
During 1997 the Company acquired four new management agreements, including
the agreement with Fertility Centers of Illinois, S.C. ("FCI"), the most
significant management agreement to date. The Company also consummated an equity
offering which raised gross proceeds of $9.6 million and net proceeds of
approximately $8.3 million, a significant portion of which were used to acquire
certain fixed assets of and the right to manage FCI. In addition the Company
achieved Revenues, net growth of approximately 31.8%, Network Sites'
contribution growth of approximately 65% and its first full year of positive
earnings per share.
During the first quarter of 1998, the Company closed on an equity private
placement of $5.5 million with Morgan Stanley Venture Partners III, L.P., the
venture capital affiliate of Morgan Stanley, Dean Witter, Discover & Co.
providing for the purchase of 3,235,294 shares of the Company's Common Stock at
a price of $1.70 per share and 240,000 warrants to purchase shares of the
Company's Common Stock, at a nominal exercise price. Approximately half of these
funds were or will be used by the Company to purchase the capital stock of Shady
Grove Fertility Centers, Inc. ("Shady Grove") and the right to manage Levy,
Sagoskin and Stillman M.D., P.C. (the "Shady Grove P.C.") an infertility
physician group practice comprised of six physicians and four locations in the
greater Washington, D.C. area. The Shady Grove management agreement represents
the second most significant management agreement entered into by the Company to
date.
Effective in October 1997 and January 1998, due to the Company revising the
terms of the management agreements related to the Long Island and Boston Network
Sites, respectively, the Company will no longer display patient service revenues
of the Long Island and Boston Medical Practices in "Revenues, net" in the
Company's consolidated statement of operations. The revised management
agreements provide for the Company to receive a specific management fee which
the Company will report in "Revenues, net" in its consolidated statement of
operations. Under the revised management agreement for the Long Island Network
Site, as compensation for its management services, the Company will receive a
fixed fee (initially equal to $345,000 per annum), subject to annual increases,
plus reimbursed costs of services. Under the revised management agreement for
the Boston Network Site, as compensation for its management services, the
Company will receive a three-part management fee consistent to the majority of
the Company's existing management agreements. The revised agreements provide for
increased incentives and risk-sharing for the Company's affiliated Medical
Practices. The terms of the revised management agreements and the change in
reporting revenues associated therewith, will most likely result in lower
comparative revenues for the Long Island and Boston Network Sites, however, the
Company believes the Network Site contribution related to the Long Island and
Boston Network Sites will not be adversely impacted. As the Company will no
longer be displaying patient service revenues for the Long Island and Boston
Network Sites, the "Medical Provider retainage" line item in the Company's
consolidated statement of operations and the "Controlled assets of Medical
Practices" section in the Company's consolidated balance sheet will no longer be
applicable. Refer to the following RSC Division discussion.
During 1997, the Company derived its revenue pursuant to ten management
agreements and from the AWM Division. For the year ended December 31, 1997, the
management agreements relating to the Boston, New Jersey and Chicago ("FCI")
Network Sites each provided over 10% of the Company's revenues.
The Medical Practices managed by the Company are parties to managed care
contracts. Approximately 61% and 65% of the Company's revenues, net for the
years ended December 31, 1997 and 1996, respectively, were derived from revenues
received by the Medical Practices from third-party payors. To date, the Company
has not been negatively impacted by existing trends related to managed care
contracts. As the Company's management fees for managing such Medical Practices
are based on revenues and/or earnings of the respective Medical Practices,
24
changes in managed care practices, including changes in covered procedures or
reimbursement rates could adversely affect the Company's management fees in the
future.
Recent Acquisitions
In January 1997, the Company acquired certain assets of Bay Area Fertility
and acquired the right to manage the Bay Area Fertility and Gynecology Medical
Group, Inc., a California professional corporation which is the successor to Bay
Area Fertility's medical practice. The aggregate purchase price was
approximately $2.1 million, consisting of $1.5 million in cash and 333,333
shares of Common Stock. The majority of the purchase price was allocated to
exclusive management rights.
In June 1997, the Company acquired certain assets of and the right to
manage Reproductive Sciences Medical Center, Inc. ("RSMC"), a California
professional corporation located near San Diego, CA (the "San Diego
Acquisition"). The aggregate purchase price for the San Diego Acquisition was
approximately $900,000, consisting of $50,000 in cash and 145,454 shares of
Common Stock payable at closing and $650,000 payable upon the achievement of
certain specified milestones, at RSMC's option, in cash or in shares of the
Company's Common Stock, based on the closing market price of the Common Stock on
the third business day prior to issuance. On March 10, 1998, the Company
received notice from RSMC claiming that the Company has materially breached its
management agreement with RSMC and demanding that the alleged breaches be
remedied. Contrary to RSMC's assertions, the Company believes both that it has
materially performed its obligations under the management agreement with RSMC
and that RSMC has materially breached its obligations to the Company under the
management agreement, as well as other agreements with the Company. While the
Company continues to perform, it is endeavoring to submit the dispute to binding
arbitration, which is the governing dispute-resolution process required under
the management agreement, and may be compelled to seek rescission of all
agreements with RSMC. The Company can offer no assurance that resolution of this
matter will not result in the termination of the management agreement or
otherwise adversely impact the Company.
In August 1997, the Company acquired certain fixed assets of and the right
to manage Fertility Centers of Illinois, S.C. ("FCI"), a physician group
practice comprised of six physicians and six locations in the Chicago, Illinois
area. The aggregate purchase price was approximately $8.6 million, consisting of
approximately $6.6 million in cash and 1,009,464 shares of Common Stock.
Approximately $8.0 million of the aggregate purchase price was allocated to
exclusive management rights and $559,000 was allocated to certain fixed assets.
Simultaneous with closing on the FCI transaction, the Company, on behalf of
FCI, completed its first in-market merger with the addition of Edward L. Marut,
MD to the FCI practice. The aggregate purchase price was $803,000 in cash, of
which $750,000 was allocated to exclusive management rights and $53,000 was
allocated to certain fixed assets.
In January 1998, the Company completed its second in-market merger with the
addition of two physicians to the FCI practice. The Company acquired certain
assets of Advocate Medical Group, S.C. ("AMG") and Advocate MSO, Inc. and
acquired the right to manage AMG's infertility practice conducted under the name
Center for Reproductive Medicine ("CFRM"). Simultaneous with closing on this
transaction, the Company amended its management agreement with FCI to include
two of the three physicians practicing under the name CFRM. The aggregate
purchase price was approximately $1.5 million, consisting of approximately $1.2
million in cash and 184,314 shares of Common Stock. The majority of the purchase
price was allocated to exclusive management rights.
In March 1998, the Company acquired the majority of the capital stock of
Shady Grove Fertility Centers, Inc. ("Shady Grove"), currently a Maryland
business corporation which provides management services, and formerly a Maryland
professional corporation engaged in providing infertility services. Prior to the
closing of the transaction, Shady Grove had entered into a twenty-year
management agreement with Levy, Sagoskin and Stillman, M.D., P.C. (the "Shady
Grove P.C."), an infertility physician group practice comprised of six
physicians and four locations surrounding the greater Washington, D.C. area. The
Company will acquire the balance of the Shady Grove capital stock on or about
November 1, 1998. The aggregate purchase price for all of the Shady Grove
25
capital stock was approximately $5.7 million, consisting of approximately $2.8
million in cash, $1.4 million in Common Stock, and $1.5 million in promissory
notes. The promissory notes are payable in two aggregate annual installments of
$750,000, due on April 1, 1999 and 2000, respectively, and bear interest at an
annual rate of 8.5%. On March 12, 1998, the closing date, the following
consideration was paid to two of the three shareholder physicians: (i)
approximately $1.8 million in cash, (ii) approximately $1.2 million in stock or
639,551 shares of Common Stock, and (iii) approximately $1.1 million in
promissory notes. The Company will pay the balance of the aggregate purchase
price on or about November 1, 1998 (the "Second Closing Date"), when the balance
of the Shady Grove stock is transferred to the Company. The number of shares of
Company Common Stock to be issued on the Second Closing Date, which will have a
fair market value of approximately $200,000, will be determined based upon the
average closing price of the Company's Common Stock for the ten-day trading
period prior to the third business day before the Second Closing Date; provided,
however, that in no event will the price per share exceed $2.00 or be less than
$1.70 for purposes of this calculation.
In regard to the shares of Company Common Stock issued in the above
transactions, with the exception of the shares issued in the Bay Area Fertility
transaction, Gerardo Canet, President and Chief Executive Officer of the
Company, was granted a voting proxy with respect to (i) the election of
Directors or any amendment to the Company's Certificate of Incorporation
affecting Directors and (ii) any change in stock options for management and
directors for a two-year period from each transaction's respective closing date.
The Company is evaluating and is engaged in discussions with regard to
several potential acquisitions. However, the Company has no agreements relating
to any acquisitions and there can be no assurance that any definitive agreements
will be entered into by the Company or that any additional acquisitions will be
consummated.
RSC Division
During the year ended December 31, 1997, the operations of the RSC Division
were conducted pursuant to ten management agreements.
Under six of the Company's management agreements, the Company receives a
three-part management fee as compensation for its management services comprised
of: (i) a fixed percentage of net revenues generally equal to 6%, (ii)
reimbursed costs of services (costs incurred in managing a Network Site and any
costs paid on behalf of the Network Site) and (iii) a fixed or variable
percentage of earnings after the Company's management fees and any guaranteed
physician compensation, or an additional fixed or variable percentage of net
revenues which generally results in the Company receiving up to an additional
15% of net revenues. Direct costs incurred by the Company in performing its
management services and costs incurred on behalf of the Network Site are
recorded as cost of services rendered. The physicians receive as compensation
all earnings remaining after payment of the Company's management fee. The
Company's compensation pursuant to the management agreement relating to Shady
Grove will also be determined and recorded in this manner.
Under the Company's management agreements for the Boston and Long Island
Network Sites in effect for the year ended December 31, 1997, the Company
displayed the patient service revenues of the Medical Practices which are
reflected in "Revenues, net" on its consolidated statement of operations. Under
these agreements, the Company recorded all patient service revenues and, out of
such revenues, the Company paid the Medical Practices' expenses, physicians' and
other medical compensation, direct materials and certain hospital contract fees
(the "Medical Practice retainage"). Specifically, under the management agreement
for the Boston Network Site, the Company guaranteed a minimum physician
compensation based on an annual budget primarily determined by the Company.
Remaining revenues, if any, which represented the Company's management fees,
were used by the Company for other direct administrative expenses which were
recorded as costs of services. Under the management agreement for the Long
Island Network Site, the Company's management fee was payable only out of
remaining revenues, if any, after the payment of all expenses of the Medical
Practice. The management agreements related to the Long Island and Boston
Network Sites were revised effective in October 1997 and January 1998,
respectively. As a result, the Company will no longer display the patient
service revenues of the Medical Practices in "Revenues, net" in its consolidated
statement of operations. See "Overview".
26
Under the Company's management agreement for the New Jersey Network Site,
the Company primarily provides endocrine testing and administrative and finance
services for a fixed percentage of revenues, equal to 15% of net revenues, and
reimbursed costs of services. Under the management agreement for the Walter Reed
Network Site, the Company's revenues are derived from certain ART laboratory
services performed, and the Company bills patients directly for these services.
The Company's direct costs are reimbursed out of these revenues with the balance
representing the Company's Network Site contribution. All direct costs incurred
by the Company are recorded as costs of services.
The management agreements are typically for terms of ten to 25 years and
are generally subject to termination due to insolvency, bankruptcy or material
breach of contract by the other party.
AWM Division
The AWM Division's operations are currently conducted through and owned by
the Women's Medical & Diagnostic Center, Inc., a Florida corporation and a
wholly-owned subsidiary of the Company. The Company bills and records all
clinical revenues of the AWM Division and records all direct costs incurred as
costs of services rendered. The Company retains as Network Site contribution an
amount determined using the three-part management fee calculation described
above. The remaining balance is paid as compensation to the employed physicians
and is recorded by the Company as costs of services rendered. The employed
physicians receive a fixed monthly draw which may be adjusted quarterly by the
Company based on the Network Site's actual operating results.
Revenues in the AWM Division also include amounts earned under contracts
relating to clinical trials performed by the AWM Division. The AWM Division has
contracted with major pharmaceutical companies to participate in clinical trials
to determine the safety and efficacy of drugs under development. Research
revenues are recognized pursuant to each respective contract in the period in
which the medical services (as stipulated by the clinical trial protocol) are
performed and collection of such fees is considered probable. Net realization is
dependent upon final approval by the sponsor that procedures were performed
according to trial protocol. Payments collected from sponsors in advance for
services are included in accrued liabilities, and costs incurred in performing
the clinical trials are included as costs of services rendered.
The Company's 51% interest in the National Menopause Foundation, Inc.
("NMF") is included in the Company's consolidated financial statements. The
Company records 100% of the revenues and costs of NMF and reports 49% of any
profits of NMF as minority interest on the Company's consolidated balance sheet.
Results of Operations
Calendar Year 1997 Compared to Calendar Year 1996
Revenues for 1997 were approximately $24.2 million as compared to
approximately $18.3 million for 1996, an increase of 31.8%. Revenues under
management agreements relating to Network Sites managed by the Company prior to
January 1, 1997, excluding the Westchester and East Long Meadow, MA Network Site
agreements which were terminated in November 1996 and January 1997,
respectively, increased 23.4%. This increase in existing Network Site revenue
was due to a full year of operations from two Network Sites which were acquired
in 1996 and to an increase in procedure volume at certain other existing Network
Sites. For the year ended December 31, 1997, the Company's RSC Division and AWM
Division contributed 91.4% and 8.6%, respectively, of the Company's total
revenues compared to 95.9% and 4.1% for the same period in 1996, respectively.
RSC Division revenues for the year ended December 31, 1997 were
approximately $22.1 million as compared to $17.6 million for the year ended
December 31, 1996, an increase of 25.6%. Revenues under the RSC Division were
comprised of (i) patient service revenues, (ii) three-part management fees and
(iii) at the New Jersey Network Site, management fees based on a percentage of
revenues and reimbursed costs of services. Patient service revenues for the year
ended December 31, 1997 were $10.2 million compared to $11.4 million for the
year ended December 31, 1996 , a decrease of 11.3%. Patient service revenues
27
decreased due to the termination of the Westchester Network Site agreement in
November 1996. The decrease in patient service revenues was partially offset by
significant increases in revenue at the Long Island and Walter Reed Network
Sites attributable to increases in procedure volume at such Network Sites.
Three-part management fee revenues more than doubled to approximately $8.3
million for the year ended December 31, 1997 compared to approximately $3.2
million for the year ended December 31, 1996. The increase in three-part
management fee revenues was primarily attributable to new management agreements
entered into in 1997 and to there being a full year of revenues for the two
agreements which were entered into during 1996, partially offset by the
termination of the East Long Meadow, MA Network Site agreement in January 1997.
Management fees based on a percentage of revenues and reimbursed costs of
services of the New Jersey Network Site were approximately $3.7 million in 1997
compared to approximately $3.0 million in 1996, an increase of 23.7%,
attributable to an increase in procedure volume at such Network Site. AWM
Division revenues for the year ended December 31, 1997 were approximately $2.1
million as compared to approximately $757,000 for the year ended December 31,
1996, primarily attributable to there being a full year of operations in this
Division in 1997 as compared to approximately seven months of operations in
1996.
Medical Practice retainage for 1997 was approximately $1.5 million as
compared to approximately $2.7 million in 1996, a decrease of 42.9%, due to the
termination of the Westchester Network Site agreement in November 1996.
Revenues after Medical Practice retainage were approximately $22.6 million
in 1997 as compared to $15.7 million in 1996, an increase of 44.5%, due to the
increase in "Revenues, net" and decrease in Medical Practice retainage discussed
above.
Costs of services rendered were approximately $17.3 million in 1997 as
compared to approximately $12.4 million in 1996, an increase of 39.1%. Such
increase was primarily due to the new management agreements entered into in 1997
and a full year of operations related to two Network Sites acquired in 1996 and
procedure volume growth at certain existing Network Sites, partially offset by
the termination of the Westchester and East Long Meadow, MA Network Site
agreements in November 1996 and January 1997, respectively. Costs of services in
1996 included a $365,000 charge recorded in the third quarter of 1996 associated
with closing the Westchester Network Site.
General and administrative expenses were approximately $4.2 million in 1997
as compared to approximately $4.7 million in 1996, a decrease of 10.1%. Such
decrease was primarily attributable to the absence of $522,000 in costs related
to establishing the AWM Division which were incurred in 1996 and to lower salary
and administrative costs related to regional offices, partly attributable to the
Company allocating portions of such costs to the respective Network Site's
operations commencing in the third quarter of 1997 and to the consolidation of
regional offices within the respective Network Site locations. These decreases
were partially offset by increases in consulting and investor relations costs.
Amortization of intangible assets was approximately $766,000 in 1997 as
compared to approximately $331,000 in 1996 and principally represented the
amortization of the purchase price paid by the Company for the exclusive right
to manage Network Sites and goodwill and other intangible asset amortization
related to the establishment of the AWM Division in June 1996. At December 31,
1997, the Company's consolidated financial statements reflect goodwill and other
intangible assets of approximately $18.4 million, which is being amortized over
periods ranging from three to 40 years. The Company anticipates that any future
acquisitions will involve the recording of a significant amount of goodwill and
intangible assets on its balance sheet.
Interest income for 1997 decreased to approximately $109,000 from
approximately $415,000 in 1996 due to a lower cash balance.
The provision for income taxes primarily reflected state income taxes in
1997 and 1996.
Net income was approximately $374,000 in 1997 as compared to a net loss of
approximately $1.5 million in 1996. This net income was primarily due to a $2.1
million increase in Network Site contribution attributable to the new management
agreements entered into in 1997, a full year of operations related to two
Network Sites acquired in 1996, procedure volume growth at certain existing
Network Sites, and the absence of losses associated with the Westchester Network
Site agreement which was terminated in November 1996.
28
In addition, general and administrative expenses decreased by $470,000. These
positive variances were partially offset by a $435,000 increase in amortization
of intangible assets and a $306,000 decrease in interest income.
Calendar Year 1996 Compared to Calendar Year 1995
Revenues for 1996 were approximately $18.3 million as compared to
approximately $16.7 million for 1995, an increase of 9.8%. For the year ended
December 31, 1996, the Company's RSC Division and AWM Division contributed 95.9%
and 4.1%, respectively, of the Company's total revenues.
RSC Division revenues for the year ended December 31, 1996 were
approximately $17.6 million as compared to $16.7 million for the year ended
December 31, 1995, an increase of 5.2%. Revenues under the RSC Division were
comprised of (i) patient service revenues, (ii) three-part management fees and
(iii) at the New Jersey Network Site, management fees based on a percentage of
revenues and reimbursed costs of services. Patient service revenues for the year
ended December 31, 1996 were $11.4 million compared to $13.8 million for the
year ended December 31, 1995, a decrease of 17.1%. Patient service revenues
decreased due to a 52.9% decrease in patient service revenues related to the
Westchester Network Site agreement which the Company terminated in November 1996
and to the effects of the Company's new management agreement related to the New
Jersey Network Site, pursuant to which the Company's revenues now consist of a
fixed percentage of the New Jersey Network Site's revenues and reimbursed costs
of services (as described below) and are no longer recorded as patient service
revenues. The decrease in patient service revenues was partially offset by a
7.1% increase in revenue at the Boston Network Site and a 11.7% increase in
revenue at the Long Island Network Site, both of which were attributable to an
increase in volume at such Network Sites. The increase in volume at the Long
Island Network Site in 1996 was primarily attributable to increased revenues
generated from additional facility agreements entered into with physicians at
such Network Site in 1996. The 1996 results also reflect a full year of
operations at the Long Island Network Site as compared to 1995, during which
period such Network Site was closed for approximately five months to implement
operational changes at such Network Site. Three-part management fee revenues
were approximately $3.2 million for the year ended December 31, 1996 compared to
approximately $981,000 for the year ended December 31, 1995. The increase in
three-part management fee revenues was primarily attributable to new management
agreements entered into in the second quarter of 1996 and to there being a full
year of revenues for those agreements that were entered into during 1995.
Management fees based on a percentage of revenues and reimbursed costs of
services of the New Jersey Network Site were approximately $3.0 million in 1996
compared to approximately $1.9 million in 1995, an increase of 55.9%,
attributable to there being a full year under the new management agreement. AWM
Division revenues for the year ended December 31, 1996 were approximately
$757,000.
Medical Practice retainage for 1996 was approximately $2.7 million as
compared to approximately $3.1 million in 1995, a decrease of 12.5%, primarily
due to the decrease in volume and a negotiated reduction in hospital contract
fees at the Westchester Network Site, management contract changes related to the
New Jersey Network Site and to operational changes at the Long Island Network
Site. This decrease was partially offset by an increase in physician
compensation at the Boston Network Site attributable to the addition of a
physician who commenced services at such Network Site in July 1995 and to
renegotiated physician compensation at such Network Site.
Revenues after Medical Practice retainage were approximately $15.7 million
in 1996 as compared to $13.6 million in 1995, an increase of 14.8%. The increase
was due to the new management agreements entered into in the second quarter of
1996. The increase in revenues was partially offset by the net decrease in
management fees related to the Boston, Westchester, Long Island and New Jersey
Network Sites. Management fees (i.e., patient service revenues less Medical
Practice retainage) related to the Boston, Westchester and Long Island Network
Sites (in which the Company displayed the patient service revenues on its
consolidated statement of operations for the year ended December 31, 1996) were
approximately $8.2 million in 1996 compared to management fees related to the
Boston, Westchester, Long Island and New Jersey Network Sites (in which the
Company displayed the patient service revenues on its consolidated statement of
operations for the year ended December 31, 1995) which were approximately $10.8
million in 1995, a decrease of 23.4%. The decrease was primarily due to the
29
decrease in patient service revenues at the Westchester Network Site and the
termination of the Westchester Network Site Agreement in November 1996. In
addition, the decrease was also due to the effects of the Company's new
management agreement related to the New Jersey Network Site, pursuant to which
the Company's revenues now consist of a fixed percentage of the New Jersey
Network Site's revenues and reimbursed costs of services and are no longer
recorded as patient service revenues. While the change in the New Jersey
agreement resulted in a decrease in management fees for the Network Sites in
which the Company displayed patient service revenues, the revenues after Medical
Practice retainage related to the New Jersey Network Site were approximately the
same for both periods. The decrease in such management fees was partially offset
by the increase in management fees related to the Long Island Network Site.
Costs of services rendered were approximately $12.4 million in 1996 as
compared to approximately $10.0 million in 1995, an increase of 24.2%. Such
increase was primarily due to the Network Sites acquired by the Company in the
second and fourth quarters of 1995 and the second quarter of 1996, and to a
$365,000 charge recorded in the third quarter of 1996 associated with closing
the Westchester Network Site. These increases were partially offset by the
effects of the new management contract related to the New Jersey Network Site,
which included the reversal of $120,000 in deferred rent, and lower occupancy
and direct material costs related to the Long Island Network Site due to the
relocation and operational changes effected at this Network Site in the second
quarter of 1995.
General and administrative expenses were approximately $4.7 million in 1996
as compared to approximately $4.0 million in 1995, an increase of 17.4%. Such
increase was primarily attributable to $522,000 of costs incurred primarily in
establishing the AWM Division and administrative costs attributable to the
opening of regional offices in the third quarter of 1995 and in 1996.
Amortization of intangible assets was approximately $331,000 in 1996 as
compared to approximately $73,000 in 1995 and principally represented the
amortization of the purchase price paid by the Company for the exclusive right
to manage Network Sites that were acquired in the second and fourth quarters in
1995 and the second quarter of 1996. The 1996 expense amount also included
goodwill and other intangible asset amortization related to the establishment of
the AWM Division in June 1996. At December 31, 1996, the Company's consolidated
financial statements reflect goodwill and other intangible assets of
approximately $5.9 million, which is being amortized over periods ranging from
three to 40 years. The Company anticipates that the Bay Area Acquisition and the
Pending Acquisition, as well as any future acquisitions, will involve the
recording of a significant amount of goodwill and intangible assets on its
balance sheet.
Interest income for 1996 was approximately $415,000 compared to
approximately $626,000 in 1995. This decrease was due to a lower cash balance
and lower short-term interest rates.
The provision for income taxes primarily reflected state income taxes in
1996 and 1995.
Net loss was approximately $1.5 million in 1996 as compared to net income
of approximately $70,000 in 1995. This net loss was primarily due to a $397,000
decrease in Network Site contribution attributable to a $1.4 million decrease in
contribution related to the Westchester Network Site, inclusive of a $365,000
non-recurring charge to account for the closing of this Network Site, and a
decrease in contribution from the Boston Network Site, partially offset by
significant increases in contribution from the New Jersey and Long Island
Network Sites. In addition, general and administrative expenses increased by
$659,000 largely due to non-recurring charges associated with the establishment
of the AWM Division, a $258,000 increase in amortization of intangible assets,
and a $211,000 decrease in interest income.
Liquidity and Capital Resources
Historically, the Company has financed its operations primarily through
sales of equity securities. In August 1997, the Company consummated an offering
of 6,400,000 shares of Common Stock (the "Offering"). The Offering raised gross
proceeds of $9.6 million and net proceeds of approximately $8.3 million.
Approximately $6.6 million of the net proceeds of the Offering was used to
acquire certain fixed assets of and the right-to-manage FCI.
30
During the first quarter of 1998, the Company closed on an equity private
placement of $5.5 million with Morgan Stanley Venture Partners III, L.P., the
venture capital affiliate of Morgan Stanley, Dean Witter, Discover & Co.
providing for the purchase of 3,235,294 shares of the Company's Common Stock at
a price of $1.70 per share and 240,000 warrants to purchase shares of the
Company's Common Stock, at a nominal exercise price. Approximately half of these
funds were or will be used by the Company to purchase the capital stock of Shady
Grove Fertility Centers, Inc. and the right to manage the Shady Grove, P.C.'s
infertility medical practice.
The balance of the proceeds of the Offering and the equity private
placement have been and will continue to be used for working capital and other
general corporate purposes, including possible future acquisitions of the assets
of, and the right to manage, additional physician practices.
At December 31, 1997, the Company had working capital of approximately
$4.1 million, approximately $1.9 million of which consisted of cash and cash
equivalents, compared to working capital of $7.1 million at December 31, 1996
(including $650,000 of controlled assets of Medical Practices), approximately
$6.0 million of which consisted of cash and cash equivalents (including $191,000
of controlled cash) and short term investments. The net decrease in working
capital at December 31, 1997 was principally due to payments of $10.6 million
for exclusive management rights and related asset purchase acquisition costs and
payments of approximately $2.1 million for the purchase of fixed assets and
leasehold improvements related to new and existing Network Sites, partially
offset by $8.3 million in net proceeds from the Offering and an aggregate
increase in receivables and other current assets.
During 1997, the Company entered into three new management agreements and
completed its first in-market merger with the addition of one physician to the
FCI practice. The aggregate purchase price of these transactions, exclusive of
acquisition costs, was approximately $12.4 million, consisting of approximately
$9.0 million in cash and 1,488,251 shares of the Company's Common Stock.
Included in this aggregate purchase price is $650,000 payable upon the
achievement of certain specified milestones, at RSMC's option, in cash or in
shares of the Company's Common Stock, based on the closing market price of the
Common Stock on the third business day prior to issuance.
During the first quarter of 1998, the Company completed its second
in-market merger with the addition of two physicians to the FCI practice and
entered into one new management agreement with the Shady Grove, P.C. The
aggregate purchase price of these transactions, exclusive of acquisition costs,
was approximately $7.2 million, consisting of approximately $4.0 million in
cash, $1.5 million in promissory notes, 823,865 shares of the Company's Common
Stock, and approximately an additional $200,000 in shares of the Company's
Common Stock. A portion of the aggregate purchase price related to the Shady
Grove acquisition will be paid in November 1998 as follows: approximately $1.0
million in cash, $403,000 in promissory notes and approximately $200,000 in
shares of the Company's Common Stock. The promissory notes are payable in two
aggregate annual installments of $750,000, due on April 1, 1999 and 2000,
respectively, and bear interest at an annual rate of 8.5%. The number of shares
of Company Common Stock to be issued in November 1998 will be determined based
upon the average closing price of the Company's Common Stock for the ten-day
trading period prior to the third business day before the Second Closing Date,
provided, however, that in no event will the price per share exceed $2.00 or be
less than $1.70 for purposes of this calculation.
The Company anticipates that its acquisition strategy will continue to
require substantial capital investment. Capital is needed not only for
additional acquisitions, but also for the effective integration, operation and
expansion of the existing Network Sites. The Medical Practices may require
capital for renovation and expansion and for the addition of medical equipment
and technology. The Company is in the process of obtaining a line of credit to
fund its acquisition strategy over the next year.
As of December 31, 1997, under two of its management agreements, the
Company is obligated to advance funds to the Medical Practices to provide a
minimum physician draw (up to an aggregate of approximately $265,000 in 1998)
and to provide new services, utilize new technologies, fund projects, purchase
the net accounts receivable of the Medical Practices and for other purposes. Any
advances are to be repaid monthly and will bear interest at the prime rate used
by the Company's primary bank in effect at the time of the advance.
31
As of December 31, 1997, $250,000 was outstanding under the Company's $1.5
million credit facility dated November 21, 1996 (the "Credit Facility") with
First Union National Bank (the "Bank"). As March 15, 1998, $1.5 million was
outstanding under the Credit Facility. Borrowings under the Credit Facility bear
interest at the Bank's prime rate plus 0.75% per annum. The Credit Facility
terminates on July 1, 1998 and is secured by the Company's assets.
On November 13, 1997, the Company entered into a $4.0 million non-restoring
line of credit dated November 13, 1997 with the Bank (the "New Credit
Facility"). Borrowings under the New Credit Facility bear interest at the Bank's
prime rate plus 1% per annum. Accrued interest only on borrowings is payable
commencing December 1, 1997 and all principal and accrued interest is due and
payable on April 30, 1999. The New Credit Facility will be cross collateralized
and cross-defaulted with the Credit Facility and is secured by the Company's
assets. As of December 31, 1997, no amounts were outstanding under the New
Credit Facility. As of March 15, 1998, $750,000 was outstanding under the New
Credit Facility.
The Company has commitments to fund clinical services development pursuant
to various collaboration agreements. Effective July 1, 1995, the Company entered
into a new three-year agreement with Monash University that provides for Monash
to conduct research in ART services and techniques to be funded by a minimum
annual payment of 220,000 Australian dollars, the results of such research to be
jointly owned by the Company and Monash. If certain milestones are met as
specified in this agreement, the Company's annual payment may be a maximum of
300,000 Australian dollars in year two and 380,000 Australian dollars in year
three. Minimum payments of 55,000 Australian dollars and payments for the
attainment of certain research milestones will be made quarterly throughout the
term of this agreement. The Company expensed approximately $144,000 and $189,000
under this agreement for the years ended December 31, 1997 and 1996,
respectively.
As of December 31, 1997, dividend payments of $464,000 on the Series A
Cumulative Convertible Preferred Stock (the "Convertible Preferred Stock") were
in arrears. The Company does not anticipate the payment of any dividends on the
Convertible Preferred Stock in the foreseeable future.
New Accounting Standards
In 1997, the Company adopted Statement of Financial Accounting Standards
No. 128, "Earnings per Share" ("SFAS 128"). Under SFAS 128, the Company
disclosed dual presentation of basic and diluted earnings per share (EPS) on the
face of the statement of operations and a reconciliation of the numerator and
denominator of the basic EPS computation to the numerator and denominator of the
diluted EPS computation in Note 10 of the Consolidated Financial Statements.
The Company adopted Statement of Financial Accounting Standards ("SFAS")
No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to be Disposed Of," in the first quarter of 1996. The Company
periodically reviews the fair value of long-lived assets, the results of which
have had no material effect on the Company's financial position or results of
operations.
The Company also adopted SFAS No. 123, "Accounting for Stock Based
Compensation" ("SFAS 123"), on January 1, 1996. Under SFAS 123, companies can,
but are not required to, elect to recognize compensation expense for all stock
based awards using a fair value method. The Company has adopted the disclosure
only provisions, as permitted by SFAS 123.
In 1997, the Emerging Issues Task Force of the Financial Accounting
Standards Board (the "EITF") issued EITF No. 97-2. The EITF reached a consensus
concerning certain matters relating to the physician practice management ("PPM")
industry with respect to the consolidation of professional corporation revenues
and the accounting for business corporations. As an interim step before the
consensus, the EITF allowed PPMs to display the revenues and expenses of managed
physician practices in the statement of operations (the "alternative display
method") if the terms of the management agreement provided the PPM with a "net
profits or equivalent interest" in the net profits of the medical services
furnished by the Medical Practices. It is the Company's understanding that the
EITF did not and would not object to the use of the alternative display method
in PPM financial statements for periods ending before December 15, 1998. As the
Company does not consolidate its managed Network Sites, the adoption of EITF
97-2 in 1998 will not have a material impact on the Company's financial
32
position, cash flows or results of operations. As discussed below, the Company
will discontinue the display of revenues for its Long Island and Boston Network
Sites due to changes in the respective management agreements.
Since inception through December 31, 1997, the management agreements
related to the Long Island and Boston Network Sites have been incorporated in
the Company's consolidated financial statements via the display method as the
Company believed that these management agreements provided it with a "net
profits or equivalent interest" in the net profits of the medical services
furnished by the Medical Practices at the Long Island and Boston Network Sites.
Consequently, for the Long Island and Boston Network Sites, the Company has
presented the Medical Practices' patient services revenue, less amounts retained
by the Medical Practices, or "Medical Practice retainage", as "Revenues after
Medical Practice retainage" in the accompanying consolidated statement of
operations ("display method"). Effective in October 1997 and January 1998, due
to changes in the management agreements related to the Long Island and Boston
Network Sites, respectively, the Company will no longer display the patient
services revenue of the Long Island and Boston Medical Practices. The revised
management agreements provide for the Company to receive a specific management
fee which the Company will report in "Revenues, net" in the statement of
operations.
Also in 1997, Statement of Financial Accounting Standards No. 131,
"Disclosure about Segments of an Enterprise and Related Information," was
issued. It establishes standards for reporting information about operating
segments in annual financial statements and interim financial reports. It also
establishes standards for related disclosures about products and services,
geographic areas and major customers. The Company is currently evaluating its
options for disclosure and will adopt the statement for the fiscal year
commencing January 1, 1998.
Forward Looking Statements
This Form 10-K and discussions and/or announcements made by or on behalf of
the Company, contain certain forward-looking statements within the meaning of
the "safe harbor" provisions of the Private Securities Litigation Reform Act of
1995, the attainment of which involve various risks and uncertainties.
Forward-looking statements may be identified by the use of forward-looking
terminology such as, "may," "will," "expect," "believe," "estimate,"
"anticipate," "continue," or similar terms, variations of those terms or the
negative of those terms. The Company's actual results may differ materially from
those described in these forward-looking statements due to the following
factors: the Company's ability to acquire additional management agreements,
including the Company's ability to finance future growth, the loss of
significant management agreement(s), the profitability or lack thereof at
Network Sites managed by the Company, the Company's ability to transition sole
practitioners to group practices, the development of the AWM Division, increases
in overhead due to expansion, the exclusion of infertility, ART and other
women's reproductive healthcare services from insurance coverage, government
laws and regulation regarding health care, changes in managed care contracting,
and the timely development of and acceptance of new infertility, ART, genetic
and/or women's healthcare technologies and techniques.
ITEM 7A. Quantitative and Qualitative Disclosures About Market Risk
Not applicable.
ITEM 8. Financial Statements and Supplementary Data
See Index to Financial Statements and Financial Statement Schedules on
page F-1.
ITEM 9. Changes in and Disagreements with Accountants on Accounting and
Financial Disclosure
None.
33
PART III
ITEM 10. Directors and Executive Officers of the Registrant
Information with respect to the executive officers and directors of
the Company is incorporated by reference from the Company's Proxy Statement
relating to the Annual Meeting of Shareholders to be held on June 9, 1998.
ITEM 11. Executive Compensation
This information is incorporated by reference from the Company's Proxy
Statement relating to the Annual Meeting of Shareholders to be held on June 9,
1998.
ITEM 12. Security Ownership of Certain Beneficial Owners and Management
This information is incorporated by reference to the Company's Proxy
Statement relating to the Annual Meeting of Shareholders to be held on June 9,
1998.
ITEM 13. Certain Relationships and Related Transactions
This information is incorporated by reference to the Company's Proxy
Statement relating to the Annual Meeting of Shareholders to be held on June 9,
1998.
PART IV
ITEM 14. Exhibits, Financial Statements, Schedules, and Reports on Form 8-K
(a) (1) and (2) Financial Statements and Financial Statement Schedules.
See Index to Financial Statements and Financial Statement
Schedules on page F-1.
(3) The exhibits that are listed on the Index to Exhibits
herein which are filed herewith as a management agreement or
compensatory plan or arrangement are: 10.95, 10.96, 10.97,
10.98, 10.99, 10.100, 10.101, 10.102, 10.103, 10.104, 10.105,
10.106, 10.107, 10.108, 10.109, 10.110, 10.111, and 10.112
(b) Reports on Form 8-K.
On January 20, 1997, the Company filed with the Securities
and Exchange Commission a Form 8-K reporting the
completion of an asset purchase and long term management
agreement with Bay Area Fertility and Gynecology Medical
Group.
(c) Exhibits.
34
The list of exhibits required to be filed with this Annual Report on
Form 10-K is set forth in the Index to Exhibits herein.
FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE
Item 8 and 14 (a)(1) and (2)
Contents
Page
INTEGRAMED AMERICA, INC.
Report of Independent Accountants................................. F-2
Consolidated Balance Sheet as of December 31, 1997 and 1996....... F-3
Consolidated Statement of Operations for the years ended
December 31, 1997, 1996 and 1995............................... F-4
Consolidated Statement of Shareholders' Equity for the
years ended December 31, 1997, 1996 and 1995.................. F-5
Consolidated Statement of Cash Flows for the years ended
December 31, 1997, 1996 and 1995.............................. F-6
Notes to Consolidated Financial Statements........................ F-7
FERTILITY CENTERS OF ILLINOIS, S.C.
Report of Independent Accountants.................................... F-29
Combined Balance Sheet as of August 19, 1997 and December 31, 1996... F-30
Combined Statement of Operations for the period January 1, 1997
through August 19, 1997 and for the years ended
December 31, 1996 and 1995........................................ F-31
Combined Statement of Shareholders' Equity for the period
January 1, 1997 through August 19, 1997 and for the
years ended December 31, 1996 and 1995............................ F-32
Combined Statement of Cash Flows for the period January 1, 1997
through August 19, 1997 and for the years ended
December 31, 1996 and 1995....................................... F-33
Notes to Combined Financial Statements............................... F-34
MPD MEDICAL ASSOCIATES (MA), P.C
Report of Independent Accountants................................. F-40
Balance Sheet as of December 31, 1997 and 1996.................... F-41
Statement of Operations for the years ended December 31, 1997,
1996 and 1995................................................... F-42
Notes to Financial Statements..................................... F-43
FINANCIAL STATEMENT SCHEDULE
Report of Independent Accounts on Financial Statement Schedule... S-1
II Valuation and Qualifying Accounts.......................... S-2
F-1
REPORT OF INDEPENDENT ACCOUNTANTS
To the Board of Directors and Shareholders of
IntegraMed America, Inc.
In our opinion, the accompanying consolidated balance sheet and related
consolidated statements of operations, of shareholders' equity and of cash flows
present fairly, in all material respects, the financial position of IntegraMed
America, Inc. and its subsidiaries at December 31, 1997 and 1996, and the
results of their operations and their cash flows for each of the three years in
the period ended December 31, 1997, in conformity with generally accepted
accounting principles. These financial statements are the responsibility of the
Company's management; our responsibility is to express an opinion on these
financial statements based on our audits. We conducted our audits of these
statements in accordance with generally accepted auditing standards which
require that we plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement. An audit
includes examining, on a test basis, evidence supporting the amounts and
disclosures in the financial statements, assessing the accounting principles
used and significant estimates made by management, and evaluating the overall
financial statement presentation. We believe that our audits provide a
reasonable basis for the opinion expressed above.
/s/ Price Waterhouse LLP
- ------------------------
Price Waterhouse LLP
Stamford, Connecticut
February 16, 1998
F-2
INTEGRAMED AMERICA, INC.
CONSOLIDATED BALANCE SHEET
(all amounts in thousands)
December 31,
------------
1997 1996
---- ----
ASSETS
Current assets:
Cash and cash equivalents....................................................... $ 1,930 $ 3,761
Short term investments.......................................................... -- 2,000
Patient accounts receivable, less allowance for doubtful accounts
of $180 and $113 in 1997 and 1996, respectively............................... 7,061 2,770
Management fees receivable, less allowance for doubtful accounts
of $214 and $50 in 1997 and 1996, respectively................................ 1,600 1,249
Other current assets............................................................ 1,757 1,129
Controlled assets of Medical Practices (see Note 2)
Cash.......................................................................... -- 191
Accounts receivable, less allowance for doubtful accounts
of $146 in 1996............................................................. -- 459
------- --------
Total controlled assets of Medical Practices.......................... -- 650
Total current assets.................................................. 12,348 11,559
------- --------
Fixed assets, net.................................................................. 4,742 3,186
Intangible assets, net............................................................. 18,445 5,894
Other assets....................................................................... 566 211
------- --------
Total assets.......................................................... $36,101 $ 20,850
======= ========
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Accounts payable................................................................ $ 1,475 $ 1,020
Accrued liabilities............................................................. 2,260 1,652
Due to Medical Practices--(see Notes 2 and 7)................................... 1,745 326
Dividends accrued on Preferred Stock............................................ 464 331
Current portion of exclusive management rights obligation....................... 472 222
Note payable and current portion of long-term debt.............................. 614 426
Patient deposits................................................................ 1,236 490
------- --------
Total current liabilities............................................. 8,266 4,467
------- --------
Exclusive management rights obligation............................................. 1,391 1,213
Long-term debt..................................................................... 451 692
Commitments and Contingencies-- (see Note 14)...................................... -- --
Shareholders' equity:
Preferred Stock, $1.00 par value 3,165,644 shares authorized in 1997 and 1996--
2,500,000 undesignated; 665,644 shares designated as Series A Cumulative
Convertible of which 165,644 were issued and outstanding in 1997 and 1996,
respectively.................................................................. 166 166
Common Stock, $.01 par value-- 25,000,000 shares authorized; 17,198,616
and 9,230,557 shares issued and outstanding in 1997 and 1996, respectively.... 172 92
Capital in excess of par........................................................ 46,471 35,410
Accumulated deficit............................................................. (20,816) (21,190)
------- --------
Total shareholders' equity............................................ 25,993 14,478
------- --------
Total liabilities and shareholders' equity............................ $36,101 $ 20,850
======= ========
See accompanying notes to the consolidated financial statements
F-3
INTEGRAMED AMERICA, INC.
CONSOLIDATED STATEMENT OF OPERATIONS
(all amounts in thousands, except per share amounts)
For the years ended December 31,
--------------------------------
1997 1996 1995
---- ---- ----
Revenues, net (see Note 2)........................................ $24,169 $18,343 $16,711
Medical Practice retainage (see Note 2)........................... 1,531 2,680 3,063
------- ------- -------
Revenues after Medical Practice retainage (see Note 2)............ 22,638 15,663 13,648
Costs of services rendered........................................ 17,251 12,398 9,986
------- ------- -------
Network Sites' contribution....................................... 5,387 3,265 3,662
------- ------- -------
General and administrative expenses............................... 4,192 4,662 3,970
Amortization of intangible assets................................. 766 331 73
Interest income................................................... (109) (415) (626)
Interest expense.................................................. 60 36 20
------- ------- -------
Total other expenses.............................................. 4,909 4,614 3,437
------- ------- -------
Income (loss) before income taxes................................. 478 (1,349) 225
Provision for income and capital taxes............................ 104 141 155
------- ------- -------
Net income (loss)................................................. $ 374 $(1,490) $ 70
======= ======= =======
Basic earnings (loss) per share before consideration
for induced conversion of Preferred Stock (see Note 10)........ $ 0.02 $ (0.21) $ (0.09)
======= ======= =======
Diluted earnings (loss) per share before consideration
for induced conversion of Preferred Stock (see Note 10)........ $ 0.02 $ (0.21) $ (0.09)
======= ======= =======
Basic earnings (loss) per share (see Note 10)..................... $ 0.02 $ (0.68) $ (0.09)
======= ======= =======
Diluted earnings (loss) per share (see Note 10)................... $ 0.02 $ (0.68) $ (0.09)
======= ======= =======
Weighted average shares - basic................................... 12,405 7,602 6,087
======= ======= =======
Weighted average shares - diluted................................. 12,616 7,602 6,087
======= ======= =======
See accompanying notes to the consolidated financial statements.
F-4
INTEGRAMED AMERICA, INC.
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY
(all amounts in thousands, except share amounts)
Cumulative Convertible Total
Preferred Stock Common Stock
---------------- ---------------- Capital in Accumulated Shareholders'
Shares Amount Shares Amount Excess of Par Deficit Equity
------ ------ ------ ------ ------------- ------- ------
BALANCE AT DECEMBER 31, 1994..... 863,878 $864 6,086,910 $61 $32,664 $(19,770) $13,819
Dividends accrued to preferred
shareholders ................ -- -- -- -- (600) -- (600)
Purchase and retirement of
Preferred Stock.............. (78,500) (79) -- -- (279) -- (358)
Net income....................... -- -- -- -- -- 70 70
------- ----- ---------- ---- ------- -------- -------
BALANCE AT DECEMBER 31, 1995..... 785,378 785 6,086,910 61 31,785 (19,700) 12,931
Conversion of Preferred Stock to
Common Stock, net of issuance
costs and the reversal of
accrued Preferred Stock
dividends.................... (608,234) (608) 2,432,936 24 1,298 -- 714
Issuance of Common Stock
for acquisition.............. -- -- 666,666 7 2,493 -- 2,500
Dividends accrued to preferred
shareholders ................ -- -- -- -- (132) -- (132)
Purchase and retirement of
Preferred Stock.............. (11,500) (11) -- -- (72) -- (83)
Exercise of Common Stock options. -- -- 44,045 -- 38 -- 38
Net loss......................... -- -- -- -- -- (1,490) (1,490)
------- ----- ---------- ---- ------- -------- -------
BALANCE AT DECEMBER 31, 1996..... 165,644 166 9,230,557 92 35,410 (21,190) 14,478
Issuance of Common Stock, net of
issuance costs............... -- -- 6,400,000 64 8,229 -- 8,293
Issuance of Common Stock
for acquisition.............. -- -- 1,488,251 14 2,860 -- 2,874
Other issuances of Common Stock.. -- -- 61,058 1 83 -- 84
Dividends accrued to preferred
shareholders ................ -- -- -- -- (133) -- (133)
Exercise of Common Stock options. -- -- 18,750 1 22 -- 23
Net income....................... -- -- -- -- -- 374 374
------- ----- ---------- ---- ------- -------- -------
BALANCE AT DECEMBER 31, 1997..... 165,644 $ 166 17,198,616 $172 $46,471 $(20,816) $25,993
======= ===== ========== ==== ======= ======== =======
See accompanying notes to the consolidated financial statements.
F-5
INTEGRAMED AMERICA, INC.
CONSOLIDATED STATEMENT OF CASH FLOWS
(all amounts in thousands)
For the years ended December 31,
--------------------------------
1997 1996 1995
---- ---- ----
Cash flows from operating activities:
Net income (loss)............................................ $ 374 $(1,490) $ 70
Adjustments to reconcile net income (loss) to
net cash provided by (used in) operating activities:
Depreciation and amortization.............................. 1,812 1,116 775
Writeoff of fixed and intangible assets.................... 95 -- 21
Changes in assets and liabilities net of effects from
acquired businesses --
(Increase) decrease in assets:
Patient accounts receivable................................ (4,291) (1,318) (94)
Management fees receivable................................. (351) (124) (1,125)
Other current assets....................................... (628) (369) (304)
Other assets............................................... (333) (13) (21)
(Increase) decrease in controlled assets of Medical Practices:
Patient accounts receivable................................ 459 990 806
Other current assets....................................... -- 14 25
Increase (decrease) in liabilities:
Accounts payable........................................... 455 839 (502)
Accrued liabilities........................................ 608 106 3
Due to Medical Practices................................... 1,419 (280) (131)
Patient deposits........................................... 746 79 (77)
------- ------- --------
Net cash provided by (used in) operating activities.............. 365 (450) (554)
------- ------- --------
Cash flows (used in) provided by investing activities:
Purchase of short term investments........................... -- (500) (1,500)
Proceeds from short term investments......................... 2,000 -- --
Payment for exclusive management rights and acquired
physician practices........................................ (10,007) (984) (177)
Purchase of net assets of acquired businesses................ (661) (394) (168)
Purchase of fixed assets and leasehold improvements.......... (2,053) (1,498) (1,152)
Proceeds from sale of fixed assets and leasehold
improvements............................................... 139 86 651
------- ------- --------
Net cash (used in) provided by investing activities.............. (10,582) (3,290) (2,346)
------- ------- --------
Cash flows provided by (used in) financing activities:
Proceeds from issuance of Common Stock....................... 9,601 -- --
Used for stock issue costs................................... (1,308) -- --
Proceeds from bank under Credit Facility..................... 250 -- --
Principal repayments on debt................................. (235) (193) (84)
Principal repayments under capital lease obligations ........ (136) (216) (173)
Repurchase of Convertible Preferred Stock.................... -- (83) (358)
Used for recapitalization costs.............................. -- (33) --
Proceeds from exercise of Common Stock options............... 23 38 --
------- ------- --------
Net cash provided by (used in) financing activities.............. 8,195 (487) (615)
------- ------- --------
Net decrease in cash............................................. (2,022) (4,227) (3,515)
Cash at beginning of period...................................... 3,952 8,179 11,694
------- ------- --------
Cash at end of period............................................ $ 1,930 $ 3,952 $ 8,179
======= ======= ========
See accompanying notes to the consolidated financial statements.
F-6
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 -- THE COMPANY:
IntegraMed America, Inc. (the "Company") is a physician practice management
company specializing in women's reproductive health care, with a focus on
infertility and assisted reproductive technology ("ART") services. The Company
provides comprehensive management services to a nationwide network of medical
providers (each, a "Network Site"). Each Network Site consists of a location or
locations where the Company has a management agreement with a physician group or
hospital (each, a "Medical Practice") which employs the physicians or where the
Company directly employs the physicians.
The Company operates under two divisions: the Reproductive Science Center
Division (the "RSC Division"), which provides management services to Medical
Practices focused on infertility and ART services, and the Adult Women's Medical
Division (the "AWM Division"), which provides management services to Medical
Practices focused on health care services for peri- and post-menopausal women.
As of December 31, 1997, there were ten Network Sites in the RSC Division (the
"Reproductive Science Centers") with seventeen locations in eight states and the
District of Columbia and there was one Network Site with two locations under the
AWM Division which commenced operations in June 1996.
NOTE 2 -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Basis of consolidation --
The consolidated financial statements comprise the accounts of IntegraMed
America, Inc. and its wholly owned subsidiaries, IVF America (NY), Inc., IVF
America (MA), Inc., IVF America (PA), Inc., IVF America (NJ), Inc., IVF America
(MI), Inc. and the Adult Women's Medical Center, Inc. All significant
intercompany transactions have been eliminated. The Company derives its revenues
from patient service revenues, management agreements with a three-part
management fee and, with respect to the New Jersey Network Site, a management
agreement with fees based on a percentage of the revenues and reimbursed costs
of services of such Network Site. The Company does not consolidate the results
of its managed Network Sites.
In 1997, the Emerging Issues Task Force of the Financial Accounting
Standards Board (the "EITF") issued EITF No. 97-2. The EITF reached a consensus
concerning certain matters relating to the physician practice management ("PPM")
industry with respect to the consolidation of professional corporation revenues
and the accounting for business corporations. As an interim step before the
consensus, the EITF allowed PPMs to display the revenues and expenses of managed
physician practices in the statement of operations (the "alternative display
method") if the terms of the management agreement provided the PPM with a "net
profits or equivalent interest" in the net profits of the medical services
furnished by the Medical Practices. It is the Company's understanding that the
EITF did not and would not object to the use of the alternative display method
in PPM financial statements for periods ending before December 15, 1998. As the
Company does not consolidate its managed Network Sites, the adoption of EITF
97-2 in 1998 will not have a material impact on the Company's financial
position, cash flows or results of operations. As discussed below, the Company
will discontinue the display of revenues for its Long Island and Boston Network
Sites due to changes in the respective management agreements.
Since inception through December 31, 1997, the management agreements
related to the Long Island and Boston Network Sites have been incorporated in
the Company's consolidated financial statements via the display method as the
Company believed that these management agreements provided it with a "net
profits or equivalent interest" in the net profits of the medical services
furnished by the Medical Practices at the Long Island and Boston Network Sites.
Consequently, for the Long Island and Boston Network Sites, the Company has
presented the
F-7
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Medical Practices' patient services revenue, less amounts retained by the
Medical Practices, or "Medical Practice retainage", as "Revenues after Medical
Practice retainage" in the accompanying consolidated statement of operations
("display method"). Effective in October 1997 and January 1998, due to changes
in the management agreements related to the Long Island and Boston Network
Sites, respectively, the Company will no longer display the patient services
revenue of the Long Island and Boston Medical Practices. The revised management
agreements provide for the Company to receive a specific management fee which
the Company will report in "Revenues, net" in the consolidated statement of
operations.
These consolidated financial statements are prepared in accordance with
generally accepted accounting principles which requires the use of management's
estimates. The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
Revenue and cost recognition --
RSC Division
During 1997, the RSC Division's operations were comprised of ten management
agreements.
Under six of the agreements the Company receives as compensation for its
management services a three-part management fee comprised of: (i) a fixed
percentage of net revenues generally equal to 6%, (ii) reimbursed cost of
services (costs incurred in managing a Medical Practice and any costs paid on
behalf of the Medical Practice) and (iii) a fixed or variable percentage of
earnings after management fees and any guaranteed physician compensation, or an
additional fixed or variable percentage of net revenues which generally results
in the Company receiving up to an additional 15% of net revenues. All management
fees are reported as "Revenues, net" by the Company. Direct costs incurred by
the Company in performing its management services and costs incurred on behalf
of the Medical Practice are recorded in costs of services rendered. The
physicians receive as compensation all remaining earnings after payment of the
Company's management fee.
Under another form of management agreement, which had been in use at two
Network Sites during 1997, the Company recorded all patient service revenues
and, out of such revenues, the Company paid the Medical Practices' expenses,
physicians' and other medical compensation, direct materials and certain
hospital contract fees. Specifically, under the management agreement for the
Boston Network Site, the Company guaranteed a minimum physician compensation
based on an annual budget jointly determined by the Company and the physicians.
Remaining revenues, if any, which represented the Company's management fees,
were used by the Company for other direct administrative expenses which were
recorded as costs of services. Under the management agreement for the Long
Island Network Site, the Company's management fee was payable only out of
remaining revenues, if any, after the payment of all expenses of the Medical
Practice. Under these arrangements, the Company had been liable for payment of
all liabilities incurred by the Medical Practices and had been at risk for any
losses incurred in the operation thereof. Effective in October 1997 and January
1998, due to changes in the management agreements related to the Long Island and
Boston Network Sites, respectively, the Company will no longer display patient
service revenues of the Long Island and Boston Medical Practices which have been
reflected in "Revenues, net" in the Company's consolidated statement of
operations. The revised management agreements provide for the Company to receive
a specific management fee which the Company will report in "Revenues, net" in
its consolidated statement of operations. Under the revised management agreement
for the Long Island Network Site, as compensation for its management services
the Company will receive a fixed fee (initially equal to $345,000 per annum),
subject to annual increases, plus reimbursed costs of services. Under the
revised management agreement
F-8
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
for the Boston Network Site, as compensation for its management services the
Company will receive a three-part management fee consistent to the majority of
the Company's existing management agreements. The revised agreements provide for
increased incentives and risk-sharing for the Company's affiliated Medical
Providers.
Two of the Company's Network Sites are affiliated with medical centers.
Under one of these management agreements, the Company primarily provides
endocrine testing and administrative and finance services for a fixed percentage
of revenues, equal to 15% of net revenues, and reimbursed costs of services.
Under the second of these management agreements, the Company's revenues are
derived from certain ART laboratory services performed, and directly billed to
the patients by the Company; out of these patient service revenues, the Company
pays its direct costs and the remaining balance represents the Company's Network
Site contribution. All direct costs incurred by the Company are recorded as
costs of services.
AWM Division
The AWM Division's operations are currently comprised of one Network Site
with three locations which are directly owned by the Company and a 51% interest
in the National Menopause Foundation ("NMF"), a company which develops
multifaceted educational programs regarding women's healthcare and publishes a
quarterly women's health digest. The Network Site is also involved in clinical
trials with major pharmaceutical companies.
The Company bills and records all patient service revenues of the Network
Site and records all direct costs incurred as costs of services. The Company
retains as Network site contribution an amount determined using the three-part
management fee calculation described above with regard to the RSC Division, and
the balance is paid as compensation to the Medical Practices and is recorded by
the Company in costs of services rendered. The Medical Practices receive a fixed
monthly draw which may be adjusted quarterly by the Company based on the
respective Network Site's actual operating results.
Revenues in the AWM Division also include amounts earned under contracts
relating to clinical trials between the Network Site and various pharmaceutical
companies. The Network Site contracts with major pharmaceutical companies
(sponsors) to perform women's medical care research mainly to determine the
safety and efficacy of a medication. Research revenues are recognized pursuant
to each respective contract in the period which the medical services (as
stipulated by the research study protocol) are performed and collection of such
fees is considered probable. Net realization is dependent upon final approval by
the sponsor that procedures were performed according to study protocol. Payments
collected from sponsors in advance for services are included in accrued
liabilities, and costs incurred in performing the research studies are included
in costs of services rendered.
The Company's 51% interest in NMF is included in the Company's consolidated
financial statements. The Company records 100% of the patient service revenues
and costs of NMF and reports 49% of any profits of NMF as minority interest on
the Company's consolidated balance sheet. Minority interest at December 31, 1997
and 1996 was $0.
Cash and cash equivalents --
The Company considers all highly liquid debt instruments with original
maturities of three months or less to be cash equivalents.
F-9
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Short term investments --
Short term investments consist of investments in corporate commercial paper
with an original maturity of less than one year but greater than three months
and are available for sale. Investments are recorded at cost, which approximates
market.
Patient accounts receivable --
Patient accounts receivable represent receivables from patients for medical
services provided by the Medical Practices. Such amounts are recorded net of
contractual allowances and estimated bad debts and risk of loss due to
non-collectibility is borne by the Company. As of December 31, 1997, of the
total patient accounts receivable of approximately $7.1 million, approximately
$4.5 million of accounts receivable was a function of Network Site revenue
(i.e., the Company purchased the accounts receivable from the Medical Practice)
and the balance of approximately $2.6 million was a function of net revenues of
the Company (see Note 2 -- "Revenue and cost recognition" above).
Management fees receivable --
Management fees receivable represent fees owed to the Company pursuant to
its management agreements with certain Network Sites (see Note 2 -- "Revenue and
cost recognition" above).
Controlled assets of Medical Practices --
Controlled cash represents segregated cash held in the name of certain
Medical Practices; controlled accounts receivable represent patient receivables
due to certain Medical Practices, and controlled other current assets represent
assets owned by and held in the name of certain Medical Practices, all of which
are reflected on the Company's consolidated balance sheet due to the Company's
unilateral control of such assets.
At December 31, 1996, of the $650,000 controlled assets of Medical
Practices, $117,000 was restricted for payment of the amounts due to Medical
Practices and the balance of $533,000 was payable to the Company.
Controlled assets at December 31, 1997 were $0.
Fixed assets --
Fixed assets are valued at cost less accumulated depreciation and
amortization. Depreciation is computed on a straight-line basis over the
estimated useful lives of the related assets, generally three to five years.
Leasehold improvements are amortized over the shorter of the asset life or the
remaining term of the lease. Assets under capital leases are amortized over the
term of the lease agreements. The Company periodically reviews the fair value of
long-lived assets, the results of which have had no material effect on the
Company's financial position or results of operations.
When assets are retired or otherwise disposed of, the costs and related
accumulated depreciation are removed from the accounts. The difference between
the net book value of the assets and proceeds from disposition is recognized as
gain or loss. Routine maintenance and repairs are charged to expenses as
incurred, while costs of betterments and renewals are capitalized.
F-10
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Intangible assets --
Intangible assets at December 31, 1997 and 1996 consisted of the following
(000's omitted):
1997 1996
---- ----
Exclusive management rights.................. $15,539 $ 2,178
Goodwill..................................... 3,890 3,935
Trademarks................................... 395 394
------- -------
Total................................... 19,824 6,507
Less-- accumulated amortization.............. (1,379) (613)
------- -------
Total................................... $18,445 $ 5,894
======= =======
Exclusive Management Rights, Goodwill and Other Intangible Assets
Exclusive management rights, goodwill and other intangible assets represent
costs incurred by the Company for the right to manage and/or acquire certain
Network Sites and are valued at cost less accumulated amortization.
Trademarks
Trademarks represent trademarks, service marks, trade names and logos
purchased by the Company and are valued at cost less accumulated amortization.
Amortization and recoverability
The Company periodically reviews its intangible assets to assess
recoverability; any impairments would be recognized in the consolidated
statement of operations if a permanent impairment were determined to have
occurred. Recoverability of intangibles is determined based on undiscounted
expected earnings from the related business unit or activity over the remaining
amortization period. Exclusive management rights are amortized over the term of
the respective management agreement, usually ten to twenty-five years. Goodwill
and other intangibles are amortized over periods ranging from three to forty
years. Trademarks are amortized over five to seven years. Accumulated
amortization of exclusive management rights, goodwill and trademarks was
$802,000, $283,000 and $294,000 at December 31, 1997, respectively, and
$270,000, $91,000 and $252,000 at December 31, 1996, respectively.
Due to Medical Practices --
As of December 31, 1997, Due to Medical Practices primarily represents net
distributions owed by the Company to the Medical Practices related to earnings
of the respective Medical Practice, the Company's management fee, the Company's
purchase of the Medical Practice's patient accounts receivable and the Company's
advances to the Medical Practice, if any.
As of December 31, 1996, Due to Medical Practices represents liabilities
the Company was obligated to pay on behalf of, or directly to, the Medical
Practices from the controlled assets of Medical Practices, which may be offset
by advances made by the Company to certain Medical Practices for professional
and affiliate fees.
F-11
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Due to Medical Practices excludes amounts owed by the Company to Medical
Practices for exclusive management rights (see Note 7).
Stock based employee compensation --
The Company adopted Financial Accounting Standards No. 123, "Accounting for
Stock Based Compensation" (FAS 123), on January 1, 1996. Under FAS 123,
companies can, but are not required to, elect to recognize compensation expense
for all stock based awards, using a fair value method. The Company has adopted
the disclosure only provisions, as permitted by FAS 123.
Concentrations of credit --
Financial instruments which potentially expose the Company to
concentrations of credit risk consist primarily of trade accounts receivable.
The Company's trade receivables are primarily from third party payors,
principally insurance companies and health maintenance organizations.
Income taxes --
The Company accounts for income taxes utilizing the asset and liability
approach.
Earnings per share --
The Company determines earnings (loss) per share in accordance with
Financial Accounting Standards No. 128, "Earnings Per Share" (FAS 128) which the
Company adopted in December 1997. All historical earnings (loss) per share have
been presented in accordance with FAS 128.
F-12
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 3 -- REVENUES, MEDICAL PRACTICE RETAINAGE AND COSTS OF SERVICES:
The following table sets forth for the years ended December 31, 1997, 1996
and 1995, revenues, Medical Practice retainage and costs of services for each of
the Company's three types of management agreements (patient service revenues,
three-part management fee and percent of revenues and reimbursed costs of
services) and revenues and costs of services for the AWM Division (000's
omitted):
For the years ended December 31,
---------------------------------
1997 1996 1995
------- ------- -------
Revenues, net:
RSC Division --
Patient service revenues.................................. $10,154 $11,449 $13,820
Management fees--three part management fee................ 8,251 3,159 981
Management fees-- percent of revenues and reimbursed
costs of services of the New Jersey Network Site....... 3,685 2,978 1,910
------- ------- -------
Total RSC Division revenues, net............... 22,090 17,586 16,711
------- ------- -------
AWM Division-- revenues................................... 2,079 757 --
------- ------- -------
Total revenues, net............................ $24,169 $18,343 $16,711
======= ======= =======
Medical Practice retainage:
RSC Division --
Medical Practice retainage related to
patient service revenues............................ $ 1,531 $ 2,680 $3,063
======= ======= ======
Costs of services:
RSC Division --
Costs related to patient service revenues................. $6,282 $ 7,465 $ 7,963
Costs related to three part management fees............... 7,112 3,049 933
Costs related to New Jersey Network Site ................. 1,546 1,095 1,090
------- ------- -------
Total RSC division costs of services.............. 14,940 11,609 9,986
------- ------- -------
AWM Division--Costs of services.............................. 2,311 789 --
------- ------- -------
Total costs of services........................... $17,251 $12,398 $ 9,986
======= ======= =======
For the years ended December 31, 1997 and 1996, the Boston Network Site,
which is reflected as patient service revenues under the RSC Division, provided
28.4% and 38.5% and 35.2% and 58.8% of "Revenues, net" and Network Sites'
contribution, respectively, of the Company. Summary financial information for
this Network Site is as follows (000's omitted):
For the years ended December 31,
--------------------------------
1997 1996 1995
------- ------- -------
Revenues, net............................................. $6,868 $7,063 $6,594
Medical Practice retainage................................ 1,105 1,015 556
------ ------ ------
Revenues after Medical
Practice retainage..................................... 5,763 6,048 6,038
Costs of services rendered............................... 3,867 4,126 3,970
------ ------ ------
Network Site's contribution.............................. $1,896 $1,922 $2,068
====== ====== ======
F-13
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
In addition, for the years ended December 31, 1997 and 1996, the New Jersey
Network Site, which management fee is based upon a percentage of revenues,
provided 15.3% and 16.2% and 39.7% and 57.7% of "Revenues, net" and Network
Sites' contribution, respectively, of the Company.
NOTE 4 -- FIXED ASSETS, NET:
Fixed assets, net at December 31, 1997 and 1996 consisted of the following
(000's omitted):
1997 1996
------- -------
Furniture, office and other equipment..... $2,768 $ 2,145
Medical equipment......................... 2,093 1,954
Leasehold improvements.................... 2,408 1,246
Assets under capital leases............... 1,234 1,426
------ ------
Total................................. 8,503 6,771
Less--Accumulated depreciation and
amortization.......................... (3,761) (3,585)
------ -------
$4,742 $ 3,186
====== =======
Assets under capital leases primarily consist of medical equipment.
Accumulated amortization relating to capital leases at December 31, 1997 and
1996 was $1,011,000 and $1,065,000, respectively.
NOTE 5 -- ACCRUED LIABILITIES:
Accrued liabilities at December 31, 1997 and 1996 consisted of the
following (000's omitted):
1997 1996
---- ----
Accrued insurance............................... $ 483 $ --
Deferred compensation........................... 367 357
Accrued payroll and benefits.................... 239 226
Deferred research revenue....................... 223 118
Accrued state taxes............................. 198 166
Deferred rent................................... 147 166
Westchester Network Site closing reserve........ -- 90
Other........................................... 603 529
------ ------
Total accrued liabilities....................... $2,260 $1,652
====== ======
NOTE 6 -- ACQUISITIONS AND MANAGEMENT AGREEMENTS:
The transactions detailed below were accounted for by the purchase method
and the purchase price has been allocated to the assets acquired and liabilities
assumed based upon the estimated fair value at the date of acquisition. The
consolidated financial statements at and for the year ended December 31, 1997
and 1996 include the results of these transactions from their respective dates
of acquisition.
On January 7, 1997, the Company acquired certain assets of the Bay Area
Fertility and Gynecology Medical Group, a California partnership (the
"Partnership"), and acquired the right to manage the Bay Area Fertility and
Gynecology Medical Group, Inc., a California professional corporation which is
the successor to the Partnership's medical practice ("Bay Area Fertility"). The
aggregate purchase price was approximately $2.0 million, consisting of $1.5
million in cash and $0.5 million in the form of the Company's Common Stock, or
333,333 shares of the Company's Common Stock. In addition to the exclusive right
to manage Bay Area Fertility, the Company acquired other assets which primarily
consisted of the name "Bay Area Fertility" and medical equipment and furniture
and fixtures which will continue to be used by Bay Area Fertility in the
provision of infertility and ART services.
F-14
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
In June 1997, the Company acquired certain assets of and the right to
manage Reproductive Science Medical Center, Inc. ("RSMC"), a California
professional corporation located near San Diego, CA (the "San Diego
Acquisition"). The aggregate purchase price for the San Diego Acquisition was
approximately $900,000, consisting of $50,000 in cash and 145,454 shares of
Common Stock payable at closing and $650,000 payable upon the achievement of
certain specified milestones, at RSMC's option, in cash or in shares of the
Company's Common Stock, based on the closing market price of the Common Stock on
the third business day prior to issuance. See Note 17.
In August 1997, the Company acquired certain fixed assets of and the right
to manage Fertility Centers of Illinois, S.C. ("FCI"), a physician group
practice comprised of six physicians and six locations in the Chicago, Illinois
area. The aggregate purchase price was approximately $8.6 million, consisting of
approximately $6.6 million in cash and 1,009,464 shares of Common Stock.
Approximately $8.0 million of the aggregate purchase price was allocated to
exclusive management rights and $559,000 was allocated to certain fixed assets.
Simultaneous with closing on the FCI transaction, the Company, on behalf of
FCI, completed its first in- market merger with the addition of Edward L. Marut,
MD to the FCI practice. The aggregate purchase price was $803,000 in cash, of
which $750,000 was allocated to exclusive management rights and $53,000 was
allocated to certain fixed assets.
On June 7, 1996, the Company entered into an Agreement and Plan of Merger
(the "Agreement") pursuant to which INMD Acquisition Corp. ("IAC"), a Florida
corporation and wholly-owned subsidiary of the Company, acquired all of the
outstanding stock of the following three related Florida corporations: The
Climacteric Clinic, Inc. ("CCI"), Midlife Centers of America, Inc. ("MCA"), and
Women's Research Centers, Inc. ("WRC"), America, (collectively, the "Merger
Companies"), and 51% of the outstanding stock of NMF, a related Florida
corporation. Pursuant to the Agreement, the Merger Companies were merged with
and into IAC, the surviving corporation in the Merger, which will continue its
corporate existence under the laws of the State of Florida under the name Adult
Women's Medical Center, Inc. ("AWMC"). In exchange for the shares of the Merger
Companies, the Company paid cash in an aggregate amount of $350,000 and issued
666,666 shares of Common Stock which had a market value of $2.5 million. In
exchange for the 51% of the outstanding stock of NMF, the Company paid cash in
an aggregate amount of $50,000 and issued a note in an amount of $600,000, which
is payable in sixteen quarterly installments of $37,500 beginning September 1,
1996 with simple interest at a rate of 4.16%. The Merger Companies and NMF
represent one of the locations under the Women's Medical & Diagnostic Center
("WMDC").
The aggregate purchase price of the Merger Companies of $2,850,000 was
allocated as follows to assets acquired and liabilities assumed: $338,000 to
current assets, $99,000 to fixed assets, $214,000 to intangible assets which
will be amortized over a three-year period, $235,000 to accrued liabilities,
$97,000 to debt and the balance of $2,531,000 to goodwill, which will be
amortized over a forty-year period. The aggregate purchase price of NMF of
$650,000 was allocated as follows: $2,000 to current assets, $30,000 to fixed
assets, $10,000 to current liabilities and the $628,000 balance to goodwill,
which will be amortized over a forty-year period.
On May 15, 1996, the Company acquired certain assets of and the right to
manage W.F. Howard, M.D., P.A. near Dallas, Texas (the "RSC of Dallas"), a
provider of conventional infertility and assisted reproductive technology
services. The aggregate purchase price was approximately $701,500 of which
approximately $244,000 was paid at closing and the Company issued a promissory
note for the $457,500 balance which is payable as follows: $100,000 on the last
business day of May 1997 and 1998, and $36,786 on the last business day of May
in each of the seven years thereafter, thru May 2005. The aggregate purchase
price was allocated to fixed assets in the amount of $144,000 and the balance of
$557,500 to exclusive management rights, which will be amortized over the ten
year term of the agreement.
The following unaudited pro forma results of operations for the year ended
December 31, 1997 have been prepared by management based on the audited
financial information of FCI and the unaudited financial information
F-15
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
for Shady Grove, the Maryland professional corporation (Refer to Note 17 --
Subsequent Events -- regarding the Shady Grove acquisition), adjusted where
necessary, with respect to pre-acquisition periods, to the basis of accounting
used in the historical financial statements of the Company. Bay Area Fertility
results for the year ended December 31, 1997 are included from the date of
acquisition, January 7, 1997. The following unaudited pro forma results of
operations for the year ended December 31, 1996 have been prepared by management
based on the audited financial information of Bay Area Fertility Reproductive
Sciences Medical Center and of FCI and the unaudited financial information of
Shady Grove (the Maryland professional corporation), the Merger Companies and
NMF and the RSC of Dallas, adjusted where necessary, with respect to
pre-acquisition periods, to the basis of accounting used in the historical
financial statements of the Company. Such adjustments include modifying the
results to reflect operations as if the related management agreements had been
consummated on January 1, 1997 and 1996, respectively. Additional general
corporate expenses which would have been required to support the operations of
the new Network Sites are not included in the pro forma results. The unaudited
pro forma results may not be indicative of the results that would have occurred
if the management agreement had been in effect on the dates indicated or which
may be obtained in the future.
For the years ended
December 31,
(000's omitted)
-------------------
1997 1996
---- ----
(unaudited)
Revenues, net.............................................................. $33,813 $30,047
Income (loss) before income taxes (1)...................................... $ 1,700 $ (602)
Net income (loss) before consideration for induced conversion of
Preferred Stock in 1996................................................. $ 1,356 $ (889)
Basic earnings (loss) per share before consideration for induced
conversion of Preferred Stock in 1996................................... $ 0.08 $ (0.09)
Diluted earnings (loss) per share before consideration for induced
conversion of Preferred Stock in 1996................................... $ 0.08 $ (0.09)
(1) Income (loss) before income taxes includes approximately $1.4 million and
$1.2 million of amortization of exclusive management rights and goodwill in
1997 and 1996, respectively.
NOTE 7 -- EXCLUSIVE MANAGEMENT RIGHTS OBLIGATION:
Exclusive management rights obligation represents the liability owed by the
Company to Medical Practices for the cost of acquiring the exclusive right to
manage the non-medical aspects of the Medical Practices' infertility practices.
Typically, the Company will pay cash for a portion of such cost at the inception
of the management agreement and pay the balance in equal installments over a
two- to three-year period or over the life of the agreement, where the term is
equal to ten years.
At December 31, 1997, aggregate exclusive management rights obligation
payments in future years were as follows (000's omitted):
1998........................................... $ 472
1999........................................... 459
2000........................................... 259
2001........................................... 159
2002........................................... 159
Thereafter..................................... 355
Total payments................................. $1,863
F-16
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 8 -- DEBT:
Debt at December 31, 1997 and 1996 consisted of the following (000's
omitted):
1997 1996
---- ----
Acquisition note payable............................. $ 375 $ 525
Note payable to Bank................................. 292 --
Notes payable to Medical Practices employed
by the Company................................. 220 220
Obligations under capital lease...................... 178 269
Construction loan.................................... -- 51
Other................................................ -- 53
----- ------
Total debt........................................... 1,065 1,118
Less--Current portion................................. (614) (426)
----- ------
Long-term debt....................................... $ 451 $ 692
===== ======
In November 1996, the Company obtained a $1.5 million revolving credit
facility (the "Credit Facility") issued by First Union National Bank (the
"Bank"). Borrowings under the Credit Facility bear interest at the Bank's prime
rate plus 0.75% per annum, which at December 31, 1997, was 9.25%. The Credit
Facility terminates on July 1, 1998 and is secured by the Company's assets. At
December 31, 1997, $250,000 was outstanding under the Credit Facility and is
included in "Note payable and current portion of long-term debt" in the
accompanying consolidated balance sheet. At December 31, 1996, no amounts were
outstanding under the Credit Facility.
On November 13, 1997, the Company entered into a $4.0 million non-restoring
line of credit dated November 13, 1997 with the Bank (the "New Credit
Facility"). Borrowings under the New Credit Facility bear interest at the Bank's
prime rate plus 1% per annum. Accrued interest only on borrowings is payable
commencing December 1, 1997 and all principal and accrued interest is due and
payable on April 30, 1999. The New Credit Facility will be cross collateralized
and cross-defaulted with the Credit Facility and is secured by the Company's
assets. As of December 31, 1997, no amounts were outstanding under the New
Credit Facility.
In June 1996, the Company purchased a 51% interest in NMF for a total
purchase price of $650,000, of which $50,000 was paid at closing and the balance
is to be paid in sixteen quarterly installments of $37,500 beginning September
1, 1996. Interest is payable quarterly at the rate of 4.16% (see Note 15).
On December 30, 1996, the Company acquired North Central Florida Ob-Gyn
Associates which it then merged into WMDC. The total purchase price of the
acquisition was $320,000 of which $220,000 is to be paid in four equal
installments of $55,000 for each of the next four years commencing December 30,
1997. In January 1998, as part of a termination agreement, this note was
canceled.
In May 1992, the Company obtained a $350,000 construction loan for the
development of its New Jersey Network Site of which $0 and $51,000 were
outstanding at December 31, 1997 and 1996, respectively. The debt was payable in
fifty-four monthly installments of $6,481 commencing on April 1, 1993 through
September 1, 1997. Interest was payable at the bank's prime rate which was 8.25%
at December 31, 1996.
Capital lease obligations relate primarily to furniture and medical
equipment for the Network Sites. The current portion of capital lease
obligations was $131,000 and $139,000 at December 31, 1997 and 1996,
respectively.
The Company has operating leases for its corporate headquarters and for
medical office space relating to its managed Network Sites. In 1997 and 1996,
the Company also entered into operating leases for certain medical
F-17
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
equipment. Aggregate rental expense under operating leases was $1,284,000,
$540,000 and $522,000 for the year ended December 31, 1997, 1996 and 1995,
respectively. Refer to Note 14 -- "Commitments and Contingencies -- Commitments
to Medical Practices."
At December 31, 1997, the minimum lease payments for assets under capital
and noncancelable operating leases in future years were as follows (000's
omitted):
Capital Operating
------- ---------
1998........................................... $140 $1,290
1999........................................... 46 1,164
2000........................................... 4 633
2001........................................... -- 462
2002........................................... -- 789
Thereafter..................................... -- 634
---- ------
Total minimum lease payments................... 190 $4,972
======
Less-- Amount representing interest............ (12)
----
Present value of minimum lease payments........ $178
====
NOTE 9 -- INCOME TAXES
The deferred tax provision was determined under the asset and liability
approach. Deferred tax assets and liabilities were recognized on differences
between the book and tax basis of assets and liabilities using presently enacted
tax rates. The provision for income taxes was the sum of the amount of income
tax paid or payable for the year as determined by applying the provisions of
enacted tax laws to the taxable income for that year and the net change during
the year in the Company's deferred tax assets and liabilities. The provision for
the years ended December 31, 1997, 1996 and 1995 of $104,000, $141,000 and
$155,000, respectively, was comprised of current state taxes payable.
The Company's deferred tax assets primarily represented the tax benefit of
operating loss carryforwards. However, such deferred tax asset was fully reduced
by a valuation allowance due to the uncertainty of its realization.
At December 31, 1997, the Company had operating loss carryforwards of
approximately $18.2 million which expire in 2002 through 2012. For tax purposes,
there is an annual limitation of approximately $2.0 million on the utilization
of net operating losses resulting from changes in ownership attributable to the
Company's May 1993 Preferred Stock Offering and the August 1997 Common Stock
Offering and FCI acquisition.
Significant components of the noncurrent deferred tax assets (liabilities)
at December 31, 1997 and 1996 were as follows (000's omitted):
December 31,
------------
1997 1996
----- -----
Net operating loss carryforwards........... $6,900 $6,777
Other...................................... 500 438
Valuation allowance........................ (7,250) (7,115)
------ ------
Deferred tax assets........................ 150 100
Deferred tax liabilities................... (150) (100)
------- ------
Net deferred taxes......................... $ -- $ --
======= ======
F-18
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
The financial statement income tax provision differed from income taxes
determined by applying the statutory Federal income tax rate to the financial
statement income or loss before income taxes for the year ended December 31,
1997, 1996 and 1995 as a result of the following:
For the years ended December 31,
--------------------------------
1997 1996 1995
---- ---- ----
Tax expense (benefit) at Federal statutory rate.......... $167,000 $(472,000) $ 79,000
State income taxes....................................... 104,000 141,000 155,000
Net operating profit or loss (providing)
not providing current year tax benefit................. (167,000) 472,000 (79,000)
-------- --------- ----------
Provision for income taxes............................... $104,000 $141,000 $ 155,000
======== ======== =========
NOTE 10 -- EARNINGS PER SHARE:
The reconciliation of the numerators and denominators of the basic and
diluted EPS computations for the years ended December 31, 1997, 1996, and 1995
is as follows (000's omitted, except for per share amounts):
1997 1996(1) 1995
----------------------------- ----------------------------- ----------------------------
Income Shares Per-Share Income Shares Per-Share Income Shares Per-Share
(Numerator)(Denominator)Amount (Numerator)(Denominator)Amount (Numerator)(Denominator)Amount
--------- ----------- ------ ----------- ----------- ------ ---------- ----------- ------
Net income (loss)............ $374 $(1,490) $ 70
Less: Preferred stock
dividends accrued......... (133) (132) (600)
---- -------- -----
Basic EPS
Income (loss) available to
Common stockholders....... $241 12,405 $0.02 $(1,622) 7,602 $(0.21) $(530) 6,087 $(0.09)
==== ====== ===== ======= ===== ====== ===== ===== ======
Effect of Dilutive Securities
Options...................... -- 187 -- -- -- --
Warrants..................... -- 24 -- -- -- --
---- ------ ------- ----- ----- ----
Diluted EPS (1)
Income (loss) available to
Common stockholders + assumed
conversions............... $241 12,616 $0.02 $(1,622) 7,602 $(0.21) $(530) 6,087 $(0.09)
==== ====== ===== ======= ===== ====== ===== ===== ======
(1) For the year ended December 31, 1996, basic and diluted earnings per share
of $(0.21) exclude the effect of the induced conversion of Preferred Stock in
1996. Net loss applicable to Common Stock before consideration for induced
conversion of Preferred Stock of $1,622,000 would be increased by $3,292,000,
the assumed value of Common Stock issued to induce conversion of Preferred
Stock, net of the reversal of $973,000 of accrued Preferred Stock dividends, to
arrive at the net loss applicable to Common Stock after consideration for
induced conversion of Preferred Stock of $4,914,000. The assumed per share value
of the conversion inducement was $(0.47) bringing the basic and diluted loss per
share of Common Stock to $(0.68) (after induced conversion of Preferred Stock).
F-19
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Options to purchase 1,190,419 shares of Common Stock at prices ranging from
$1.87 to $3.75 per share were outstanding as of December 31, 1997 but were not
included in the computation of diluted EPS because the options' exercise price
was greater than the average market price of the Common shares. The approximate
remaining weighted average life of these options is 8.1 years.
For the year ended December 31, 1997, the 492,791 incremental shares from
the assumed conversion of Preferred Stock are excluded in computing the diluted
per share amount as they are antidilutive.
For the years ended December 31, 1996 and 1995, the effect of the assumed
conversion of options to purchase 1,066,816 shares of Common Stock at a weighted
average exercise price of $1.92 and options to purchase 843,202 shares of Common
Stock at a weighted average exercise price of $1.63, respectively, and 250 and
980 of incremental shares from the assumed conversion of Preferred Stock are
excluded in computing the diluted per share amount as they are antidilutive.
NOTE 11 -- SHAREHOLDERS' EQUITY:
In August 1997, the Company consummated an offering of 6,400,000 shares of
Common Stock (the "Offering"). The Offering raised gross proceeds of $9.6
million and net proceeds of approximately $8.3 million. Approximately $6.6
million of the net proceeds was used for the asset purchase and right-to-manage
agreement with Fertility Centers of Illinois, S.C. The balance of the proceeds
of the Offering have been and will continue to be used for working capital and
other general corporate purposes, including possible future acquisitions of the
assets of, and the right to manage, additional physician practices. In
connection with the Offering, five-year warrants to purchase 79,627 shares of
Common Stock at $1.81 per share were issued to Vector Securities International,
Inc. See Note 17.
As a result of the issuance of the Common Stock pursuant to the Company's
acquisitions in 1997 and 1996 and the Offering, the anti-dilution rights of the
Preferred Stock, the conversion rate of the Preferred Stock is subject to
increase and each share of Preferred Stock was convertible into Common Stock at
a conversion rate equal to 2.975 shares of Common Stock for each share of
Preferred Stock as of December 31, 1997.
On June 6, 1996, the Company made its second conversion offer (the "Second
Offer") to the holders of the 773,878 outstanding shares of the Company's
Preferred Stock. Under the Second Offer, Preferred Stockholders received four
shares of the Company's Common Stock upon conversion of a share of Preferred
Stock and respective accrued dividends, subject to the terms and conditions set
forth in the Second Offer. The Second Offer was conditioned upon a minimum of
400,000 shares of Preferred Stock being tendered; provided that the Company
reserved the right to accept fewer shares. Upon expiration of the Second Offer
on July 17, 1996, the Company accepted for conversion 608,234 shares, or 78.6%
of the Preferred Stock outstanding, constituting all the shares validly
tendered. Following the transaction, there were 9,198,375 shares of IntegraMed
America's Common Stock outstanding and 165,644 shares of Preferred Stock
outstanding.
Under the Second Offer, Preferred Stockholders received four shares of
Common Stock for each share of Preferred Stock and respective accrued dividends
converted. This Second Offer represented an increase from the original terms of
the Preferred Stock which provided for 1.45 shares of Common Stock for each
share of Preferred Stock (after adjustment for the failure of the Company to pay
eight dividends and after adjustment for the issuance of Common Stock pursuant
to its acquisition of WMDC and NMF). Since the Company issued an additional
1,550,997 shares of Common Stock in the conversion offer compared to the shares
that would have been issued under the original terms of the Preferred Stock, the
Company was required, pursuant to a recently enacted accounting pronouncement,
to deduct the fair value of these additional shares of approximately $4,265,000
from earnings available to Common Stockholders. This non-cash charge, partially
F-20
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
offset by the reversal of $973,000accrued dividends attributable to the
conversion, resulted in the increase in net loss per share by approximately
$(.47) for the year ended December 31, 1996. While this charge is intended to
show the cost of the inducement to the owners of the Company's Common Stock
immediately before the conversion offer, management does not believe that it
accurately reflects the impact of the conversion offer on the Company's Common
Stockholders. As a result of the conversion, the Company reversed $973,000 in
accrued dividends from its balance sheet and the conversion will save the
Company from accruing annual dividends of $486,000 and the need to include these
dividends in earnings per share calculations. The conversion has also eliminated
a $6.1 million liquidation preference related to the shares of Preferred Stock
converted.
Dividends on the Preferred Stock are payable at the rate of $.80 per share
per annum, quarterly on the fifteenth day of August, November, February and May
of each year commencing August 15, 1993. In May 1995, as a result of the
Company's Board of Directors suspending four quarterly dividend payments,
holders of the Preferred Stock became entitled to one vote per share of
Preferred Stock on all matters submitted to a vote of stockholders, including
election of directors; once in effect, such voting rights are not terminated by
the payment of all accrued dividends. The Company does not anticipate the
payment of any cash dividends on the Preferred Stock in the foreseeable future.
As of December 31, 1997, fourteen quarterly dividend payments have been
suspended resulting in approximately $464,000 of dividend payments being in
arrears.
In conjunction with the Second Offer, the Company entered into an agreement
with two representatives of the underwriters of such offering (the
"Representatives") to issue warrants to one or both of the Representatives.
Pursuant to this agreement (the "Warrant Agreement"), the Company issued to the
Representatives warrants to purchase through May 21, 1998 (a) up to an aggregate
200,000 shares of Preferred Stock at an initial price of $16.00 per share, (b)
up to 220,000 shares, subject to certain adjustments, of Common Stock at an
initial exercise price of $14.54 per share of Common Stock or (c) any
combination of such securities at the respective exercise prices which results
in an aggregate exercise price of $3,200,000, all subject to the terms and
conditions of the Warrant Agreement. No warrants have been exercised through
December 31, 1997.
As of December 31, 1997, an aggregate of 774,805 warrants were outstanding
at a weighted average exercise price of $4.60.
NOTE 12 -- STOCK OPTIONS:
Under the 1988 Stock Option Plan (as amended), (the "1988 Plan") and the
1992 Stock Option Plan (the "1992 Plan"), 161,627 and 1,300,000 shares,
respectively, are reserved for issuance of incentive and non-incentive stock
options. Under both the 1988 and 1992 Plans, incentive stock options, as defined
in Section 422 of the Internal Revenue Code, may be granted only to employees
and non-incentive stock options may be granted to employees, directors and such
other persons as the Board of Directors (or a committee (the "Committee")
appointed by the Board) determines will contribute to the Company's success at
exercise prices equal to at least 100%, or 110% for a ten percent shareholder,
of the fair market value of the Common Stock on the date of grant with respect
to incentive stock options and at exercise prices determined by the Board of
Directors or the Committee with respect to non-incentive stock options. The 1988
Plan provides for the payment of a cash bonus to eligible employees in an amount
equal to that required to exercise incentive stock options granted. Stock
options issued under the 1988 Plan are exercisable, subject to such conditions
and restrictions as determined by the Board of Directors or the Committee,
during a ten-year period, or a five-year period for incentive stock options
granted to a ten percent shareholder, following the date of grant; however, the
maturity of any incentive stock option may be accelerated at the discretion of
the Board of Directors or the Committee. Under the 1992 Plan, the Board of
Directors or the Committee determines the exercise dates of options granted;
however, in no event may incentive stock options be exercised prior to one year
from date of grant. Under both the 1988 and 1992 Plans, the Board of Directors
or the Committee selects the optionees, determines the number of shares of
Common Stock subject to each option and otherwise administers the Plans. Under
the 1988 Plan, options expire one month from the date of the holder's
F-21
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
termination of employment with the Company or six months in the event of
disability or death. Under the 1992 Plan, options expire three months from the
date of the holder's termination of employment with the Company or twelve months
in the event of disability or death.
Under the 1994 Outside Director Stock Purchase Plan ("Outside Director
Plan"), 125,000 shares of Common Stock are reserved for issuance. Under the
Outside Director Plan, directors who are not full-time employees of the Company
may elect to receive all or a part of their annual retainer fees, the fees
payable for attending meetings of the Board of Directors and the fees payable
for serving on Committees of the Board, in the form of shares of Common Stock
rather than cash, provided that any such election be made at least six months
prior to the date that the fees are to be paid. At December 31, 1997 and 1996,
there were no options outstanding under the Outside Director Plan.
Stock option activity, under the 1988 and 1992 Plans combined, is
summarized as follows:
Number of
shares of
Common Stock
underlying Weighted Average
options exercise price
----------- ----------------
Options outstanding at December 31, 1994... 732,627 $1.44
Granted
Option Price = Fair Market Value...... 130,250 $2.62
Canceled................................... (19,675) $2.06
---------
Options outstanding at December 31, 1995... 843,202 $1.63
Granted
Option Price = Fair Market Value...... 119,500 $3.42
Option Price > Fair Market Value...... 225,000 $2.37
Exercised.................................. (44,045) $1.31
Canceled................................... (76,841) $2.37
---------
Options outstanding at December 31, 1996... 1,066,816 $1.92
Granted
Option Price = Fair Market Value...... 362,484 $2.08
Exercised.................................. 18,750 $1.20
Canceled................................... 215,135 $2.38
---------
Options outstanding at December 31, 1997... 1,195,415 $1.90
=========
Options exercisable at:
December 31, 1995..................... 270,035 $1.47
December 31, 1996..................... 406,968 $1.54
December 31, 1997..................... 583,897 $1.66
Included in options that were canceled during 1997, 1996 and 1995 were
forfeitures (representing canceled unvested options only) of 155,580, 56,710 and
16,034, with weighted average exercise prices of $1.99, $2.30 and $2.10,
respectively.
The average remaining life of the 1,195,415 options outstanding at December
31, 1997, under the 1988 and 1992 Plan combined, was 7.8 years at exercise
prices ranging from $0.63 to $3.75.
F-22
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Pro forma information:
FAS 123 requires pro forma disclosures of net income and earnings per share
amounts as if compensation expense, using the fair value method, was recognized
for options granted after 1994. Using this approach, pro forma net income would
be $771,000 lower and diluted earnings per share would be $0.05 lower for the
year ended December 31, 1997. Pro forma net loss and earnings per share for the
year ended December 31, 1996 would be $313,000 and $0.04 higher, respectively,
versus reported amounts. Pro forma net income would be $38,000 lower and loss
per share would be $0.01 higher for the year ended December 31, 1995. The
weighted average fair value of options granted during the years ended December
31, 1997, 1996 and 1995 was $1.58, $2.91 ( $1.99 for options granted at prices
higher than fair value) and $2.28, respectively. These values, which were used
as a basis for the pro forma disclosures, were estimated using the Black-Scholes
Options-Pricing Model with the following assumptions used for grants in the
years ended December 31, 1997, 1996 and 1995, respectively; dividend yield of 0%
in each year; volatility of 86.28%, 108.72%, and 115.18% in 1997, 1996 and 1995,
respectively; risk-free interest rate of 6.3%, 6.7% and 6.3% in 1997, 1996 and
1995, respectively; and an expected term of 6 years for each year.
These pro forma disclosures may not be representative of the effects for
future years since options vest over several years and options granted prior to
1995 are not considered in these disclosures. Also, additional awards generally
are made each year.
The Company recognizes compensation cost for stock-based employee
compensation plans over the vesting period based on the difference, if any,
between the quoted market price of the stock and the amount an employee must pay
to acquire the stock. Deferred employee compensation cost at December 31, 1997
and 1996 was $367,000 and $357,000, respectively. Total compensation cost
recognized in income for the years ended December 31, 1997 and 1996 was $20,000
and $43,000, respectively.
NOTE 13 -- QUARTERLY FINANCIAL DATA (UNAUDITED):
Summarized quarterly financial data for 1997 and 1996 (in thousands, except
per share data) appear below:
Network Sites' Net Net income (loss)
Revenues, net contribution income (loss) per share (1)
------------- ------------ ------------- -------------
1997 1996 1997 1996 1997 1996 1997 1996
---- ---- ---- ---- ---- ---- ---- ----
First quarter....... $ 5,088 $ 4,175 $1,077 $ 818 $(45) $ (74) $(.01) $(0.04)
Second quarter...... 5,466 4,822 1,307 1,116 94 85 .01 (0.01)
Third quarter....... 5,822 5,016 1,326 577 108 (693) .01 (0.08)
Fourth quarter...... 7,793 4,330 1,677 754 217 (808) .01 (0.09)
------- ------- ------ ------- ---- -------
Total year.......... $24,169 $18,343 $5,387 $ 3,265 $374 $(1,490) $0.02 $(0.21)
======= ======= ====== ======= ==== =======
(1) Refer to Note 11 -- Shareholders' Equity -- regarding the impact of the
Company's Second Offer on net loss per share in 1996.
F-23
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 14 -- COMMITMENTS AND CONTINGENCIES:
Clinical Services Development
The Company has commitments to fund clinical services development pursuant
to various collaboration agreements. Effective July 1, 1995, the Company entered
into a new three-year agreement with Monash University which provides for Monash
to conduct research in ART and human fertility to be funded by a minimum annual
payment of 220,000 in Australian dollars, the results to be jointly owned by the
Company and Monash. If certain milestones are met as specified in the Agreement,
the Company's annual payment may be a maximum of 300,000 Australian dollars in
year two and 380,000 Australian dollars in year three. Minimum payments of
55,000 Australian dollars and payments for the attainment of certain research
milestones will be made quarterly throughout the term of the Agreement, July 1,
1995 through June 30, 1998. The Company expensed approximately $144,000 and
$189,000 under this agreement for the years ended December 31, 1997 and 1996.
Under its contract for a joint development program for genetic testing with
Genzyme Genetics ("Genzyme"), the Company funded approximately $0 and $56,000 in
the years ended December 31, 1997 and 1996, respectively. The Company and
Genzyme mutually agreed to terminate this contract in December 1996; the Company
retained the right to use the technology developed under the contract through
this date.
Operating Leases
Refer to Note 8 for a summary of lease commitments.
Reliance on Third Party Vendors
The Network sites under the RSC Division are dependent on three third-party
vendors that produce patient fertility medications (lupron, metrodin and
fertinex)which are vital to the provision of ART services. Should any of these
vendors experience a supply shortage of medication, it may have an adverse
impact on the operations of the Network sites. To date, the Network sites under
the RSC Division have not experienced any such adverse impacts.
Employment Agreements
The Company has entered into employment and change in control severance
agreements with certain of its management employees, which include, among other
terms, noncompetitive provisions and salary and benefits continuation. The
Company's minimum aggregate commitment under these agreements at December 31,
1997 was approximately $1.8 million.
Commitments to Medical Practices
Pursuant to most new management contracts entered into by the Company in
1995, the Company is obligated to perform the following: (i) advance funds to
the Network Site to guarantee a minimum physician salary and/or to provide new
services, utilize new technologies, fund projects, etc.; and (ii) on or before
the fifteenth business day of each month purchase the net accounts receivable of
the Network site arising during the previous month and to transfer or pay to the
Network Site such amount of funds equal to the net accounts receivable less any
amounts owed to the Company for management fees and/or advances. Any advances
are to be repaid monthly and interest expense, computed at the prime rate used
by the Company's primary bank in effect at the time of the advance, will be
charged by the Company for funds advanced. Under two management agreements, the
Company has guaranteed certain physicians of the Medical Practices an annual
F-24
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
amount of compensation (i.e., medical practice distributions) during the first
twelve months of the agreement. Minimum annual physician salary guaranteed at
December 31, 1997 was $265,000.
Under certain management agreements which expire through 2001, the Company
pays the affiliated Medical Practice a fee for the use of space and other
facility services. Such fee is a fixed amount and/or a fee based upon the number
of "procedures" or "cycles", as defined in the respective agreement, performed
at the Network Site. The aggregate amount expensed pursuant to such agreements
was $558,000, $856,000 and $1,136,000, for the years ended December 31, 1997,
1996 and 1995.
Litigation
In November 1994, the Company was served with a complaint in a matter
captioned Karlin v. IVF America, et. al., pending in the Supreme Court of the
State of New York, County of Westchester. The suit also named, as co-defendants,
Vicki L. Baldwin, a Director of the Company, United Hospital and Dr. John
Stangel. The action purported to be a class-action, initiated by plaintiffs on
behalf of themselves and a class of persons similarly situated. The Complaint
alleged that the defendants, individually and collectively, had, in the
communication of clinical outcome statistics, inaccurately stated success rates
or failed to communicate medical risks attendant to ART procedures. These
allegations gave rise to the central issue of the case, that of informed
consent. The plaintiffs' application for class certification was denied by the
Court. The Court ruled that the potential class of patients treated at the
Westchester Network Site did not meet the criteria for class action status as
required by New York law. The plaintiffs appealed this decision. In June 1997,
the Appellate Division of the Supreme Court of the State of New York, Second
Department affirmed the lower court decision. As a result of prior court
proceedings and the June 1997 decision, the plaintiffs are left with lack of
informed consent as the sole claim against defendants for which defendants have
moved for summary judgment based on the untimeliness of this claim.
There are a few other legal proceedings to which the Company is a party. In
the Company's view, the claims asserted and the outcome of these proceedings
will not have a material adverse effect on the financial position or the results
of operations of the Company.
Insurance
The Company and its affiliated Medical Practices are insured with respect
to medical malpractice risks on a claims made basis. Management is not aware of
any claims against it or its affiliated Medical Practices which might have a
material impact on the Company's financial position or results of operations.
NOTE 15 -- RELATED PARTY TRANSACTIONS:
SDL Consultants, a company owned by Sarason D. Liebler, who became a
director of the Company in August, 1994, rendered consulting services to the
Company during 1997, 1996 and 1995 for aggregate fees of approximately $93,000,
$17,000 and $22,000, respectively.
Pursuant to the Company's management agreement with FCI, Aaron Lifchez,
M.D., an employed shareholder physician of FCI, became a member of the Company's
Board of Directors in August 1997.
Under its contract for a joint development program for genetic testing with
Genzyme, the Company funded approximately $0, $56,000 and $134,000 in the years
ended December 31, 1997, 1996 and 1995, respectively. The Company and Genzyme
mutually agreed to terminate this contract in December 1996; the Company
retained the right to use the technology developed under the contract through
such date.
F-25
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
In connection with the Company's acquisition of WMDC in June 1996 (see Note
7), Morris Notelovitz, M.D., Ph.D. (the "Physician") became a member of the
Company's Board of Directors, and under two long term employment agreements (the
"Employment Agreements"), one being with the Company and the other with AWMC,
the Physician agreed to serve as Vice President for Medical Affairs and Medical
Director of the AWM Division and agreed to provide medical services under the
AWM Division, as defined, respectively. Effective January 1, 1997, Dr.
Notelovitz resigned from his position as a director of the Company and
terminated the Employment Agreements (medical services under the Employment
Agreement with AWMC were terminated effective March 31, 1997) (see Note 8).
NOTE 16 -- SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION AND NON-CASH
TRANSACTIONS:
In 1997, in connection with the Company's acquisition of certain assets of
and the right to manage Bay Area Fertility, RSMC and FCI, the Company issued an
aggregate of 1,488,251 shares of Common Stock.
In connection with the Company's acquisition of WMDC and NMF in June 1996,
the Company issued 666,666 shares of Common Stock, acquired tangible assets of
$469,000, assumed current liabilities of $245,000, and debt of $97,000, and
acquired $214,000 of intangible assets and $3,159,000 of goodwill. In connection
with this transaction, the Company also issued a note payable in the amount of
$600,000 with annual interest payable at 4.16%.
In May 1996, in connection the Company's acquisition of certain assets of
and the right to manage W.F. Howard, M.D., P.A. located near Dallas, Texas, the
Company incurred a $550,000 obligation (see Note 7).
In 1996, in connection with the Company's acquisition of certain assets of
and the right to manage the Philadelphia Network Site, the Company incurred a
$1,000,000 obligation (see Note 7).
At December 31, 1997 and 1996 there were accrued dividends on Preferred
Stock outstanding of $464,000 and $331,000, respectively, (see Note 11).
Pursuant to the Second Offer (see Note 11), 608,234 shares of Preferred
Stock were converted into 2,432,936 shares of Common Stock during the year ended
December 31, 1996.
Controlled cash of Medical Practices decreased $191,000, $105,000 and
$193,000 for the years ended December 31, 1997, 1996, and 1995, respectively.
State taxes, which primarily reflect Massachusetts income taxes and
Connecticut capital taxes, of $93,000, $119,000 and $155,000 were paid in the
years ended December 31, 1997, 1996 and 1995, respectively.
Interest paid in cash during the year ended December 31, 1997, 1996 and
1995, amounted to $60,000, $35,000 and $20,000, respectively. Interest received
during the years ended December 31, 1997, 1996 and 1995 amounted to $179,000,
$412,000 and $648,000, respectively.
F-26
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 17 -- SUBSEQUENT EVENTS -- (Unaudited):
In January 1998, the Company completed its second in-market merger with the
addition of two physicians to the FCI practice. The Company acquired certain
assets of Advocate Medical Group, S.C. ("AMG") and Advocate MSO, Inc. and
acquired the right to manage AMG's infertility practice conducted under the name
Center for Reproductive Medicine ("CFRM"). Simultaneous with closing on this
transaction, the Company amended its management agreement with FCI to include
two of the three physicians practicing under the name CFRM. The aggregate
purchase price was approximately $1.5 million, consisting of approximately $1.2
million in cash and 184,314 shares of Common Stock. The majority of the purchase
price was allocated to exclusive management rights.
On March 10, 1998, the Company received notice from RSMC claiming that the
Company has materially breached its management agreement with RSMC and demanding
that the alleged breaches be remedied. Contrary to RSMC's assertions, the
Company believes both that it has materially performed its obligations under the
management agreement with RSMC and that RSMC has materially breached its
obligations to the Company under the management agreement, as well as other
agreements with the Company. While the Company continues to perform, it is
endeavoring to submit the dispute to binding arbitration, which is the governing
dispute-resolution process required under the management agreement, and may be
compelled to seek rescission of all agreements with RSMC. The Company can offer
no assurance that resolution of this matter will not result in the termination
of the management agreement or otherwise adversely impact the Company.
During the first quarter of 1998, the Company closed on an equity private
placement of $5.5 million with Morgan Stanley Venture Partners III, L.P., the
venture capital affiliate of Morgan Stanley, Dean Witter, Discover & Co.
providing for the purchase of 3,235,294 shares of the Company's Common Stock at
a price of $1.70 per share and 240,000 warrants to purchase shares of the
Company's Common Stock, at a nominal exercise price. The Company used or will
use approximately half of these funds to acquire the majority of the capital
stock of Shady Grove Fertility Centers, Inc. ("Shady Grove"), currently a
Maryland business corporation which provides management services, and formerly a
Maryland professional corporation engaged in providing infertility services.
Prior to the closing of the transaction, Shady Grove had entered into a
twenty-year management agreement with Levy, Sagoskin and Stillman, M.D., P.C.
(the " Shady Grove P.C."), an infertility physician group practice comprised of
six physicians and four locations surrounding the greater Washington, D.C. area.
The Company will acquire the balance of the Shady Grove capital stock on or
about November 1, 1998. The aggregate purchase price for all of the Shady Grove
capital stock was approximately $5.7 million, consisting of approximately $2.8
million in cash, $1.4 million in Common Stock, and $1.5 million in promissory
notes The promissory notes are payable in two aggregate annual installments of
$750,000, due on April 1, 1999 and 2000, respectively, and bear interest at an
annual rate of 8.5%. The purchase price was allocated to the various assets and
liabilities assumed and the balance was allocated to exclusive management
rights. On March 12, 1998, the Closing Date, the following consideration was
paid: (i) approximately $1.8 million in cash, (ii) approximately $1.2 million in
stock or 639,551 shares of Common Stock, and (iii) approximately $1.1 million in
promissory notes. The Company will pay the balance of the aggregate purchase
price on or about November 1, 1998 (the "Second Closing Date"), when the balance
of the Shady Grove capital stock is transferred to the Company. The number of
shares of Company Common Stock to be issued on the Second Closing Date, which
will have a fair market value of approximately $200,000, will be determined
based upon the average closing price of the Company's Common Stock for the
ten-day trading period prior to the third business day before the Second Closing
Date, provided, however, that in no event will the price per share exceed $2.00
or be less than $1.70 for purposes of this calculation.
In connection with the Company's January 1998 equity private placement with
Morgan Stanley Venture Partners, M. Fazle Husain, General Partner, became a
member of the Company's Board of Directors.
F-27
INTEGRAMED AMERICA, INC.
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
Pursuant to the Company's management agreement with Shady Grove, Michael J.
Levy, M.D., an employed shareholder physician of the P.C., became a member of
the Company's Board of Directors effective March 12, 1998.
In March 1998, pursuant to Amendment No. 5 to the FCI management agreement,
the Company issued an aggregate of 60,000 warrants at an exercise price of $1.80
to the three shareholder physicians of FCI in exchange for an extension of the
term of the Company's management agreement from twenty to twenty-five years.
F-28
REPORT OF INDEPENDENT ACCOUNTANTS
To the Stockholders of
Fertility Centers of Illinois, S.C.
In our opinion, the accompanying combined balance sheet and related combined
statements of operations, of stockholders' equity and of cash flows present
fairly, in all material respects, the financial position of Fertility Centers of
Illinois, S.C. and its affiliated companies (the "Company") at August 19, 1997
and December 31, 1996, and the results of their operations and their cash flows
for the period January 1, 1997 through August 19, 1997 and the years ended
December 31, 1996 and 1995 in conformity with generally accepted accounting
principles. These financial statements are the responsibility of the Company's
management; our responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these statements in
accordance with generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for the opinion expressed
above.
As discussed in Note 3 to the combined financial statements, the Company
entered into agreements on August 19, 1997 to sell certain assets and give
IntegraMed America, Inc. the right to manage the Company over a twenty-year
period.
/s/Price Waterhouse LLP
- -----------------------
Price Waterhouse LLP
Stamford, Connecticut
February 16, 1998
F-29
FERTILITY CENTERS OF ILLINOIS, S.C.
COMBINED BALANCE SHEET
August 19, December 31,
---------- ------------
1997 1996
---------- -----------
ASSETS
Current assets:
Cash and cash equivalents........................................... $ 885,296 $ 427,707
Patient accounts receivable, less allowance for doubtful accounts
of $378,124 and $165,352 in 1997 and 1996, respectively........... 1,819,394 1,583,230
Receivable from IVF Illinois........................................ 53,600 106,312
Note receivable from related party.................................. 100,000 100,000
Other current assets................................................ 82,213 64,385
---------- ----------
Total current assets.......................................... 2,940,503 2,281,634
---------- ----------
Fixed assets, net................................................... 620,601 598,462
Investment in IVF Illinois.......................................... 75,000 75,000
Other assets........................................................ 216,274 57,784
---------- ----------
Total assets.................................................. $3,852,378 $3,012,880
========== ==========
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities............................ $ 400,359 $207,700
Equipment payable................................................... -- 76,259
Taxes payable....................................................... 588,879 215,039
Employee loans...................................................... 41,865 33,520
Accrued pension and profit sharing.................................. 64,066 90,241
Current portion of long-term debt................................... 27,494 162,060
Patient deposits.................................................... 392,335 504,381
Other liabilities................................................... 41,148 5,602
---------- ----------
Total current liabilities......................................... 1,556,146 1,294,802
---------- ----------
Long-term debt...................................................... 119,547 159,568
Commitments and contingencies....................................... -- --
Stockholders' equity:
Common stock (4,050 shares issued and outstanding at
August 19, 1997 and December 31, 1996, respectively).............. 4,500 4,500
Capital in excess of par............................................ 29,000 29,000
Accumulated earnings................................................ 2,143,185 1,525,010
---------- ----------
Total stockholders' equity.................................... 2,176,685 1,558,510
---------- ----------
Total liabilities and stockholders' equity.................... $3,852,378 $3,012,880
========== ==========
See accompanying notes to the combined financial statements.
F-30
FERTILITY CENTERS OF ILLINOIS, S.C.
COMBINED STATEMENT OF OPERATIONS
For the period
January 1, 1997 For the For the
through year ended year ended
August 19, December 31, December 31,
----------- ----------- -----------
1997 1996 1995
----------- ----------- -----------
Revenues, net.................................. $ 6,112,707 $ 8,338,791 $ 7,044,850
Costs of services rendered..................... 3,919,614 6,735,923 5,601,743
----------- ----------- -----------
Contribution................................... 2,193,093 1,602,868 1,443,107
General and administrative expenses............ 953,840 1,122,407 1,073,302
Interest income................................ (151) (11,679) (4,486)
Interest expense............................... 11,442 33,168 24,296
----------- ----------- -----------
Total other expenses........................... 965,131 1,143,896 1,093,112
----------- ----------- -----------
Income before income taxes..................... 1,227,962 458,972 349,995
Provision for taxes............................ 429,787 145,102 92,823
----------- ----------- -----------
Net income..................................... $ 798,175 $ 313,870 $ 257,172
=========== =========== ===========
See accompanying notes to the combined financial statements.
F-31
FERTILITY CENTERS OF ILLINOIS, S.C.
COMBINED STATEMENT OF STOCKHOLDERS' EQUITY
Capital Total
Common Stock in Excess Accumulated Stockholders'
Shares Amount of Par Earnings Equity
------ ------ ------ -------- ------
Balance as of January 1, 1995............. 4,050 $4,500 $29,000 $1,187,468 $1,220,968
Net income................................ -- -- -- 257,172 257,172
Distributions to stockholders............. -- -- -- (130,000) (130,000)
----- ------ ------- ---------- ----------
Balance as of December 31, 1995........... 4,050 4,500 29,000 1,314,640 1,348,140
Net income................................ -- -- -- 313,870 313,870
Distributions to stockholders............. -- -- -- (103,500) (103,500)
----- ------ ------- ---------- ----------
Balance as of December 31, 1996........... 4,050 4,500 29,000 1,525,010 1,558,510
Net income................................ -- -- -- 798,175 798,175
Distributions to stockholders............. -- -- -- (180,000) (180,000)
----- ------ ------- ---------- ----------
Balance as of August 19, 1997............. 4,050 $4,500 $29,000 $2,143,185 $2,176,685
===== ====== ======= ========== ==========
See accompanying notes to the combined financial statements.
F-32
FERTILITY CENTERS OF ILLINOIS, S.C.
COMBINED STATEMENT OF CASH FLOWS
For the period
January 1, 1997 For the For the
through year ended year ended
August 19, December 31, December 31,
---------- ------------ ------------
1997 1996 1995
---------- ------------ ------------
Cash flows from operating activities:
Net income.................................................... $ 798,175 $313,870 $257,172
Adjustments to reconcile net income to net cash provided by
operating activities:
Depreciation and amortization............................... 91,555 137,146 112,517
Loss on sale of fixed assets................................ -- 42,268 27,956
Bad debt reserve............................................ 212,772 83,451 41,081
Changes in assets and liabilities:
(Increase) decrease in assets:
Patient accounts receivable............................... (448,936) (645,094) (345,827)
Other assets.............................................. 34,884 (11,580) (50,346)
Increase (decrease) in liabilities:
Accounts payable and accrued liabilities.................. 116,400 3,200 76,655
Taxes payable............................................. 373,840 126,754 85,783
Employee loans............................................ 7,628 (33,248) 2,905
Accrued pension and profit sharing........................ (26,175) (264,159) 354,400
Patient deposits.......................................... (112,086) 464,923 31,958
Other accrued liabilities................................. 36,236 81,861 (10,000)
--------- -------- ---------
Net cash provided by operating activities........................ 1,084,293 299,392 584,254
--------- -------- ---------
Cash flows used in investing activities:
Purchase of fixed assets and leasehold
improvements................................................ (272,117) (169,850) (238,270)
---------- --------- ---------
Cash flows (used in) provided by financing activities:
Net (decrease) increase in debt............................... (174,587) 74,693 (41,379)
Note receivable............................................... -- (100,000) --
Distributions to stockholders................................. (180,000) (103,500) (130,000)
---------- --------- ---------
Net cash used in financing activities............................ (354,587) (128,807) (171,379)
Net increase in cash............................................. 457,589 735 174,605
Cash at beginning of period...................................... 427,707 426,972 252,367
---------- --------- ---------
Cash at end of period............................................ $ 885,296 $427,707 $426,972
========= ======== ========
Supplemental information:
Taxes paid in cash............................................ $ 23,196 $ 20,990 $ 8,765
========= ======== ========
Interest paid in cash......................................... $ 11,442 $ 33,168 $ 24,296
========= ======== ========
See accompanying notes to the combined financial statements.
F-33
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
NOTE 1 -- THE COMPANY:
Fertility Centers of Illinois, S.C. and its affiliated companies (the
"Company") is a seven physician group practice with several locations in the
Chicago area. Four of the physicians own 100% of the common stock of the
Company. The Company specializes in providing infertility and related ultrasound
services in the Chicago area. The Company owns a 42.9% interest in IVF Illinois,
Incorporated ("IVF Illinois") which provides in-vitro services.
(See Note 9)
NOTE 2 -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Basis of combination --
The accompanying combined financial statements of the Company comprise the
accounts of Fertility Centers of Illinois, S.C. and the following entities, each
of which is owned by one of the physician shareholders of Fertility Centers of
Illinois, S.C. (the "affiliated companies"): F.R.E.A. Ultrasound Services, Ltd.;
Fertility and Reproductive Medicine Associates, S.C.; Fertility and Reproductive
Endocrinology Associates, S.C.; and Jacob Moise, M.D.S.C. The combination of
these entities has been reflected at historical cost. All significant
intercompany transactions have been eliminated. The Company accounts for its
42.9% interest in IVF Illinois under the equity method of accounting.
Revenues and cost recognition: --
Revenues consist of services rendered for patients and are recognized upon
performance of such services. Revenues are recorded on a net realizable basis
after deducting contractual allowances and consist of patient fees for
infertility and related services performed by the Company. Related direct costs
are recognized in the period in which the clinical and/or laboratory services
are rendered. Net realization is dependent upon benefits provided by the
patient's insurance policy or agreements between the Company and third-party
payors. Payments collected from patients in advance for services are included in
patient deposits.
Cash and cash equivalents --
The Company considers all highly liquid instruments with original
maturities of three months or less to be cash equivalents.
Patient accounts receivable and deposits --
Patient accounts receivable represent receivables from patients for medical
services provided by the Company. Such amounts are recorded net of contractual
allowances and estimated bad debts. Contractual allowances were $941,794 and
$709,240 at August 19, 1997 and December 31, 1996, respectively. Patient
deposits represent patient deposits for medical services to be provided by the
Company.
Fixed assets --
Fixed assets are valued at cost less accumulated depreciation and
amortization. Depreciation is computed on a straight-line basis over the
estimated useful lives of the related assets, generally five to ten years.
Leasehold improvements are amortized over the shorter of the asset life or the
F-34
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
remaining term of the lease. The Company periodically reviews the fair value of
long-lived assets, the results of which have had no material effect on the
Company's financial position or results of operations.
When assets are retired or otherwise disposed of, the costs and related
accumulated depreciation are removed from the accounts. The difference between
the net book value of the assets and proceeds from disposition is recognized as
a gain or loss. Routine maintenance and repairs are charged to expenses as
incurred, while costs of betterments and renewals are capitalized.
Income taxes --
The Company accounts for income taxes utilizing the asset and liability
approach. Deferred tax assets and liabilities are determined based on
differences between financial reporting and tax bases of assets and liabilities
and are measured using the enacted tax rates and laws.
Financial instruments --
The carrying value of the Company's financial instruments, including cash
and cash equivalents, accounts receivable, accounts payable, and long-term debt,
as reported in the accompanying combined balance sheet, approximates fair value.
Major payors --
The majority of the Company's receivables and revenues at and during the
period January 1, 1997 through August 19, 1997 and the year ended December 31,
1996 were from insurance companies.
Common stock --
The Company has 4,050 shares of common stock outstanding at August 19, 1997
and December 31, 1996, of which 3,000 shares each have a par value of $1; 1,000
shares have a stated value of $1,000; and 50 shares each have a par value of
$10.
Use of estimates in the preparation of the combined financial statements --
The preparation of these combined financial statements in conformity with
generally accepted accounting principles requires management of the Company to
make estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosures of contingent assets and liabilities, at the date of
the financial statements, and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
NOTE 3 -- MANAGEMENT AGREEMENT WITH INTEGRAMED AMERICA, INC.
On August 19, 1997, the Company sold certain fixed assets and the right to
manage the Company to IntegraMed America, Inc. ("INMD"). The management
agreement provides INMD the rights to manage the Company through 2017. Pursuant
to the management agreement, the medical providers employed by the Company
provide all medical services and INMD provides all management and administrative
services to the Company's medical practice. In addition, INMD purchases all
accounts receivable generated subsequent to August 19, 1997 on a monthly basis.
F-35
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
Simultaneous with the closing of the sale to INMD, INMD, on behalf of the
Company, completed an in-market merger with the addition of Edward L. Marut, MD,
to the Company's practice.
The following unaudited supplemental information presents the operations of
the Company for the period January 1, 1997 through December 31, 1997. The period
from August 20, 1997 through December 31, 1997 represents the operating results
of the Company under its management agreement with IntegraMed America, Inc.
(in 000's):
For the period For the period
January 1, 1997 August 20, 1997 For the
through through year ended
August 19, December 31, December 31,
-------------- ------------ ------------
1997 1997 1997
-------------- ------------ ------------
Revenues............................................. $6,113 $4,547 $10,660
Cost of services..................................... 3,920 2,045 5,965
Management fee to IntegraMed America................. -- 2,582 2,582
-------- ------- ---------
Contribution......................................... 2,193 (80) 2,113
General and administrative expenses.................. 954 -- 954
Interest expense, net................................ 11 -- 11
--------- -------- -----------
Total other expenses................................. 965 -- 965
-------- -------- ----------
Income (loss) before income taxes.................... 1,228 (80) 1,148
Provision for taxes.................................. 430 -- 430
-------- -------- ----------
Net income (loss).................................... $ 798 $ (80) $ 718
======= ======== =========
Physician compensation expense was approximately $1.6 million and $2.0
million for the period January 1, 1997 to August 19, 1997 and for the period
August 20, 1997 to December 31, 1997, respectively.
NOTE 4 -- FIXED ASSETS, NET:
Fixed assets, net at August 19, 1997 and December 31, 1996 consisted of the
following:
August 19, December 31,
---------- ------------
1997 1996
---------- ------------
Furniture, office and other equipment............ $500,360 $ 575,820
Medical equipment................................ 287,131 510,412
Leasehold improvements........................... 119,875 144,316
--------- ----------
Total......................................... 907,366 1,230,548
Less-- accumulated depreciation and
amortization.................................. (286,765) (632,086)
-------- ----------
$620,601 $ 598,462
======== ==========
Depreciation and amortization expense totaled $91,555, $137,146, and
$112,517 for the period from January 1, 1997 through August 19, 1997 and the
years ended December 31, 1996 and 1995, respectively.
F-36
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
NOTE 5 -- DEBT:
Debt at August 19, 1997 and December 31, 1996 consisted of the following:
August 19, December 31,
---------- ------------
1997 1996
---------- ------------
Business term loan........................ $147,041 $ 321,628
Less-- current portion.................... (27,494) (162,060)
-------- ---------
Long-term debt............................ $119,547 $ 159,568
======== =========
The Company amended an existing term loan and outstanding line of credit
into a new business term loan ($427,814) in June 1996 with principal and
interest payments of $13,505 due monthly. The bank maintains a first security
interest in the Company's assets. Interest is fixed at 8.5%. The Company also
maintains a $160,000 line of credit, $0 of which was outstanding at August 19,
1997. The line of credit expired in March 1997 and was extended through March
1998.
NOTE 6 -- OPERATING LEASES:
The Company leases certain office space and equipment under lease
agreements extending one to five years. All lease obligations were transferred
to INMD on August 19, 1997 as part of the management agreement.
Rent expense under operating leases was $314,076, $463,428 and $227,712 for
the period January 1, 1997 through August 19, 1997 and the years ended December
31, 1996 and 1995, respectively.
NOTE 7 -- INCOME TAXES:
The Company's tax provision primarily represents current federal and state
income taxes. The Company had no significant deferred tax assets or liabilities
at August 19, 1997 or December 31, 1996.
Certain of the affiliated companies have elected, under the Internal
Revenue Code, S corporation status. As a result, no provision for federal income
taxes has been included for these companies.
The income tax provision differed from income taxes determined by applying
the statutory federal income tax rate to the income from the period from January
1, 1997 through August 19, 1997 and the years ended December 31, 1996 and 1995,
respectively, as a result of the following:
1997 1996 1995
---- ---- ----
Tax expense at federal statutory rate.......... 35% 35% 35%
State income taxes, net of federal benefit..... 5% 5% 5%
Rate differential for S corporation status..... (5%) (8%) (13%)
--- --- ----
Provision for income taxes..................... 35% 32% 27%
=== === ====
F-37
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
NOTE 8 -- COMMITMENTS AND CONTINGENCIES:
The Company is subject to certain federal and state laws and regulations,
many of which have not been the subject of judicial or regulatory
interpretation. Management believes the Company's operations are in substantial
compliance with applicable laws and regulations. Although an adverse review or
determination by any such authority could be significant to the Company,
management believes the effects of any such review or determination would not be
material to the Company's financial condition, cash flows, or results of
operations.
NOTE 9 -- RELATED PARTY TRANSACTIONS:
The Company owns a 42.9% interest in IVF Illinois. The physicians of the
Company perform certain procedures for IVF Illinois for which the Company
receives a fee. Fees earned for period from January 1, 1997 through August 19,
1997 and the years ended December 31, 1996 and 1995 were $897,103, $1,213,536
and $906,193, respectively, have been reflected in "Revenues, net" in the
statement of operations. Accounts receivable from IVF Illinois was $53,600 and
$106,312 at August 19, 1997 and December 31, 1996, respectively. The Company's
interest in earnings of IVF Illinois was insignificant for the period January 1,
1997 through August 19, 1997 and the year ended December 31, 1996 and 1995,
respectively.
The $100,000 note receivable at August 19, 1997 and December 31, 1996
represents a note receivable from one physician which is due on demand with
interest payable of 6%.
NOTE 10 -- EMPLOYEE BENEFIT PLANS:
The Company has a defined benefit pension plan (the "plan") covering
certain of the Company's physicians and certain employees as specified under the
plan's eligibility requirements. The plan is funded through a trust agreement
and has met the minimum funding requirements for 1997 and 1996, based on the
funding requirements of U.S. federal governmental laws and regulations.
Net periodic pension costs for the period from January 1, 1997 through
August 19, 1997 and for the year ended December 31, 1996 and 1995 included the
following components:
August 19, December 31,
-------- ----------------------
1997 1996 1995
-------- -------- --------
Service costs - benefits earned during period........ $271,350 $278,176 $264,704
Interest cost on projected benefit obligation........ 21,628 15,882 --
Actual return on assets.............................. (52,438) (16,531) --
Net amortization and deferral........................ 352 1,984 --
-------- -------- --------
Net periodic pension costs........................... $240,892 $279,511 $264,704
======== ======== ========
F-38
FERTILITY CENTERS OF ILLINOIS, S.C.
NOTES TO COMBINED FINANCIAL STATEMENTS
The following table sets forth the plan's funded status at August 19, 1997
and December 31, 1996:
August 19, December 31,
--------- -----------
1997 1996
-------- --------
Actuarial present value of:
Vested benefit obligations.................. $636,567 $405,357
======== ========
Accumulated benefit obligations............. 887,396 563,045
======== ========
Projected benefit obligations............... 887,396 563,045
======== ========
Plan assets at fair value...................... 835,704 534,360
Unrecognized net loss.......................... -- 6,874
-------- --------
Projected benefit obligation in excess of
plan assets................................. $ 51,692 $ 21,811
======== ========
The assumptions used in the determination of net periodic pension cost and
the plan's funded status for the period January 1, 1997 through August 19, 1997
and the year ended December 31, 1996 were as follows:
1997 1996
------- -------
Rate of increase in future compensation levels...... 0% 0%
Discount rate....................................... 6.0% 7.5%
Expected long-term rate of return on plan assets.... 6.0% 6.0%
The Company also maintains a profit sharing plan for certain physicians and
employees of the Company. Contributions to the plan amounted to $36,775, $47,346
and $39,696 for the period from January 1, 1997 through August 19, 1997 and for
the years ended December 31, 1996 and 1995, respectively.
F-39
REPORT OF INDEPENDENT ACCOUNTANTS
To the Shareholder of MPD Medical Associates (MA), P.C.
In our opinion, the accompanying balance sheet and related statement of
operations present fairly, in all material respects, the financial position of
MPD Medical Associates (MA), P.C. (the "P.C.") at December 31, 1997 and 1996,
and the results of its operations for each of the three years in the period
ended December 31, 1997 in conformity with generally accepted accounting
principles. These financial statements are the responsibility of the P.C.'s
management; our responsibility is to express an opinion on these financial
statements based on our audits. We conducted our audits of these statements in
accordance with generally accepted auditing standards which require that we plan
and perform the audit to obtain reasonable assurance about whether the financial
statements are free of material misstatement. An audit includes examining, on a
test basis, evidence supporting the amounts and disclosures in the financial
statements, assessing the accounting principles used and significant estimates
made by management, and evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for the opinion expressed
above.
As described in Note 5, a statement of cash flows has been excluded from the
presentation of financial data related to the P.C., as under the terms of a
management agreement, IntegraMed America, Inc. controls all cash inflows and
outflows related to the P.C.'s operations.
/s/Price Waterhouse LLP
- ------------------------
Price Waterhouse LLP
Stamford, Connecticut
February 16, 1998
F-40
MPD MEDICAL ASSOCIATES (MA), P.C.
BALANCE SHEET
(all dollar amounts in thousands, except per share amounts)
December 31,
-----------------
1997 1996
---- ----
ASSETS
Current assets:
Cash.................................................... $2 $2
-- --
Total current assets................................. 2 2
-- --
Total assets......................................... $2 $2
== ==
SHAREHOLDER'S EQUITY
Shareholder's equity:
Common Stock, $.01 par value -- 200,000 shares authorized,
issued and outstanding in 1997 and 1996, respectively... $2 $2
-- --
Total shareholder's equity........................... $2 $2
== ==
See accompanying notes to the financial statements.
F-41
MPD MEDICAL ASSOCIATES (MA), P.C.
STATEMENT OF OPERATIONS
(all amounts in thousands)
For the years ended December 31,
--------------------------------
1997 1996 1995
------- ------- ------
Revenues, net (see Note 2)..................... $6,869 $7,063 $6,594
Physician compensation......................... 971 1,015 556
Management fee expense (see Notes 1 and 2)..... 5,898 6,048 6,038
------- ------- ------
Net income..................................... $ -- $ -- $ --
======= ======= ======
See accompanying notes to the financial statements.
F-42
MPD MEDICAL ASSOCIATES (MA), P.C.
NOTES TO FINANCIAL STATEMENTS
NOTE 1 -- THE COMPANY:
MPD Medical Associates (MA), P.C. (the "P.C.") is a medical practice
located in the greater Boston, Massachusetts area which specializes in providing
gynecology and infertility services. The P.C. is 100% owned by Patricia McShane,
M.D.
The P.C. is managed by IntegraMed America, Inc. ("INMD") a public physician
practice management company. INMD has managed this practice since July 1988 and
the term of its current management agreement with the P.C. (the "management
agreement") expires in January 2006. Pursuant to the management agreement, the
medical providers employed by the P.C. provide all medical services and INMD
provides all management and administrative services to the P.C.'s medical
practice. Under the management agreement, INMD has guaranteed physician
compensation, or medical practice retainage, and is liable for all liabilities
incurred by the P.C. and is at risk for any loss in the operation thereof. As
compensation for its management services, the P.C. pays INMD any revenues
remaining after payment of physician compensation. Out of these remaining
revenues INMD pays all other costs of services related to the P.C. and the
balance, if any, represents INMD's net management fee.
NOTE 2 -- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES:
Revenue and cost recognition --
Revenues consist of patient service revenues. Patient revenues are recorded
on a net realizable basis after deducting contractual allowances and consist of
patient fees collected by INMD on behalf of the P. C. for gynecology and
infertility services performed by the P.C. Patient revenues and related direct
costs are recognized in the period in which the clinical and/or laboratory
services are rendered. Net realization is dependent upon benefits provided by
the patient's insurance policy or agreements between the P.C. and the third
party payor.
Operating Assets and Liabilities --
Under the management agreement, INMD owns all operating assets of the P.C.
and is liable for all expenses and obligations of the P.C., therefore all
operating assets and liabilities related to the P.C.'s operations are reported
by INMD on its consolidated balance sheet.
Fixed assets --
INMD owns all of the fixed assets utilized by the P.C.'s medical providers.
Management fee expense --
Management fee expense represents payment to INMD for management and
administrative services to the P.C.
F-43
Income taxes --
The P.C. has historically not incurred significant tax liabilities for
federal or state income taxes. Compensation to physician owners and INMD has
traditionally reduced taxable income to nominal levels. This relationship would
be expected to continue in the future. As a result of this practice, provisions
for income taxes and deferred tax assets and liabilities are not material and
have not been reflected in the financial statements.
Use of estimates in the preparation of the financial statements --
The preparation of these financial statements in conformity with generally
accepted accounting principles requires management of the P.C. to make estimates
and assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities, at the date of the financial
statements, and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
NOTE 3 -- DEPENDENCE UPON REIMBURSEMENT BY THIRD PARTY PAYORS:
In Massachusetts, state mandate requires insurance coverage of conventional
infertility services as well as certain assisted reproductive technology
services. Approximately 85% to 91% of the P.C.'s revenues for the years ended
December 31, 1997, 1996 and 1995 were derived from revenues received from third
party payors.
NOTE 4 -- RELATED PARTY INFORMATION:
Patricia McShane, M.D. owns 100% of the outstanding common stock of the
P.C. and became a director of IntegraMed America in March 1997.
NOTE 5 -- CASH FLOW INFORMATION:
Under the management agreement INMD controls all cash inflows and outflows
related to the P.C.'s operations, therefore all operating, investing, and
financing cash flow activity is reported by INMD on its consolidated statement
of cash flows.
NOTE 6 -- SUBSEQUENT EVENT (unaudited):
Effective January 1, 1998, the P.C. entered into a new management agreement
which provides INMD the right to manage the P.C. through 2007. Pursuant to the
management agreement, the medical providers employed by the P.C. provide all
medical services and INMD provides all management and administrative services to
the P.C.'s medical practice. In return for these management and administrative
services, INMD receives a percentage of revenues and net income and reimbursed
costs of services.
F-44
REPORT OF INDEPENDENT ACCOUNTANTS ON
FINANCIAL STATEMENT SCHEDULE
To the Board of Directors
of IntegraMed America, Inc.
Our audits of the consolidated financial statements referred to in our
report dated February 16, 1998 appearing on page F-2 of the 1997 Annual Report
to Shareholders of IntegraMed America, Inc. also included an audit of the
Financial Statement Schedule listed in Item 14(a) of this Form 10-K. In our
opinion, this Financial Statement Schedule presents fairly, in all material
respects, the information set forth therein when read in conjunction with the
related consolidated financial statements.
/s/Price Waterhouse LLP
- -----------------------
Price Waterhouse LLP
Stamford, Connecticut
February 16, 1998
S-1
SCHEDULE II
INTEGRAMED AMERICA, INC.
VALUATION AND QUALIFYING ACCOUNTS
For the Years Ended December 31, 1997, 1996 and 1995
Additions-
Balance at Charged to Balance at
Beginning Costs and End of
of Period Expenses Deductions (1) Period
--------- -------- -------------- ------
Year Ended December 31, 1997
Allowance for
doubtful accounts......................... $309,000 $470,000 $385,000 $394,000
Year Ended December 31, 1996
Allowance for
doubtful accounts......................... $ 89,000 $344,000 $124,000 $309,000
Year Ended December 31, 1995
Allowance for
doubtful accounts......................... $125,000 $119,000 $155,000 $ 89,000
- ----------------
(1) Uncollectible accounts written off.
S-2
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on
its behalf by the undersigned thereunto duly authorized.
INTEGRAMED AMERICA, INC.
Dated: March 20, 1997
By /s/ GERARDO CANET
---------------------------------------------
Gerardo Canet
President, Chief Executive Officer, Director and
Acting Chief Financial Officer
(Principal Financial and Accounting Officer)
Pursuant to the requirements of the Securities Exchange Act of 1934,
this report has been signed below by the following persons on behalf of the
Registrant and in the capacities and on the dates indicated.
Signature Title Date
--------- ----- ----
/s/ GERARDO CANET
- ------------------------------
Gerardo Canet President, March 20, 1998
Chief Executive Officer,
Director and Acting Chief
Financial Officer
(Principal Executive Officer)
/s/ VICKI L. BALDWIN
- ------------------------------
Vicki L. Baldwin Director March 20, 1998
/s/ ELLIOTT D. HILLBACK, JR.
- ------------------------------
Elliott D. Hillback, Jr. Director March 20, 1998
/s/ M. FAZLE HUSAIN
- ------------------------------
M. Fazle Husain Director March 20, 1998
/s/ MICHAEL J. LEVY
- ------------------------------
Michael J. Levy Director March 20, 1998
/s/ SARASON D. LIEBLER
- ------------------------------
Sarason D. Liebler Director March 20, 1998
/s/ AARON LIFCHEZ, M.D.
- ------------------------------
Aaron Lifchez, M.D. Director March 20, 1998
/s/ PATRICIA M. MCSHANE, M.D.
- ------------------------------
Patricia M. McShane, M.D. Director March 20, 1998
/s/ LAWRENCE J. STUESSER
- ------------------------------
Lawrence J. Stuesser Director March 20, 1998
/s/ CLAUDE E. WHITE
- ------------------------------
Claude E. White General Counsel and
Secretary March 20, 1998
INDEX TO EXHIBITS
Item 14(c)
Exhibit
Number Exhibit
- ------- -------
3.1(a) -- Amended and Restated Certificate of Incorporation of Registrant
effecting, inter alia, reverse stock split (ii)
3.1(b) -- Amendment to Certificate of Incorporation of Registrant increasing
authorized capital stock by authorizing Preferred Stock (ii)
3.1(c) -- Certificate of Designations of Series A Cumulative Convertible
Preferred Stock (ii)
3.2 -- Copy of By-laws of Registrant (i)
3.2(a) -- Copy of By-laws of Registrant (As Amended and Restated on December
12, 1995) (xi)
3.2(b) -- Copy of By-laws of Registrant (As Amended and Restated on March 4,
1997).
4.1 -- Warrant Agreement of Robert Todd Financial Corporation. (i)
4.2 -- Copy of Warrant, as amended, issued to IG Labs. (i)
4.3 -- RAS Securities Corp. and ABD Securities Corporation's Warrant
Agreement. (ii)
4.4 -- Form of Warrants issuable to Raymond James & Associates, Inc.
(vii)
4.6 -- Warrant issued to Morgan Stanley Venture Partners III, L.P.
(xviii)
4.7 -- Warrant issed to Morgan Stanley Venture Partners III, L.P. (xviii)
4.8 -- Warrant issed to the Morgan Stanley Venture Partners Entrepreneur
Fund, L.P.
10.1 -- Copy of Registrant's 1988 Stock Option Plan, including form of
option (i)
10.2 -- Copy of Registrant's 1992 Stock Option Plan, including form of
option (i)
10.4 -- Severance arrangement between Registrant and Vicki L. Baldwin (i)
10.4(a) -- Copy of Change in Control Severance Agreement between Registrant
and Vicki L. Baldwin (vii)
10.5(a) -- Copy of Severance Agreement with Release between Registrant and
David J. Beames (iv)
10.6 -- Severance arrangement between Registrant and Donald S. Wood (i)
10.6(a) -- Copy of Executive Retention Agreement between Registrant and
Donald S. Wood, Ph.D. (viii)
10.7(a) -- Copy of lease for Registrant's executive offices relocated to
Purchase, New York (viii)
10.8 -- Copy of Lease Agreement for medical office in Mineola, New York
(i)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.8(a) -- Copy of new 1994 Lease Agreement for medical office in Mineola,
New York (v)
10.8(b) -- Copy of Letter of Credit in favor of Mineola Pavilion Associates,
Inc. (viii)
10.9 -- Copy of Service Agreement for ambulatory surgery center in
Mineola, New York (i)
10.10 -- Copy of Agreement with MPD Medical Associates, P.C. for Center in
Mineola, New York (i)
10.10 -- Copy of Agreement with MPD Medical Associates, P.C. for Center in
Mineola, New York dated September 1, 1994 (vii)
10.10(a) -- Copy of Agreement with MPD Medical Associates, P.C. for Center in
Mineola, New York dated September 1, 1994 (vii)
10.11 -- Copy of Service Agreement with United Hospital (i)
10.12 -- Copy of Service Agreement with Waltham Weston Hospital and Medical
Center (i)
10.15(a) -- Copy of post-Dissolution Consulting Agreement between Registrant
and Allegheny General Hospital (vi)
10.18(a) -- Copy of post-Dissolution Consulting, Training and License
Agreement between Registrant and Henry Ford Health Care Systems
(iii)
10.19 -- Copy of Guarantee Agreement with Henry Ford Health System (i)
10.20 -- Copy of Service Agreement with Saint Barnabas Outpatient Centers
for center in Livingston, New Jersey (i)
10.21 -- Copy of Agreement with MPD Medical Associates, P.C. for center in
Livingston, New Jersey (i)
10.22 -- Copy of Lease Agreement for medical offices in Livingston, New
Jersey (i)
10.23 -- Form of Development Agreement between Registrant and IG
Laboratories, Inc (i)
10.24 -- Copy of Research Agreement between Registrant and Monash
University (i)
10.24(a) -- Copy of Research Agreement between Registrant and Monash
University (ix)
10.28 -- Copy of Agreement with Massachusetts General Hospital to establish
the Vincent Center for Reproductive Biology and a Technical
Training Center (ii)
10.29 -- Copy of Agreement with General Electric Company relating to
Registrant's training program (ii)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.30 -- Copy of Indemnification Agreement between Registrant and Philippe
L. Sommer (vii)
10.31 -- Copy of Employment Agreement between Registrant and Gerardo Canet
(vii)
10.31(a) -- Copy of Change in Control Severance Agreement between Registrant
and Gerardo Canet (vii)
10.31(b) -- Copy of the Amendment of Change in Control Severance Agreement
between Registrant and Gerardo Canet (viii)
10.33 -- Copy of Change in Control Severance Agreement between Registrant
and Dwight P. Ryan (vii)
10.35 -- Revised Form of Dealer Manager Agreement between Registrant and
Raymond James & Associates, Inc. (vii)
10.36 -- Copy of Agreement between MPD Medical Associates, P.C. and
Patricia Hughes, M.D. (vii)
10.37 -- Copy of Agreement between IVF America (NJ) and Patricia Hughes,
M.D. (vii)
10.38 -- Copy of Management Agreement between Patricia M. McShane, M.D. and
IVF America (MA), Inc. (vii)
10.39 -- Copy of Sublease Agreement for medical office in North Tarrytown,
New York (viii)
10.40 -- Copy of Executive Retention Agreement between Registrant and
Patricia M. McShane, MD (viii)
10.41 -- Copy of Executive Retention Agreement between Registrant and Lois
Dugan (viii)
10.42 -- Copy of Executive Retention Agreement between Registrant and Jay
Higham (viii)
10.43 -- Copy of Service Agreement between Registrant and Saint Barnabas
Medical Center (ix)
10.44 -- Asset Purchase Agreement among Registrant, Assisted Reproductive
Technologies, P.C. d/b/a Main Line Reproductive Science Center,
Reproductive Diagnostics, Inc. and Abraham K. Munabi, M.D. (ix)
10.44(a) -- Management Agreement among Registrant and Assisted Reproductive
Technologies, P.C. d/b/a Main Line Reproductive Science Center and
Reproductive Diagnostics, Inc. (ix)
10.44(b) -- Physician Service Agreement between Assisted Reproductive
Technologies P.C. d/b/a Main Line Reproductive Science Center and
Abraham K. Munabi, M.D. (ix)
10.45 -- Copy of Executive Retention Agreement between Registrant and
Stephen Comess (x)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.46 -- Copy of Executive Retention Agreement between Registrant and Peter
Callan (x)
10.47 -- Management Agreement between Registrant and Robert Howe, M.D.,
P.C. (x)
10.47(a) -- P.C. Funding Agreement between Registrant and Robert Howe, M.D.
(x)
10.48 -- Management Agreement among Registrant and Reproductive Endocrine &
Fertility Consultants, P.A. and Midwest Fertility Foundations &
Laboratory, Inc. (x)
10.48(a) -- Asset Purchase Agreement among Registrant and Reproductive
Endocrine & Fertility Consultants, Inc. and Midwest Fertility
Foundations & Laboratory, Inc. (x)
10.49 -- Copy of Sublease Agreement for office space in Kansas City,
Missouri (x)
10.50 -- Copy of Lease Agreement for office space in Charlotte, North
Carolina (x)
10.51 -- Copy of Contract Number DADA15-96-C-0009 as awarded to IVF America
by the Department of the Army, Walter Reed Army Medical Center for
In Vitro Fertilization Laboratory Services (xi)
10.52 -- Agreement and Plan of Merger By and Among IVF America, Inc., INMD
Acquisition Corp., The Climacteric Clinic, Inc., Midlife Centers
of America, Inc., Women's Research Centers, Inc., America National
Menopause Foundation, Inc. and Morris Notelovitz (xii)
10.53 -- Employment Agreement between Morris Notelovitz, M.D., Ph.D. and
IVF America, Inc., d/b/a IntegraMed America (xii)
10.54 -- Physician Employment Agreement between Morris Notelovitz, M.D.,
Ph.D., and INMD Acquisition Corp. ("IAC"), a Florida corporation
and wholly owned subsidiary of IVF America, Inc. ("INMD") (xii)
10.55 -- Management Agreement between IVF America, Inc., d/b/a IntegraMed
America, Inc. and W.F. Howard, M.D., P.A. (xii)
10.56 -- Asset Purchase Agreement between IVF America, Inc., d/b/a/
IntegraMed America, Inc. and W.F. Howard M.D., P.A. (xii)
10.57 -- Business Purposes Promissory Note dated September 8, 1993 in the
amount of $100,000 (xiii)
10.58 -- Business Purposes Promissory Note dated November 18, 1994 in the
amount of $64,000 (xiii)
10.59 -- Guaranty Agreement (xiii)
10.60 -- Security Agreement (Equipment and consumer Goods) (xiii)
10.61 -- Management Agreement dated January 7, 1997 by and between the
Registrant and Bay Area Fertility and Gynecology Medical Group,
Inc. (xiv)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.62 -- Asset Purchase Agreement dated January 7, 1997 by and between the
Registrant and Bay Area Fertility and Gynecology Medical Group, a
California Partnership. (xiv)
10.63 -- Physician Employment Agreement between Robin E. Markle, M.D. and
Women's Medical & Diagnostic Center, Inc. (xv)
10.64 -- Physician Employment Agreement between W. Banks Hinshaw, Jr., M.D.
and Women's Medical & Diagnostic Center, Inc. (xv)
10.65 -- Agreement between IntegraMed America, Inc., f/k/a IVF America
Inc.; Women's Medical & Diagnostic Center, Inc., f/k/a INMD
Acquisition Corp, and Morris Notelovitz, M.D. (xv)
10.66 -- Personal Responsibility Agreement between IntegraMed America,
Inc., Bay Area Fertility and Gynecology Medical Group, Inc. and
Donald I. Galen, M.D. (xv)
10.67 -- Personal Responsibility Agreement between IntegraMed America,
Inc., Bay Area Fertility and Gynecology Medical Group, Inc. and
Louis N. Weckstein, M.D. (xv)
10.68 -- Personal Responsibility Agreement between IntegraMed America,
Inc., Bay Area Fertility and Gynecology Medical Group, Inc. and
Arnold Jacobson, M.D. (xv)
10.69 -- Copy of Executive Retention Agreement between Registrant and Glenn
G. Watkins (xv)
10.70 -- Management Agreement between Registrant and Fertility Centers of
Illinois, S.C. dated February 28, 1997 (xvi)
10.71 -- Asset Purchase Agreement between Registrant and Fertility Centers
of Illinois, S.C. dated February 28, 1997 (xvi)
10.72 -- Physician-Shareholder Employment Agreement between Fertility
Centers of Illinois, S.C. and Aaron S. Lifchez, M.D. dated
February 28, 1997 (xvi)
10.73 -- Physician-Shareholder Employment Agreement between Fertility
Centers of Illinois, S.C. and Brian Kaplan, M.D. dated February
28, 1997 (xvi)
10.74 -- Physician-Shareholder Employment Agreement between Fertility
Centers of Illinois S.C. and Jacob Moise, M.D. dated February 28,
1997 (xvi)
10.75 -- Physician-Shareholder Employment Agreement between Fertility
Centers of Illinois, S.C. and Jorge Valle, M.D. dated February 28,
1997 (xvi)
10.76 -- Personal Responsibility Agreement among Registrant, Fertility
Centers of Illinois, S.C. and Aaron S. Lifchez, M.D. dated
February 28, 1997 (xvi)
10.77 -- Personal Responsibility Agreement among Registrant, Fertility
Centers of Illinois, S.C. and Jacob Moise, M.D. dated February 28,
1997 (xvi)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.78 -- Personal Responsibility Agreement among Registrant, Fertility
Centers of Illinois, S.C. and Brian Kaplan, M.D. dated February
28, 1997 (xvi)
10.79 -- Personal Responsibility Agreement among Registrant, Fertility
Centers of Illinois, S.C. and Jorge Valle, M.D. dated February 28,
1997 (xvi)
10.80 -- Amendment to Contract Number DADA15-96-C-009 between Registrant
and the Department of the Army, Walter Reed Army Medical Center
for In Vitro Fertilization Laboratory Services dated February 11,
1997 (xvi)
10.81 -- Management Agreement between Registrant and Reproductive Sciences
Medical Center, Inc. (xvii)
10.82 -- Asset Purchase Agreement between Registrant and Samuel H. Wood,
M.D., Ph.D. (xvii)
10.83 -- Personal Responsibility Agreement between Registrant and Samual H.
Wood, M.D., Ph.D. (xvii)
10.84 -- Physician-Shareholder Employment Agreement between Reproductive
Sciences Medical Center, Inc. and Samuel H. Wood, M.D., Ph.D.
(xvii)
10.85 -- Physician-Shareholder Employment Agreement between Reproductive
Endocrine & Fertility Consultants, P.A. and Elwyn M. Grimes, M.D.
(xvii)
10.86 -- Amendment to Management Agreement between Registrant and
Reproductive Endocrine & Fertility Consultants, P.A. (xvii)
10.87 -- Amendment to Management Agreement between Registrant and Fertility
Centers of Illinois, S.C. dated May 2, 1997 (xvii)
10.88 -- Management Agreement between Registrant and MPD Medical
Associates, P.C. dated June 2, 1997 (xvii)
10.89 -- Physician-Shareholder Employment Agreement between MPD Medical
Associates P.C. and Gabriel San Roman, M.D. (xvii)
10.90 -- Amendment No. 2 to Management Agreement between Registrant and
Fertility Centers of Illinois, S.C. dated June 18, 1997 (xvii)
10.91 -- Commitment Letter dated June 30, 1997 between Registrant and First
Union National Bank (xvii)
10.92 -- Amendment No. 3 to Management Agreement between Registrant and
Fertility Centers of Illinois, S.C. dated August 19, 1997 (xviii)
10.93 -- Amendment No. 4 to Management Agreement between Registrant and
Fertility Centers of Illinois, S.C. dated January 9, 1998 (xx)
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.94 -- Investment Agreement between Registrant and Morgan Stanley Venture
Partners III, L.P.., Morgan Stanley Venture Investors III, L.P.
and the Morgan Stanley Venture Partners Entrepreneur Fund, L.P.
(xix)
10.95 -- Amendment No. 5 to Management Agreement between Registrant and
Fertility Centers of Illinois, S.C. dated March 5, 1998.
10.96 -- Termination Agreement by and among Women's Medical & Diagnostic
Center, Inc., W. Banks Hinshaw, Jr., Ph.D., M.D., and Robin E.
Markle, M.D.
10.97 -- Loan Agreement between First Union National Bank and IntegraMed
America, Inc. dated November 13, 1997.
10.98 -- Management Agreement between IntegraMed America, Inc. and MPD
Medical Associates (MA), P.C. dated October 1, 1997
10.99 -- Physician-Shareholder Employment Agreement between MPD Medical
Associates (MA), P.C. and Patricia McShane, M.D. dated October 1,
1997.
10.100 -- Asset Purchase and Sale Agreement by and among IntegraMed America,
Inc. and Fertility Centers of Illinois, S.C., Advocate Medical
Group, S.C. and Advocate MSO, Inc. dated January 9, 1998.
10.101 -- Physician Employment Agreement between Fertility Centers of
Illinois, S.C. and Laurence A. Jacobs, M.D. dated January 9, 1998.
10.102 -- Physician Employment Agreement between Fertility Centers of
Illinois, S.C. and John J. Rapisarda, M.D. dated January 9, 1998.
10.103 -- Personal Responsibility Agreement entered into by and among
IntegraMed America, Inc., Fertility Centers of Illinois, S.C. and
John J. Rapisarda, M.D. dated January 9, 1998.
10.104 -- Personal Responsibility Agreement entered into by and among
IntegraMed America, Inc., Fertility Centers of Illinois, S.C. and
Laurence A. Jacobs, M.D. dated January 9, 1998.
10.105 -- Management Agreement between Shady Grove Fertility Centers, P.C.
and Levy, Sagoskin and Stillman, M.D., P.C. dated March 11, 1998.
10.106 -- Submanagement Agreement between Shady Grove Fertility Centers,
Inc. and IntegraMed America, Inc. dated March 12, 1998.
10.107 -- Stock Purchase and Sale Agreement among Integramed America, Inc.
and Michael J. Levy, M.D., Robert J. Stillman, M.D. and Arthur W.
Sagoskin, M.D. dated March 12, 1998
10.108 -- Personal Responsibility Agreement by and among IntegraMed America,
Inc. and Arthur W. Sagoskin, M.D. dated March 12, 1998.
INDEX TO EXHIBITS (Continued)
Item 14(c)
Exhibit
Number Exhibit
- ------ -------
10.109 -- Personal Responsibility Agreement by and among IntegraMed America,
Inc. and Michael J. Levy, M.D. dated March 12, 1998.
10.110 -- Physician-Stockholder Employment Agreement between Levy, Sagoskin
and Stillman, M.D., P.C. and Michael J. Levy, M.D. dated March 11,
1998.
10.111 -- Physician-Stockholder Employment Agreement between Levy, Sagoskin
and Stillman, M.D., P.C. and Arthur W. Sagoskin, M.D. dated March
11, 1998.
10.112 -- Physician-Stockholder Employment Agreement between Levy, Sagoskin
and Stillman, M.D., P.C. and Robert J. Stillman, M.D. dated March
11, 1998.
21 -- List of Subsidiaries
23.1 -- Consent of Price Waterhouse LLP
27 -- Financial Data Schedule
INDEX TO EXHIBITS (Continued)
Item 14(c)
- ------------------------------------
(i) Filed as Exhibit with identical exhibit number to Registrant's
Statement on Form S-1 (Registration No. 33-47046) and incorporated
herein by reference thereto.
(ii) Filed as Exhibit with identical exhibit number to Registrant's
Statement on Form S-1 (Registration No. 33-60038) and incorporated
herein by reference thereto.
(iii) Filed as Exhibit with identical exhibit number to Registrant's
Quarterly Report on Form 10-Q for the period ended March 31, 1994 and
incorporated herein by reference thereto.
(iv) Filed as Exhibit with identical exhibit number to Registrant's
Quarterly Report on Form 10-Q for the period ended June 30, 1994 and
incorporated herein by reference thereto.
(v) Filed as Exhibit with identical exhibit number to Registrant's
Quarterly Report on Form 10-Q for the period ended September 30, 1994
and incorporated herein by reference thereto.
(vi) Filed as Exhibit with identical exhibit number to Registrant's
Statement on Form 10-K for the period ended December 31, 1993.
(vii) Filed as Exhibit with identical exhibit number to Registrant's
Statement on Form S-4 (Registration No. 33-82038) andincorporated
herein by reference thereto.
(viii) Files as Exhibit with identical exhibit number to Registrant's
Quarterly Report on Form 10-K for the period ended December 31, 1994.
(ix) Filed as Exhibit with identical number to Registrant's Quarterly
Report on Form 10-Q for the period ended June 30, 1995.
(x) Filed as Exhibit with identical number to Registrant's Quarterly
Report on Form 10-Q for the period ended September 30, 1995.
(xi) Filed as Exhibit with identical number to Registrant's Statement on
Form 10-K for the period ended December 31, 1995.
(xii) Filed as Exhibit with identical exhibit number to Registrant's Report
on Form 8-K dated June 20, 1996.
(xiii) Filed as Exhibit with identical exhibit number to Registrant's Report
on Form 8-K/A dated August 20, 1996.
(xiv) Filed as Exhibit with identical exhibit number to Registrant's Report
on Form 8-K dated January 20, 1997.
(xv) Filed as Exhibit with identical exhibit number to Statement on Form
10-K for the period ended December 31, 1996.
(xvi) Incorporated by Reference to the Exhibit with the identical exhibit
number to Registrant's Registration Statement on Form S-1
(registration No. 333-26551) filed with the Securities and Exchange
Commission on May 6, 1997.
INDEX TO EXHIBITS (Continued)
Item 14(c)
(xvii) Incorporated by reference to the Exhibit with the identical exhibit
number to Registrant's Registration Statement on Form S-1
(Registration No. 333-26551) filed with the Securities and Exchange
Commission on June 20, 1997.
(xviii) Filed as Exhibit with identical exhibit number to Registrant's
Quarterly Report on Form 10-Q for the period ended September 30, 1997
and incorporated herein by reference thereto.
(xix) Filed as Exhibit with identical exhibit number to Registrant's Report
on Form 8-K dated January 23, 1998.
(xx) Filed as Exhibit with identical exhibit number to Schedule 13D dated
February 11, 1998.